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Abstract 
In this thesis, we investigate automated methods for the control of rotary blood pumps in the treatment 
of heart failure. Heart failure is a common end-point for many forms of cardiovascular disease resulting 
in significant morbidity and mortality. Ventricular assist devices (VADs) are blood pumps designed to 
assist a failing heart and are used both to support patients whilst they are awaiting a heart transplant, or 
as an alternative to transplantation. Small rotary VADs can provide long-term support of the left 
ventricle (LVAD), right ventricle (RVAD) or both ventricles of the heart simultaneously. 
Unfortunately, the lack of a commercially available rotary RVAD has led to the implantation of two 
rotary LVADs as an ad hoc biventricular assist device (BiVAD). Clinicians currently operate such dual 
LVADs at a constant speed, which ensures balanced left and right pump flows for inactive patients. 
However, changes in levels of patient activity will lead to altered cardiac output requirements, which 
may disturb this balance. In turn, this can lead to undesirable events such as pulmonary venous 
congestion or ventricular suction. A control system that automatically adjusts pump speed with changes 
in the required cardiac output could alleviate such events and so offer significant benefits. However, 
while such physiological control systems have been investigated for single LVADs, limited work has 
been completed on dual LVAD control. In addition, there is no generally accepted framework for the 
evaluation of these systems that encompasses a broad range of patient scenarios, activity levels and 
heart conditions. Therefore, the primary aim of this thesis was to develop and evaluate a number of 
physiological control systems suitable for dual rotary LVADs.  
The first objective was to characterise the methods that are currently used to operate dual LVADs in 
the clinic. Using both in-vitro and in-vivo methods, it was shown that balanced left and right flow rates 
could be obtained by operating the RVAD slower than the LVAD, albeit at speeds below the 
manufacturer’s recommendations (1400 – 1800 RPM), which, according to other investigators, may 
adversely affect impeller washout. Operating both at the same design speed is only possible in patients 
with high pulmonary vascular resistance (PVR), high left ventricular contractility or high RVAD 
outflow cannula resistance. This thesis demonstrates that if the RVAD outflow cannula is restricted to 
a diameter between 6.5 and 8.1 mm, suitable steady-state haemodynamics (systemic flow rate 5 L.min-
1, MAP 90mmHg and LAP less than 25mmHg) can be achieved while maintaining impeller stability 
and optimal device washout. It was also established that changes in pump speed or outflow graft 
diameter were required to overcome elevations in pulmonary vascular resistance, thereby justifying the 
necessity of a physiological control system for dual LVADs.  
The second objective was to develop an in vitro evaluation protocol for control system testing utilising 
a mock circulation loop (MCL). The testing protocol consisted of simulating three patient scenarios 
(postural change, valsalva manoeuvre and exercise) consecutively. Four performance metrics were also 
devised, in order to quantify controller performance with respect to haemodynamic stability, congestion 
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avoidance, suction avoidance and exercise. We showed that the scenarios were useful for evaluation of 
control systems because they subjected the systems to preload and afterload changes similar to those 
observed in-vivo. However, the lack of a simulated baroreflex caused discrepancies in haemodynamics 
between the MCL and those reported in literature. The scenarios were replicated with a high degree of 
repeatability, and we showed that the performance metrics can be used for accurate and efficient 
comparisons of control system performance.  
The third objective was to experimentally compare a number of LVAD physiological control systems 
from the literature using our proposed evaluation protocol in order to determine the most suitable 
candidate for dual LVAD control. The key finding from this comparison was that a control system based 
on the native Frank-Starling response was the best performing system with respect to all aspects/metrics 
evaluated. In particular, it produced zero suction events (compared to 0.12 events per second caused by 
constant speed control), kept left atrial pressure below 15mmHg for nearly the entirety of the simulation, 
and increased pump flow in exercise by 3.1 L.min-1 (compared to 1.62 L.min-1 with constant speed 
control). This is the first time a Frank-Starling control system has been evaluated with respect to three 
different patient scenarios and the results highlight the advantages of this system over other previously 
proposed control systems.  
The final objective was to adapt the Starling-like control system into a dual LVAD control system. A 
master/slave control strategy was designed and a number of configurations compared using our 
evaluation protocol. Based on this evaluation, we demonstrated that the left/right master/slave 
physiological control system using a preload-matching slave controller produced fewer suction events 
than constant speed control (0.01 vs. 0.15 s-1), had a lower risk of pulmonary congestion than the other 
control systems, and had an effective flow increase in exercise higher than constant speed control (4.33 
vs. 2.09 L.min-1). In this way, we demonstrated the efficacy of physiological control of dual LVADs 
via a master/slave approach based on the Frank-Starling law of the heart. Potential future work could 
involve extending the evaluation framework by the inclusion of a simulation of the baroreflex, 
investigating the use of other control strategies in both single and dual LVAD Starling-like control 
systems and in-vivo and clinical validation of the dual LVAD physiological control system. 
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1 Introduction 
Cardiovascular disease (CVD) is one of the biggest killers in Australia, responsible for 31.7% of deaths 
in 2010 [1]. Cardiovascular disease is also one of the most expensive disease groups in Australia. In 
2004-05, its cost was $5.9 billion, 11% of all health expenditure [2]. The situation in Australia is similar 
to that of the developed world [3], [4]. Therefore, there is both a moral and practical obligation to treat 
CVD in an effective manner. 
Heart failure (HF) is one of the most severe forms of CVD, and describes any condition in which the 
ability of the heart to pump blood is diminished. The ideal treatment for a patient with HF is a heart 
transplant. However, the demand for donor hearts greatly outweighs supply. In 2011, there were 
approximately 260 000 patients with HF in Australia, yet only 65 transplants were performed [5]. 
Therefore alternative approaches (either surgical, pharmacological or mechanical treatments) are used. 
Surgical techniques, such as coronary artery bypass grafting, are only suitable for patients with blocked 
coronary arteries, which is a subset of heart failure patients. Surgical approaches are also associated 
with a high risk of mortality. Pharmacological methods are also associated with high mortality, with 
12-month survival rates less than 25% [6], [7]. Mechanical therapy involves implantation of a device 
into the patient to pump blood around the body, and offers improved survival rates over 
pharmacological treatment [6]. The two main types of mechanical devices are ventricular assist devices 
(VADs) and total artificial hearts (TAHs). 
Total artificial hearts are devices designed to completely replace the two failed ventricles. First 
generation TAHs (CardioWest and Abiocor) are pulsatile pumps whose percutaneous pneumatic 
drivelines (CardioWest) and large size (Abiocor) limit their use to date [8]. On the other hand, VADs 
are designed to be implanted without removing the native ventricle, making them smaller than TAHs. 
Ventricular assist devices assist a failing ventricle pump blood around the body, and have been shown 
to improve patient outcomes over pharmacological methods [6].These pumps can assist the left ventricle 
(LVAD), right ventricle (RVAD) or both ventricles simultaneously (BiVAD).The use of rotary blood 
pumps as opposed to pulsatile blood pumps has resulted in longer support durations and improved 
patient outcomes due to their smaller size, higher efficiency and smaller power consumption [9]. 
The majority of VAD patients receive only an LVAD, however there are a number of patients who 
develop right ventricular failure post-operatively and therefore require biventricular support. It is 
difficult to determine an exact proportion, with the range reported in literature between 5 and 50% [10]–
[15]. The lack of a commercially available rotary RVAD has led to clinicians implanting two rotary 
LVAD as an ad hoc biventricular assist device [16]–[19]. Despite some reported success, clinicians 
report difficulties in setting appropriate pump speeds in this configuration in order to achieve balance 
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between systemic and pulmonary flows [16], [18]. Without careful flow balancing, there is a higher risk 
of complications, such as pulmonary congestion or ventricular collapse.  
Flow balancing can be achieved by manual variation of pump speed under the guidance of 
echocardiography. However, frequent adjustments must be made. Saito et al. (2011) reported daily 
adjustments of speed in the immediate postoperative period [18]. Furthermore, as the patient's condition 
improves and they become more active, corresponding changes in the patient's circulatory system may 
disturb the flow balance previously established by the clinician in the acute care setting. This may limit 
their capacity to perform everyday tasks. As the current approach to setting pump speeds is one of “set 
and forget”, an automatic control system for pump speed could improve the quality of life of patients 
by ensuring balanced flow. This control system should adjust pump flows in a physiological manner 
similar to the native heart, because that is what the human body expects. 
Development of a physiological control system for dual LVADs requires knowledge of the limitations 
of current operating modes for these devices, in order to identify how much control action is necessary 
to restore balance between flows. Clinicians have proposed a number of different operating modes, 
which need to be compared using the same testing protocol in order to establish their advantages and 
disadvantages. Particularly, the ability of these operating modes to handle transient changes in vascular 
resistance should be assessed. 
The control system for dual LVADs will be complex due to the use of multiple input and output control 
variables. Logically, development could be aided by the development of a physiological control system 
for a single LVAD. Provided that the single LVAD control system has been evaluated thoroughly, it 
could possibly be adapted for dual LVAD use.  
Development and assessment of physiological control systems for rotary LVADs initially occurs in the 
low-cost in-silico and in-vitro environments before moving onto the more expensive in-vivo and clinical 
environments. To reduce the quantity (and therefore expense) of in-vivo trials, and to ensure maximum 
safety of participants in clinical studies, in-silico and in-vitro evaluation must be thorough. Therefore, 
a robust and comprehensive evaluation protocol must be developed. 
1.1 Aim and Objectives 
The aim of this thesis is to design and evaluate a physiological control system for a dual rotary LVAD 
system operating as a BiVAD. In order to meet this aim, the following objectives were devised. 
1. Investigate the different operating modes of dual rotary LVADs as a BiVAD that have 
previously been presented in literature. 
2. Develop an evaluation framework for in-vitro assessment of physiological control systems. 
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3. Develop a physiological control system for a rotary LVAD control system and evaluate using 
the evaluation framework. 
4. Modify the rotary LVAD physiological control system into a BiVAD physiological control 
system and assess using the evaluation framework. 
1.2 Background 
Development of a suitable rotary BiVAD control system requires knowledge of the cardiovascular 
system. The following section provides the reader with background knowledge required for 
understanding of the topic. It encompasses descriptions of the anatomy and physiology of the human 
heart and circulatory system, heart failure and its prevalence, and treatment of heart failure using VADs. 
The information that follows is an overview, and more detail can be found in references [20]–[22].  
1.2.1 The Human Heart and Circulatory System 
The human heart consists of left and right sides. The left side of the heart pumps oxygenated blood to 
the various tissues throughout the body via the systemic circulation, while the right side of the heart 
delivers deoxygenated blood to the lungs via the pulmonary circulation. Each side of the heart consists 
of two chambers, an atrium and a ventricle, connected with one-way atrioventricular valves. The 
ventricles produce the majority of force required to propel blood through the circulatory system, while 
the atria act as primer pumps to assist with ventricular filling. Figure 1.1 shows the anatomy of the 
human heart in detail. 
Figure 1.2 shows the pathway of blood through the 
heart and circulatory system. Deoxygenated blood 
flows from the systemic venous circulation into the 
right atrium (RA) via the superior and inferior vena 
cava. This blood moves into the ventricle via the 
tricuspid valve when the ventricular muscle is 
relaxed. When the ventricular muscle contracts, the 
deoxygenated blood is ejected from the right 
ventricle (RV) into the pulmonary artery (PA) via the 
pulmonary valve. The blood is oxygenated as it 
passes through the pulmonary circulation before 
returning to the left atrium (LA). Blood then passes through the mitral valve into the left ventricle (LV), 
before being ejected into the aorta via the aortic valve. Blood then passes throughout the systemic 
circulation, delivering oxygen to muscles and organs, before returning to the RA via the vena cavae to 
begin the cycle again. 
 
Figure 1.1: Anatomy of the human heart [20]. 
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Figure 1.2: Human Circulatory System [23] 
 
1.2.2 The Cardiac Cycle 
Cardiac muscles undergo a period of contraction (systole) and relaxation (diastole) each heartbeat. 
During diastole, the ventricles fill with blood, while in systole blood is ejected. The period encompassed 
by one contraction and one relaxation is referred to as the cardiac cycle. Figure 1.3 shows typical LV, 
LA and systemic arterial pressures during the different phases of the cardiac cycle. 
 
Figure 1.3: Aortic, left atrial and left ventricular pressure waveforms during the cardiac cycle [20]. 
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The cardiac cycle can be further divided into four distinct phases. In Phase I, ventricular filling, venous 
blood moves from the atria into the ventricles via the atrioventricular valves, until the intraventricular 
pressure equals the atrial pressure. There are three distinct stages of filling. In the first stage of filling, 
the ventricles rapidly fill with blood, due to the pressure difference between the atrium and the ventricle 
at the end of systole. During the next stage (diastasis), venous blood still returning from the veins flows 
directly into the ventricle. Towards the end of ventricular diastole, contraction of the atria forces even 
more blood into the ventricle. During Phase 1 the ventricular muscle is relaxed, resulting in an increase 
in ventricular volume but only a small increase in intraventricular pressure. The relationship between 
intraventricular volume and pressure during this phase is known as the end-diastolic pressure-volume 
relationship (EDPVR). An example of an EDPVR is the lower blue line in Figure 1.4. 
 
 
Phase II, isovolumic contraction, is the beginning of systole. In this phase the ventricular muscle 
contracts, causing a rapid increase in intraventricular pressure. However, the ventricular volume 
remains unchanged. This is because the one-way atrioventricular valves are closed, preventing backflow 
into the atria, while the aortic and pulmonary valves (also referred to as the semilunar valves), remain 
closed because the intraventricular pressure remains below the arterial pressure. This phase is quite 
short, as it only takes about 0.02-0.03 seconds for the ventricles to build up enough pressure to open the 
semilunar valves. 
Phase III, ejection, begins when the intraventricular pressure rises above arterial pressure (above 
80mmHg for the aorta and 8mmHg for the pulmonary artery), which enables blood to be ejected from 
the LV into the aorta and from the RV into the PA. Initially the intraventricular pressure continues to 
rise after the semilunar valves open because the ventricle is still contracting. Eventually the 
Figure 1.4: Left ventricular pressure and volume during the four phases of the cardiac cycle (red line). The blue 
lines show examples of end-systolic pressure-volume and end-diastolic pressure volume relationships [20]. 
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intraventricular pressure peaks and begins to fall as blood is ejected from the ventricle. The end of this 
phase occurs when the intraventricular pressure falls below the arterial pressure. The relationship 
between intraventricular pressure and volume at the end of this phase is referred to as the end-systole 
pressure-volume relationship (ESPVR). An example of an ESPVR is shown by the upper blue line in 
Figure 4. 
Finally, in Phase 4, isovolumic relaxation, the ventricular cardiac muscle relaxes, resulting in a rapid 
drop in intraventricular pressure. The elevated arterial pressure forces blood back towards the ventricles, 
which snaps the semilunar valves shut. The volume remains constant in this phase because the 
intraventricular pressure is greater than the atrial pressure, preventing the atrioventricular valves from 
opening. At the end of this short phase (0.03 to 0.06 seconds) the intraventricular pressures return to 
their low diastolic levels and the cardiac cycle begins again. 
1.2.3 The Frank-Starling Law of the Heart 
The strength of ventricular muscle contraction during systole is proportional to the volume of blood that 
fills the ventricle during diastole. This phenomenon is known as the Frank-Starling mechanism, and 
ensures that the ejected volume is proportional to the venous return[24]. The explanation for this 
phenomenon is that when the end-diastolic volume increases due to increased venous return, the cardiac 
muscle fibres are stretched further than normal. Like all striated muscle, higher pre-tensioning moves 
the myosin and actin filaments of the cardiac muscle closer to the optimal position for force generation. 
The result is that the muscle contracts with increased strength during the following period of systole.  
Essentially, the Frank-Starling mechanism ensures that the heart pumps all the blood that is returned to 
it from the veins (within physiological limits) [20]. This means that cardiac output (CO) becomes 
dependent on the intraventricular end-diastolic pressure, or preload, as shown by the CO curves in 
Figure 1.5. This relationship is also referred to as preload sensitivity. 
High preload sensitivity is essential because preload changes with venous return, which in turn varies 
with patient activity. For example, standing up from a supine position causes increased pooling of blood 
in the systemic venous circulation, which reduces preload to the right ventricle [25], [26].The reduced 
preload results in reduced RV stroke volume, ensuring that ventricular outflow matches inflow and 
therefore preventing the ventricle from emptying completely. Conversely, during exercise muscles 
contract around the veins, squeezing blood back to the right atrium and thereby increasing preload [20]. 
Healthy ventricles respond to this by increasing the strength of their contractions, forcing more blood 
out of the ventricle and therefore matching the increased venous return, preventing damming of venous 
blood in the atria. 
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It is important to note that no single curve describes the relationship between CO and preload. Instead, 
a family of curves is used. The slope and maximum flow rate of the curves shown in Figure 1.5 (left) 
varies with changes in contractility, caused by sympathetic and parasympathetic stimulation (Figure 
1.5, right). The slope and maximum cardiac output are also diminished in heart failure. 
1.2.4 Heart Failure 
Heart failure describes any condition that prevents the heart from pumping adequate blood flow to 
peripheral organs and tissues, preventing them from receiving sufficient oxygen[20]. Some common 
causes of HF include myocardial infarction, coronary artery disease, chronic hypertension, valve 
disease and idiopathic cardiomyopathy [21]. Regardless of the cause, the effect of heart failure is that 
the pumping ability of the heart is severely depressed. This results in a reduced preload sensitivity, 
leading to damming of venous blood in the right atrium, and a reduced maximum cardiac output. 
Reduced cardiac output means that oxygen supply to vital organs such as the kidneys, brain and liver is 
also reduced. In order to restore CO to 5 L/min, compensatory mechanisms are activated by the body. 
These mechanisms, activated by sympathetic nervous stimulation, include increased heart rate and 
contractility (where possible) to directly increase CO, and increased venous tone to increase preload 
and indirectly increase CO via the (albeit damped) Frank-Starling mechanism[20]. 
Figure 1.5: Cardiac output curves, which show the relationship between left and right ventricular output and 
preload as a result of the Frank-Starling mechanism (left). The sensitivity of cardiac output to preload and the 
maximum cardiac output increase with sympathetic nervous stimulation of the heart, and decrease with heart 
failure (right)[20]. 
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The compensatory sympathetic stimulation of 
heart rate and contractility cannot be 
maintained for extended periods of time.  The 
failure of the pumping function of the heart 
results in an increase in preload and therefore 
an increase in stroke volume. Consequently, 
there is partial restoration of CO at the 
expense of increased LAP/RAP. This 
highlighted in Figure 1.6, which shows the 
changes in CO curves before HF (red), during 
initial onset of HF (blue), after sympathetic 
nervous stimulation (dark green) and after 
further recovery (light green). The black 
points show the steady-state condition of the 
patient's CO and right atrial pressure. Even 
with compensatory mechanisms activated the slope and maximum value of the CO curve are both 
severely diminished. In order to restore CO to 5 L/min, the right RA pressure has to increase 
dramatically. The result is that when at rest, the patient may not exhibit signs of heart failure other than 
an elevated RA pressure. However, the depressed maximum cardiac output caused by heart failure 
means that the exercise capacity of these patients is limited. These patients therefore have a lower 
quality of life than their healthy counterparts. Appropriate treatment is necessary to increase the duration 
and quality of life of HF patients. 
HF can be treated surgically, pharmacologically or mechanically. Over the last thirty years mechanical 
therapy has become a viable HF treatment worldwide due to advances in blood pump technology. 
1.2.5 Treatment of Heart Failure using Mechanical Therapy 
Treatment of heart failure using mechanical therapy can be achieved using three types of devices: intra-
aortic balloon pumps (IABPs), ventricular assist devices (VADs) or total artificial hearts (TAHs). Intra-
aortic balloon pumps are one of the most commonly used cardiac assist devices in the world [27]. These 
devices unload the LV, increase cardiac output and improve coronary flow in patients with acute HF. 
However, these devices are not suitable for patients with chronic end-stage HF [28]. Furthermore, these 
devices are associated with an average complication rate of 20-30%, making them suitable for short 
term use only[29]. TAHs are devices designed to completely replace a failing heart, and are therefore 
only targeted towards patients with severe HF. Commercially available TAHs are large and difficult to 
implant in small patients, further limiting their application [30]. VADs are pumps designed to 
mechanically assist a failing ventricle of the heart pump blood around the human body, and can support 
the left ventricle (LVAD), right ventricle (RVAD), or both ventricles simultaneously (Figure 1.7). 
 
Figure 1.6: Variation of the cardiac output curves during 
various stages of heart failure. 
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Mechanically unloading the ventricles using 
VADs was proven by Rose et al. (2001) to 
have better 12 month survival rates than 
optimal medical management alone (52% vs. 
25%) [6]. Ventricular assist devices can be 
used to treat a wide variety of patients due to 
their small size, and have mechanical life spans 
ranging from 12 months to over 6 years. For 
these reasons, VADs are now an established 
method of treating HF patients, and have been 
used as a bridge-to-transplant, bridge-to-
destination (for patients ineligible for a 
transplant) and, in some rare cases, as a bridge-
to-recovery. 
1.2.6 Generations of Ventricular Assist 
Devices 
VADs are classified as first, second and third 
generation devices according to their mode of 
operation [32]. Examples of the three different 
generations are shown in Figure 1.8. 
 
 
   
Figure 1.8: Examples of first, second and third generation ventricular assist devices. Left: PVAD 
(Thoratec Corporation, Pleasanton, CA, USA). Middle: HeartMate II (Thoratec Corporation, 
Pleasanton, CA, USA). Right: HVAD (HeartWare Inc., Massachusetts, USA). 
 
  
 
Figure 1.7: Left ventricular assist device (LVAD) 
connected between the left ventricle and the aorta, and a 
right ventricular assist device (RVAD) connecting the 
right atrium and the pulmonary artery[31]. 
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First generation VADs are volume displacement pumps (commonly referred to as pulsatile pumps in 
the literature), whose pumping mechanism is similar to that of the native ventricle. These devices were 
designed with the intention of delivering a pulse to the circulatory system in order to replicate normal 
physiological flow. To meet this requirement, these devices incorporated electrically or pneumatically 
actuated diaphragms or pusher plates[22]. Most of these pumps were paracorporeal due to their large 
size, and thus utilised percutaneous cannulae and drivelines which placed limitations on the quality of 
life of the recipient. Another major complication is that their multiple moving parts result in a short 
mechanical lifespan, with expected device failure rate between 35 and 64% after 24 months[6], [33], 
[34]. Other reported complications with first generation devices include abdominal complications and 
infections caused by percutaneous driveline and/or cannulae [35], [36]. Despite the improvement in 
survival rates over medical management, the disadvantages of first generation VADs limit support 
duration as well as patient quality of life. 
Second generation VADs are rotary pumps, which have improved upon the aforementioned 
shortcomings of first generation VADs. Unlike pulsatile VADs, rotary VADs deliver a continuous flow 
of blood to the circulatory system. These VADs are either axial or centrifugal rotary blood pumps 
(RBPs), consisting of a rotating impeller providing forward flow of blood with few moving parts. In 
second generation VADs, the impeller is suspended using a mechanical bearing, such as a pivot bearing. 
These devices significantly improve patient haemodynamics and quality of life when compared to first 
generation VADs [9], [37]–[39]. However, the use of mechanical bearings and seals is associated with 
increased thrombogenicity and acquired platelet dysfunction[40].  
Third generation VADs are rotary pumps whose impeller is suspended using non-contact bearings, 
which eliminates some of the issues associated with second generation devices. These bearings can be 
hydrodynamic, magnetic or combinations of both[41]. 
The benefits of both second and third generation VADs have resulted in a steady increase in their usage 
over the last eight years, with the number of rotary LVAD implantations performed per year in the USA 
surpassing the number of heart transplants for the first time in 2009 [42]. Support duration has also 
increased, with some patients supported for over six years [43]. 
Most HF patients present with LV failure only, so implantation of a rotary LVAD is sufficient. 
However, patients with concomitant right heart failure do not benefit from only an LVAD and require 
biventricular support. Furthermore, the need for additional RV mechanical assistance post LVAD 
implantation is reportedly between 5 and 50% [10]–[15]. These patients could also benefit from 
biventricular support. Therefore, there is a need for mechanical biventricular assistance.  
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1.2.7 Dual Rotary Left Ventricular Assist Devices as Biventricular Assist Devices 
The aforementioned advantages of rotary VADs have encouraged their use as LVADs over the last 
decade. However, biventricular support with rotary VADs is difficult because there are no commercially 
available rotary RVADs. There are some rotary BiVAD systems under development [44], [45], however 
it may be a long time before these devices are ready for clinical implantation. For this reason, clinicians 
have implanted two rotary LVADs as a BiVAD [16], [17], [46]–[48]. An example of this is shown in 
Figure 1.9. The small size of rotary LVADs enabled total implantation of both pumps, whilst their long 
durability has enabled long support durations and in some cases enabled rotary BiVAD patients to be 
discharged from the acute care environment [16].  
Despite the aforementioned success of dual rotary LVAD 
systems, setting appropriate pump speeds in order to 
achieve balance between systemic and pulmonary flow is 
difficult[16], [18]. Without careful management of pump 
speeds and therefore flow rates, there is a higher risk of 
causing systemic or pulmonary oedema (flooding of the 
circulations). Flow management is performed by adjusting 
pump speeds under the guidance of echocardiography [50]. 
However, frequent adjustments must be made – Saito et al. 
(2011) report daily adjustments of speed in the immediate 
postoperative period [18]. Furthermore, as the patient's 
condition improves and they become more active, 
corresponding changes in the patient's circulatory system 
may disturb the flow balance previously established by the 
clinician in the acute care setting. This may limit their 
capacity to perform common daily tasks. 
The main reason for the problem of balancing flows in a dual rotary LVAD system is that, unlike the 
native heart, rotary blood pumps do not have a Frank-Starling mechanism. In other words, the flow rate 
of blood is not as sensitive to preload as the native ventricle. 
1.2.8 Preload Sensitivity of Rotary Ventricular Assist Devices 
The sensitivity of a native healthy ventricles to changes in preload (the Frank-Starling law) was 
discussed in Section 1.2.3. It is the primary autoregulatory method of the ventricles and ensures that the 
volume of blood ejected each heartbeat (and consequently total flow rate) depends on the volume of 
blood that fills the ventricle. In contrast, when operated at a constant speed, the flow rate produced by 
a rotary VAD depends not on the pump preload (inlet pressure) but the difference between outlet and 
inlet pressure (effectively the differential between afterload and preload). Studies by Salamonsen et al. 
 
Figure 1.9: Two HeartWare HVADs 
(HeartWare Inc., Massachusetts, USA) 
implanted as a biventricular assist device 
[49] 
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[51] and Fukamachi et al. [52] have both shown that this difference in dynamics means that rotary 
pumps are less sensitive to isolated changes in preload than the native ventricle, and even pulsatile 
pumps, when operated at a constant speed (Figure 1.10). Supporting a failing ventricle, which already 
has a diminished preload sensitivity, with a device that has low preload sensitivity may result in the 
under- or over-pumping of blood from the ventricle. Under-pumping means that increased venous return 
caused by increased patient activity will not be compensated for by sufficient increase in VAD flow. 
This may result in excess venous blood damming up the atria, placing limitations on the patient's 
exercise capacity, and may lead to pulmonary or systemic venous congestions. On the other hand, over-
pumping occurs when VAD flow exceeds venous return. This results in a reduction in ventricular 
volume. Excessive over-pumping can result in complete drainage of the ventricle, which causes collapse 
of the ventricle wall over the inlet cannula of the VAD in a phenomenon known as ventricular 
suction[53]. Suction may result in reduced forward flow of blood, haemolysis, ventricular arrhythmias 
and tissue damage at the VAD inlet cannula site [50], [53]–[56].In order to change pump flow rate more 
dramatically during significant preload changes, speed changes are required. 
 
 
Whilst the patient is in the acute care setting, speed changes can be performed under the guidance of 
echocardiography to minimise the risk of over- or under-pumping. However, VAD patients are 
commonly discharged home when their condition improves[57], [58].This means that the rotational 
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Figure 1.10: Preload sensitivity of the native left ventricle and some commercially available rotary VADs at three 
different afterloads. Data obtained from Salamonsen, Ayre and Mason (2011) [51]. 
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speed of their pumps remains fixed for longer periods of time. Discharged patients are also more active 
than their acute care counterparts, resulting in more variations in venous return as they undergo common 
patient scenarios. These two factors mean that discharged rotary BiVAD patients are more predisposed 
to ventricular suction and flow imbalance. There is clearly a need for a control system that can 
automatically vary the speed of both pumps to meet these criteria. 
1.2.9 Physiological Control of VADs 
Physiological control systems for rotary LVADs are designed to automatically adjust LVAD output in 
order to prevent ventricular suction and to match LVAD flow to meet cardiac demand. Significant 
research has been conducted in the field of rotary LVAD control, however little of this research has 
been extended into the control of dual LVADs. Literature reviews of LVAD and BiVAD control 
systems are presented in Chapters 4 and 5 respectively. 
Boston, Antaki and Simaan (2003) highlighted three design criteria that should be fulfilled by an LVAD 
physiological control system[59], based on discussions with clinicians in their institute. These criteria 
are 
 Cardiac output should be above the minimum value (usually between 3-6 L.min-1) required to 
support the activity level of the patient 
 Left atrial pressure (LAP) should be maintained below 10-15 mmHg to avoid pulmonary 
oedema and above 0mmHg to avoid suction. 
 Systolic arterial pressure should be maintained between patient specific limits to limit 
sensitivity to afterload. 
Given that arterial pressure is predominately modified pharmacologically, a physiological control 
system for an LVAD should adjust pump speed primarily to maintain preload within a reasonable range 
whilst ensuring suitable cardiac output. BiVAD control systems should also meet these criteria as well 
as the equivalent criteria for pulmonary circulation. Therefore, right atrial pressure (RAP) should be 
subject to the same criteria as left LAP, whilst pulmonary arterial pressure (PAP) should be maintained 
between patient limits like aortic pressure (AoP). 
A physiological control system that can automatically adjust the speed of both pumps to maintain 
balanced flows would improve the survivability, quality of life and exercise tolerance of dual rotary 
LVAD patients who are discharged home. Design and testing of such a system requires an appropriate 
evaluation environment. 
1.2.10 Evaluation of Control Systems for Ventricular Assist Devices 
Prior to their approval for clinical use, control systems for VADs require thorough performance 
evaluation in order to prove their efficacy. This section briefly summarises the testing apparatus used 
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for evaluation of rotary LVADs and their control systems. A literature review of the tests used to 
quantify control system performance is given in Chapter 3. 
1.2.10.1 In-silico evaluation 
Preliminary control system design and evaluation is performed in-silico, using a numerical model (NM) 
of the circulatory system. Numerical models used for control system evaluation commonly represent 
the circulatory system using lumped parameter models (Figure 1.11). Sections of the circulation are 
lumped together and given a single value for vessel resistance (R), compliance (C) and inertance (L). 
These values are represented using the electrical analogues of resistance, capacitance and inductance 
respectively. Flow and fluid pressure are represented as electrical current and voltage respectively. Each 
lumped element is effectively a second-order RLC circuit. 
 
 
The heart chambers are modelled in a slightly more complex manner. Each chamber is modelled with 
its own RLC circuit. The compliance is variable, with time-varying elastance theory used to represent 
changes in ventricular and atrial wall stiffness during the cardiac cycle. Briefly, the pressure-volume 
relationship within each heart chamber is modelled using Equation (1.1). 
 𝑃(𝑡) = 𝑒(𝑡)𝑃𝑒𝑠 + (1 − 𝑒(𝑡))𝑃𝑒𝑑 (1.1) 
 
where P(t) represents the intraventricular pressure, Pes the end-systolic pressure, Ped the end diastolic 
pressure and e(t) the time varying elastance function. This function enables transitions from end-
diastolic pressure to end-systolic pressure in a manner similar to the native heart and is independent of 
preload and afterload [61], [62] (Figure 1.12).  
Figure 1.11: Example of a lumped parameter model of an LVAD and the cardiovascular system [60]. 
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Figure 1.12: Example of a time-varying elastance function [63] 
 
Both Pes and Ped are calculated as functions of ventricular volume, known as end-systolic (ESPVR) and 
end-diastolic (EDPVR) pressure volume relationships respectively. Figure 1.13 shows an example of 
ESPVR and EDPVR curves. The ESPVR is usually linear, with the slope dictating the inotropic state 
of the heart.  Changes to ESPVR are used to change the inotropic state of the heart independently of 
preload, therefore enabling simulations of heart failure (reduced ESPVR) or exercise (higher ESPVR). 
Diodes are placed between atrial and ventricular circuits and between ventricular and arterial circuits to 
simulate the function of the heart valves to complete the simulation of the native heart. 
 
 Figure 1.13: Example of end-systolic (Es) and end-diastolic (Ed) pressure-volume 
relationshitionships used in in-silico modelling of heart chambers [63]. 
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Since the numerical model is a combination of lumped elements, the model order is governed by the 
total number of lumped elements. Thus model complexity can be scaled by increasing or reducing the 
number of lumped elements. The higher the complexity, the higher the model accuracy but the longer 
the time it takes to solve and the more difficult the control design. Conversely, over-simplification 
decreases simulation time but results in less accuracy and can result in poor control system design.  
One advantage of using numerical models for control system evaluation is that all individual circulatory 
parameters can be varied precisely. This enables detailed and quantitative understanding of low-level 
control system behaviour for a variety of circulatory conditions. This environment is therefore ideal for 
evaluating typical control system characteristics, such as rise and settling times, overshoot and steady 
state error. Additionally, numerical models provide a safe environment for control system design and 
development. Failure modes and design flaws can be identified and corrected quickly before moving to 
in-vitro or in-vivo evaluation, where the consequences of failure can be costly. One key limitation of 
numerical models is the difficulty of modelling rotary pump dynamics in-silico. The dynamic effects of 
the pump must be isolated from those of the circulatory system and pump cannulae. Only then can these 
components be independently varied in order to reflect the inter-patient differences in circulation 
dynamics, cannula length, and inflow/outflow cannula placements. Finally, another limitation of most 
models is that inclusion of more complex phenomena such as non-linear vessel wall compliance 
increases model complexity and therefore computation time.  
1.2.10.2 Mock Circulation Loops 
  
 
After control system evaluation in the NM, the system is usually next simulated in a bench top 
environment using a mock circulation loop (MCL). Like numerical models, MCLs are lumped 
parameter models. However, MCLs are mechanical rather than mathematical representations of the 
heart and circulatory system. An example of a MCL is shown in Figure 1.14. 
Figure 1.14: Mock circulation loop (left) and schematic (right), located at The Prince 
Charles Hospital [64]. 
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Mock circulation loops incorporate time-varying elastance theory to simulate the changes in ventricular 
wall stress. Early MCLs did not actively replicate the Frank-Starling mechanism of the heart, so the 
preload sensitivity of these models were very low. More recently, preload-sensitive ventricluar 
contraction has been incorporated, ensuring that the pressure-volume relationships were similar to those 
modelled numerically.  
One advantage of MCLs include the ability to test control systems using real pumps, which means that 
the effect of practical issues such as actuator limits and non-linearities on the control system can be 
evaluated. Additionally, as pump dynamics are difficult to model in-silico, in-vitro evaluation is 
required to gain a true understanding of system behaviour. The use of a bench top testing rig allows 
realistic analysis of pump control systems without the difficulties and risks associated with animal or 
human studies. Like numerical models, repeatability is high and some parameters can be easily 
controllable. However, one disadvantage is that it is generally difficult to vary the compliance in the 
loop, limiting the number of scenarios that can be simulated. Additionally, the cost and difficulty of 
adding more lumped elements to the system is greater in the MCL than in NM due to the mechanical 
nature of the system. 
1.2.10.3 In-vivo Models 
Unlike in-silico and in-vitro evaluation, in-vivo evaluation involves testing a VAD control system using 
an animal model. Sheep, goats and cows are the most commonly used. The main advantage of in-vivo 
evaluation is that the controller's effect on real, not simulated, haemodynamics can be assessed. This is 
an essential step before a controller can be clinically accepted. However, in-vivo studies are expensive. 
Long term recovery studies are more expensive than short-term acute studies because of the staff and 
equipment requirements. In-vivo experiments are also highly variable, due to the natural differences 
between animals. This is more reflective of the variable nature of clinical evaluation, however it makes 
it difficult to consistently characterise control system performance. Another disadvantage of in-vivo 
studies is that models of heart failure are difficult to obtain in a stable and reproducible manner, and 
extreme conditions cannot be tested without loss of the animal. Therefore, in-vivo evaluation should 
primarily be used to confirm control system performance already established in-silico and in-vivo, and 
to assess effects of systems on haemolysis, thrombosis and survivability.  
1.2.10.4 Clinical Trials 
Clinical trials are necessary in order for physiological control systems to gain regulatory approval and 
therefore be incorporated into medical devices. These trials are useful for established long term efficacy 
and benefits of physiological control systems. However, these trials are expensive and are inherently 
high-risk due to the use of human subjects. 
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1.3 Thesis Outline 
The structure of this thesis closely follows the aims outlined in Section 1.1. 
Chapter 2 describes the evaluation of current methods of dual LVAD operation. It highlights that while 
all current methods of dual LVAD operation can produce stable steady-state haemodynamics, speed 
changes are required to maintain pulmonary and systemic flow during changes in vascular resistance. 
This chapter sets the scene for the remainder of the thesis. This chapter is based on the publication "In-
vitro and in-vivo characterisation of three different modes of pump operation when using an LVAD as 
an RVAD" in the scientific journal Artificial Organs.  
A physiological control system may be able to automatically adjust the speed of both pumps to 
accommodate changes in the circulatory system. Before development of such as system can commence 
a suitable evaluation framework must be established. Chapter 3 describes the methodology that was 
used to assess both LVAD and BiVAD control systems developed throughout the thesis. It summarises 
previous methods of control system evaluation and justifies the case for more thorough, quantitative 
comparison. 
There has been significant work in the field of physiological control of rotary LVADs, and it may be 
possible to adapt one of the better performing single-LVAD control systems for use in a dual LVAD. 
However, inconsistent evaluation techniques between investigators means that direct comparison of 
controllers from literature is not possible. Chapter 4 describes the comparison of a number of control 
systems from literature using the evaluation framework established in Chapter 3. The result of this 
chapter is an experimental justification of the LVAD control system adapted for use in Chapter 5. 
The best control system determined from the experiments in Chapter 4 was modified to become a 
physiological control system for dual LVAD operation. The design and evaluation of this controller is 
discussed in Chapter 5. 
Chapter 6 brings together the final conclusions from all chapters, highlights some of the limitations of 
this thesis and makes recommendations for future work.   
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2 Current Operating Modes of Dual Left Ventricular Assist Devices 
The success of implantable rotary LVAD support, in conjunction with a lack of a clinically available 
long-term rotary implantable RVAD, has led to clinicians using dual implantable rotary LVADs in order 
to achieve long term biventricular support. Three methods of adapting an LVAD for right ventricular 
support have been proposed in literature. These are operating the right pump at a lower speed than the 
left pump, operating both devices at their design speeds while relying on the cardiovascular system to 
adapt, and operating both pumps at their design speeds while restricting the diameter of the RVAD 
outflow graft. These three methods have been used clinically, however their effects on haemodynamics 
have yet to be compared experimentally. 
The purpose of this chapter is to investigate how clinicians have previously managed dual LVAD 
operation in the clinical arena. The chapter begins with a review of the literature surrounding this field, 
which identifies three different operating modes. These three modes are then compared using a mock 
circulation loop and an acute non-recovery animal model in order to determine their effects on aortic 
pressure, left atrial pressure and cardiac output.  
The significance of this chapter is that it presents a thorough comparison of the three modes of operation 
of dual rotary LVADs for the first time. Clinicians can use the findings from this experiment to aid in 
identifying which approach is best for their patient. Another significant finding in this chapter is that it 
establishes that there is a need for physiological control systems for dual rotary blood pumps.  
The work completed in this chapter has been published as a manuscript entitled "In-vitro and in-vivo 
characterisation of three different modes of pump operation when using an LVAD as an RVAD" in the 
scientific journal Artificial Organs (published online March 26 2014). The methods and results of this 
chapter were taken directly from that publication. The introduction was extended to provide the reader 
with more background information, and the conclusion extended to provide context for this thesis. 
2.1 Aim 
The aim of this chapter was to assess the ability of current modes of operation of dual LVADs with 
respect to restoring resting patient haemodynamics and responding to transient changes in pulmonary 
vascular resistance (PVR) and preload. To meet this aim, a number of objectives were devised. 
 Review the literature regarding clinical and experimental use of dual LVADs as a BiVAD 
 Compare current operating modes in-vitro. 
 Compare current operating modes in-vivo. 
 Make recommendations for each mode, and highlight areas where physiological control may 
improve functionality. 
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2.2 Literature Review 
The first reported use of dual rotary LVADs as a BiVAD was by Frazier et al. (2004) who implanted 
two Jarvik 2000 LVADs (Jarvik Heart Inc., New York, NY, USA) [40]. The right pump was implanted 
because RV function worsened after LVAD-only support. The patient only lived for 12 days post-
implant, but the authors suggest that earlier RVAD implantation may have benefitted the patient. Device 
speeds were not mentioned in this paper. Since then, dual rotary LVADs have been used numerous 
times to provide biventricular assistance. 
In many of these cases, the functionality of both ventricles can be severely reduced, or sometimes non-
existent. Consequently, the flow balancing ability of the ventricles is reduced because of their 
diminished Frank-Starling response. Therefore, management of left and right pump speeds is important 
to prevent ventricular suction or venous congestion. Three different management strategies have 
emerged. 
2.2.1 Mode 1: RVAD speed lower than LVAD design speed. 
Adaptation of an LVAD for RV support may require reduction of the output power relative to the left 
pump. The simplest way that this can be achieved is by operating the RVAD at a speed lower than the 
design speed. This results in a lower flow rate for a given differential pressure. This section summarises 
all clinical and experimental reports of this mode of operation. 
Dual Jarvik 2000 support was performed by Saito et al.(2011)[19]. Initially LVAD and RVAD speeds 
were set to 10 000 and 7 000 RPM respectively. As the minimum speed of the Jarvik 2000 pump is 8 
000 RPM, a custom pump controller was manufactured in order to reach the lower RVAD speed. During 
the initial post-operative period, left and right pump speeds were adjusted frequently under the guidance 
of echocardiography. After extubation, the patient's PVR fell, resulting in a sudden increase in right 
pump flow rate. A reduction in RVAD speed to 6 000 RPM and an increase in LVAD speed to 11 000 
RPM were required to reduce the onset of pulmonary oedema. 
Saito et al. (2011) also performed biventricular support using a Terumo DuraHeart (centrifugal flow 
pump) as an LVAD and a Jarvik 2000 (axial flow pump) as an RVAD. After implantation, weaning off 
bypass was difficult because of the presence of RV suction. Normally RV suction would be mitigated 
by reducing RVAD speed, however this was impossible, because the RVAD was operated at the 
minimum pump speed for the Jarvik 2000. Weaning was therefore performed more slowly under the 
guidance of transoesphegol echocardiography with the aid of volume management and acute speed 
adjustments. More volume balancing issues occurred after extubation, which resulted in severe 
pulmonary congestion. It was thought that PVR was suddenly reduced after extubation, which lowered 
RVAD afterload (and therefore differential pressure). This resulted in an increase in right pump flow 
rate and therefore pulmonary congestion. It was relieved by increasing the LVAD speed from 1600 to 
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1900 RPM. This paper highlighted that one of the disadvantages of operating the RVAD below the 
design speed for LVAD use is that there is little to no reserve for speed reductions during RV suction 
events. 
The first reported implantation of dual HeartWare HVADs clinically was by Strueber et al. (2010) [47]. 
Initially, the LVAD was operated at 3600 RPM and the RVAD at 2000 RPM, but speeds were later 
reduced to 3100 and 1900 RPM respectively. Pump flows were estimated by the pump controllers to be 
4.5 - 5.5 Lmin-1. Spontaneous breathing caused fluctuations in LAP, which peaked at the beginning of 
inspiration. A constant low flow alarm was present from the right pump controller; however 
echocardiography revealed that there was no regurgitant flow, so the estimated flow rate was deemed 
incorrect and therefore the alarm was turned off. The high LVAD speed suggests high energy input into 
the system, yet the flow estimations were within normal ranges. This indicates that either the vascular 
resistance may have been elevated or the flow rate estimate was incorrect. 
Clearly the simplest method of adapting an LVAD to support pulmonary circulation is via reducing the 
right pump speed. This can be adjusted on a patient-by-patient basis. It must be noted, however, that 
operating the device at a low speed limits the capacity to further reduce pump speed in the event of RV 
suction. Additionally, hydrodynamically levitated impellers rely on sufficient speed to create a fluid 
film and thus may become unstable at these lower speeds. Whilst this issue is negated in 
mechanically/pivot supported impellers, the ensuing reductions in outflow pressure also potentially 
reduces the washout through the small impeller/casing clearances in the device, which in turn may 
increase the risk of thrombosis [65]. 
2.2.2 Mode 2: Operating both pumps at the same design speed 
The previous section highlighted advantages and disadvantages to operating the RVAD at a lower speed 
than the LVAD. A second mode of operation is to set both pump speeds at identical design speeds. 
However, there is a discrepancy between pump theory and experimental/clinical observations.  
Hetzer et al. (2010) speculated that operating both pumps at the same speed will result in different flow 
rates, due to different differential pressures across each device [48]. This is due to the significantly 
lower RVAD afterload, caused by much lower PVR (compared to systemic vascular resistance (SVR)). 
The right pump would therefore shift more volume than the left, resulting in overflow pulmonary 
oedema and/or RV suction. This mode appears to be dangerous to the patient, however evaluation of 
this mode would be beneficial in that it could establish the magnitude of potential complications if it 
were attempted. 
The best example of the clinical use of this mode was when the HeartWare HVAD was used for isolated 
RV support [66]. Personal correspondence with the author revealed that the pump was operated at the 
design speed for LVAD use (2400-2800 RPM). There was no evidence of overflow pulmonary oedema 
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or RV suction, which seems to contradict the assumption of Hetzer and colleagues. However, the 
healthy LV may have accommodated increased pulmonary flow via the Frank-Starling mechanism.  
Two experiments have investigated this mode using dual Jarvik 2000 LVADs, as part of a larger study. 
Kindo et al. (2004) implanted two Jarvik 2000s as a BiVAD into two calves for thirty days [67]. The 
pumps were implanted without bypass, and a custom controller was used to operate the RVAD across 
a lower range of set speeds. LVAD speed was kept constant throughout the 30 day study. For the 
majority of the 30 days the RVAD speed was kept below LVAD speed. On the final day, the effect of 
speed variations on pressures was investigated. Operating both devices at the same speed did not result 
in excessive LAPs or flow rates, and no pulmonary congestion was present. However, the authors report 
thrombus formation in the outflow graft of the RVAD. This may have acted as a flow-restrictor, 
preventing LV overflow. Furthermore, the speeds were changed in 15 minute intervals, which may have 
allowed enough time for the circulatory system to adapt to each change. Finally, ventricular contractility 
was not modified pharmacologically, which meant that the residual Frank-Starling mechanism of the 
LV could accommodate increases in right pump flow. 
Radovancevic et al. (2003) performed an acute in-vivo study of biventricular support using dual Jarvik 
2000 LVADs [68]. After implantation the heart was fibrillated to produce a worst case scenario for 
heart contractility. Both pumps were initially clamped and baseline haemodynamics were obtained. 
LVAD was unclamped first, then RVAD. Speed was gradually increased for both pumps until both 
were at the maximum (12000 RPM). Increasing RVAD speed with constant LVAD speed resulted in 
increased AoP, PAP and LAP. However all pressures and flows were kept within normal ranges for 
human cardiovascular support, with maximums of 100, 22 and 16 mmHg for AoP, PAP and LAP 
respectively. Flow rate at maximum speeds was only 4.5 L.min-1. This low flow rate at high speeds 
might be as a result of high PVR or SVR, which could explain the lack of congestion. 
In summary, the assumptions made by Hetzer and colleagues (2010) with respect to operating the right 
pump at its design speed are only sound if there is assumed to be little-to-no ventricular function, which 
may be the case during the initial post-operative period [48]. However, if the ventricular function 
recovers, then the native Frank-Starling response of the ventricles can compensate. In cases in which 
there is some ventricular function in conjunction with reduced afterload, the ventricles are able to eject 
blood through the semilunar valves in parallel to the pump flow, the quantity of which is dependent on 
ventricular preload. This may explain why Kindo et al. (2004) were able to operate both LVADs at their 
design speed without observing pulmonary or systemic venous congestion [67]. It also almost certainly 
explains why an LVAD can be used to support isolated RV failure, as discussed by Deuse et al. (2013) 
[66].  
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2.2.3 Mode 3: Operating the RVAD at design speed and restricting RVAD outflow diameter. 
The previous section summarised the theoretical difficulties with attempting to operate the RVAD at its 
design speed because of the lower differential pressure across the pump. Mode 3 involves artificially 
increasing RVAD afterload by restricting the diameter of the RVAD outflow graft, effectively reducing 
pump flow to a normal level. 
Hetzer et al. (2010) were the first to promote the concept of restricting the RVAD outflow graft when 
using a HeartWare HVAD as an RVAD. Their justification was that the HeartWare HVAD should be 
operated at its design speed to prevent impeller instability and thrombus formation inside the pump. 
However, as explained in the aforementioned section, this may result in LV overflow because of the 
low PVR. Restricting the RVAD outflow cannula increases the effective total PVR, thereby increasing 
the RVAD differential pressure and reducing pump flow (Figure 2.1) when operated at the design speed.  
 
 
 
The authors implanted dual HVADs into 8 patients, with the 6 surviving patients successfully 
discharged. In-vitro investigations revealed that banding the RVAD outflow diameter to 5mm was 
sufficient to reduce RVAD flow to a sufficient level, so this was the diameter chosen for most patients. 
One patient required a banding diameter of 7mm due to elevated PVR. This indicates that one level of 
banding diameter is not suitable for all patients, and perhaps adjustable banding would be beneficial. 
Banding was facilitated before surgery by suturing a piece of graft with 6-0 Prolene over a 5-mm Hegar 
dilator bar (Figure 2.2). 
Figure 2.1: Effect of banding of the RVAD outflow cannula on the pump curve operation[48]. 
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Numerous investigations into the effect of banding of the HVAD outflow graft have been performed by 
Krabatsch and colleagues in 2011 [16], [17], [69].The effects of varying RVAD outflow diameter from 
4 to 10mm were investigated in-vitro using a mock circulation loop. It was found that without banding 
and a normal level of PVR, the HVAD delivered between 6.5 and 8 L.min-1of flow, much higher than 
the normal resting cardiac output of 5 L.min-1. Normal flow rates were restored by restricting the 
outflow graft diameter.  
The authors stated that in order for LVAD and RVAD to operate at the same speed, the effective PVR 
(graft resistance plus vessel resistance) must equal the total systemic resistance. The authors state that 
PVR is dynamic and unpredictable, and so a dynamic restriction to automatically adjust RVAD outflow 
cannula resistance might be suitable. Alternatively, dynamic PVR could be accommodated for by fixing 
the RVAD diameter at 6mm and adjusting RVAD speed. Since rotary VADs are operated at a constant 
speed, frequent speed changes would require regular interaction with a clinician. 
Based on these successful in-vitro findings, Krabatsch and colleagues reported the implantation of dual 
HVADs into 17 patients [16]. Patients with normal PVR received a 5mm outflow graft banding 
diameter, whereas patients who presented with an elevated PVR received a 7mm banding. The authors 
reported a 50% survival at 6 months, which is comparable to recently published INTERMACS data for 
BiVAD patients [70]. The authors commented that PVR appeared to gradually decline in some patients, 
and that RVAD speed was reduced to accommodate. However, the length and rate of this decline is 
generally unpredictable. This highlights one of the difficulties of using a fixed banding diameter. The 
diameter chosen at the time of implantation must ensure that the new operating ranges for pump speed 
can accommodate the gradual decline of PVR.  
Additional case reports by Loforte and colleagues [71], [72] and McGee et al. [49] confirm that the 
banding the RVAD outflow graft to 5mm when using dual HeartWare HVADs as a BiVAD is a safe 
method of adopting an LVAD for RV support. However, the diameter is dependent on each patient's 
PVR, which is dynamic and unpredictable. The inclusion of some system to automatically adjust the 
right pump output with changes in PVR may offer some benefit. 
2.2.4 Comparisons 
The previous sections summarised the clinical use of dual LVADs as a BiVAD, and the different modes 
of operation used by clinicians. However, these methods have only been experimentally compared once, 
Figure 2.2: Banding procedure as performed by Hetzer and colleagues [48] using a 5mm dilator. 
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by Timms et al. (2011)[73]. In that study, a biventricular HF condition was simulated in a MCL and 
biventricular support provided by dual Medos DeltaStream pumps. LVAD and RVAD speeds were set 
to obtain normal systemic and pulmonary pressures and flow rates respectively. Then RVAD speed was 
varied from 500 to 4500 RPM in order to evaluate the sensitivity of speed variations on pulmonary 
pressures and flows. Then RVAD speed was set to the LVAD speed and the diameter of the RVAD 
outflow was adjusted (using a pinch valve) until normal pulmonary haemodynamics were obtained. 
Then RVAD outflow diameter was varied to evaluate the sensitivity of diameter variations on 
pulmonary pressures and flows. 
The authors found that RVAD speed should be significantly lower than LVAD speed without banding 
(3500 vs. 4900). A banding diameter of 5.4mm was required to operate both pumps at 4900 RPM. The 
authors found that sensitivity of flow and pressure was highest when the RVAD flow exceeded LVAD 
flow, which occurred between RVAD speeds of 3200 - 4400 RPM or outflow diameters of 5.3- 6.5mm. 
This indicates that only a slightly incorrect RVAD speed or outflow diameter may result in excessive 
pulmonary flow which may lead to pulmonary congestion. Whilst this study did not use long-term 
implantable rotary LVADs, the results are still relevant as the Medos pumps are centrifugal pumps like 
the HeartWare HVAD. 
2.2.5 Summary of Literature Review 
In summary, there are three modes of operation of dual rotary LVADs that are used in clinic. Firstly, 
RVAD speed can be set lower than LVAD speed. This reduces the output of the right pump relative to 
the left, reducing the likelihood of pulmonary congestion. However, this means that the RVAD speed 
will be close to the minimum pump speed, leaving no reserve to further reduce speed in the event of 
ventricular suction. Additionally, operating below the design point increases the likelihood of 
thrombosis in the pump due to lower washout, and may affect the stability of pumps that rely on 
hydrodynamic forces to lift the impeller. The second option is to operate both pump speeds at the design 
point. Theoretically, operating the RVAD and LVAD at the same speed will result in excess pulmonary 
flow, possibly leading to congestion. However, this was not observed in in-vivo experiments using two 
axial flow pumps. The final method is to operate both pumps at the same speed in conjunction with 
banding of the right pump outflow graft, effectively reducing right pump output relative to left. This 
method requires consideration of both pump speed and banding diameter, and both should be adjusted 
depending on the patient's PVR.  
Clearly there are advantages and disadvantages to each operating mode. Each mode will result in 
different patient haemodynamics, which should be characterised to provide clinicians with a more 
comprehensive understanding of dual LVAD support in the biventricular heart failure setting. 
The aim of this study was to characterise each of these three modes using an in-vitro and a preliminary 
in-vivo model of biventricular heart failure. This investigation involved measuring the steady-state 
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effects of each operating mode on mean arterial pressure (MAP), LAP and mean systemic flow rate 
(MSQ) and determining if these values remained in clinically safe regions. Pump speed changes 
required to accommodate for dynamic variations in pulmonary vascular resistance, as may occur during 
straining, were also measured. Based on these results, recommendations were made for each operating 
mode and for the future development of biventricular support with two LVADs. 
2.3 Hypothesis 
The main hypothesis for this chapter is that none of the three modes of operation would be able to 
accommodate dynamic changes in the circulatory system without changes in either banding diameter 
or pump speed.  
2.4 Methods 
2.4.1 In-Vitro Evaluation 
A physical five element Windkessel mock circulation loop (MCL) including systemic and pulmonary 
circulations was used for this study[74], [75]. In brief, ventricular systole was controlled through a 
series of electropneumatic regulators (ITV2030-012BS5, SMC Pneumatics, Tokyo, Japan) and 3/2 way 
solenoid valves (VT325-035DLS, SMC Pneumatics, Tokyo, Japan) to provide passively filled heart 
chambers and variable contractility, heart rate and systolic time. Heart rate and systolic time were 
maintained at 60 beats per minute and 35% respectively throughout this study. The inotropic state of 
each ventricle (contractility) was modified by changing the maximum regulator supply current each 
cardiac cycle, effectively a surrogate for changing the slope of the ESPVR. A Starling response was 
implemented in both left and right ventricles which actively controlled ventricular pressure (through 
electropneumatic regulator supply current) based on ventricular preload. This mechanism was 
developed in collaboration with Dr Shaun Gregory and details of its implementation and validation can 
be found in [76]. Briefly, this mechanism varied the magnitude of the ventricular air regulator voltage 
based on a logarithmic function of the end-diastolic ventricular volume. The new equation for regulator 
voltage is given in Equation (2.1). 
 𝑉𝑟𝑒𝑔(𝑡) = V𝑃(𝑡). 𝐾𝑠𝑡𝑎𝑟𝑙𝑖𝑛𝑔(𝑡). 𝐾𝑣𝑒𝑛 (2.1) 
  
where Vreg(t) is regulator voltage, VP(t) is the time varying voltage waveform sent to the 
electropnuematic regulator in order to produce true ventricular pressure waveforms (details of which 
can be found in [74]), Kven is a scalar that changes the magnitude of the waveform for RV or LV 
contractility, and Kstarling(t) scales the regulatory voltage based upon the current end-diastolic volume to 
simulate the Frank-Starling effect. Kstarling(t) is calculated at the end of diastole each cardiac cycle using 
Equation (2.2). 
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 𝐾𝑠𝑡𝑎𝑟𝑙𝑖𝑛𝑔(𝑡) = 𝐾𝑠𝑚1. 𝑙𝑛(𝐾𝑠𝑚2(𝐸𝐷𝑉(𝑡) + 𝑐𝐸𝐷𝑉)) + 𝑐𝑠𝑚1 (2.2) 
 
Where EDV(t) is the ventricular end-diastolic volume (mL), Ksm1 and Ksm2(mL-1) set the sensitivity of 
the ESPVR, and cEDV (mL) and csm1 set the horizontal and vertical offset of the ESPVR respectively. 
These constants were adjusted for left and right ventricles to match the human ESPVRs presented by 
Guyton [77]. Further details of this mechanism and its validation can be found in [76]. The values of 
Kven, Ksm1, Ksm2, CEDV and CSM1 for three cases of heart function for left and right ventricles are given 
in Appendix A. 
Mechanical check valves were used to simulate the mitral, aortic, tricuspid and pulmonary valves to 
ensure unidirectional flow throughout the circuit. Four independent Windkessel chambers were 
employed to simulate lumped systemic and pulmonary arterial and venous compliance. Socket valves 
(VMP025.03X.71, Convair Engineering, Epping, Australia) allowed easy manipulation of systemic and 
pulmonary vascular resistance respectively. The working fluid throughout this study was a 
water/glycerol mixture (60/40% by mass) with similar viscosity and density to that of blood. 
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Figure 2.3: Schematic of the MCL setup for evaluation of aortic valve regurgitation with rotary biventricular 
support. LA - left atrium, MV - mitral valve, LV - left ventricle, AoV - aortic valve, AoC - aortic compliance 
chamber, SQ - systemic flow meter, SVR - systemic vascular resistance valve, SVC - systemic venous compliance 
chamber, RA - right atrium, TV - tricuspid valve, RV - right ventricle, PV - pulmonary valve, PAC - pulmonary 
arterial compliance chamber, PQ - pulmonary flow meter, PVR - pulmonary vascular resistance valve, PVC - 
pulmonary venous compliance chamber, LVAD - left ventricular assist device, LVADQ - left ventricular assist 
device flow meter, RVAD - right ventricular assist device, RVADQ - right ventricular assist device flow meter. 
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Two VentrAssist LVADs (Ventracor Ltd., Sydney, Australia) were used to provide biventricular 
circulatory support. Each pump was cannulated with inflow connected to the ventricle and outflow to 
the aorta (LVAD) and pulmonary artery (RVAD). Half-inch diameter tubing (Tygon 06408-18, Saint 
Gobain, Paris) was used for the outflow grafts. Pumps were operated using a custom-built breakout box 
which enabled a greater range of set speeds (1200 – 3500 RPM) compared with standard VentrAssist 
controllers. 
Three experiments were performed to characterise each of the three operating modes. In the first 
experiment, steady state characteristics of all three modes were determined for a number of different 
heart and circulatory conditions. Three different combinations of left and right heart ventricular failure 
were simulated in the MCL (Table 2.1) by adjusting the maximum electrical supply current for each 
ventricle's electro-pneumatic regulator. Biventricular support was achieved using each of the three 
modes of operation. For mode 1, left and right pump speeds were set at 2800 and 2000 RPM 
respectively. For modes 2 and 3, both pumps were operated at 2400 RPM. In mode 3, the outflow 
restriction diameter was set at 6.5mm, which was determined prior to experimentation to be the 
optimum banding diameter for these speeds. 
Condition 
LVF RVF LAP 
(mmHg) 
MAP 
(mmHg) 
RAP 
(mmHg) 
MPAP 
(mmHg) 
MSQ 
(L.min-1) 
LVEDV 
(mL) 
RVEDV 
(mL) 
1 Severe Mild 14 51 9 19 2.5 270* 206 
2 Mild Severe 8 60 12 13 3 160 230 
3 Severe Severe 11 48 9 14 2.1 230 225 
 
Each combination of contractility and operating mode were subject to three different settings of vascular 
resistance. Normal resistance was defined as PVR = 100 dynes.s.cm-5and SVR = 1200 dynes.s.cm-5, 
low resistance was defined as PVR = 40 dynes.s.cm-5 and SVR = 600 dynes.s.cm-5, and high resistance 
was defined as PVR = 160 dynes.s.cm-5and SVR = 1800 dynes.s.cm-5. Steady state values of MAP, 
LAP and MSQ were measured in each condition to assess the feasibility of each mode. Feasibility was 
defined as follows: LAP below 25 mmHg to prevent pulmonary congestion [78], MAP below 
100mmHg to limit hypertension and mean systemic flow at 6 L.min-1 to limit hyper flow. Hyper flow 
describes a state in which too much flow is delivered through the circulatory system. 
In the second experiment, the relationship between RVAD outflow cannula resistance and RVAD speed 
for mode 3 was characterised. Firstly, a set of custom RVAD outflow restrictions were designed based 
on the FloWatch® Pulmonary Artery Banding System (FloWatch-PAB, EndoArt, Lausanne, 
Switzerland) [79] and manufactured using a 3-D printer (OBJET 24, Stratasys, MN, USA). These 
Table 2.1: Haemodynamic properties for each biventricular failure condition simulated in-vitro. LVF: level 
of left ventricular failure; RVF: level of right ventricular failure; LAP: left atrial pressure; MAP: mean 
aortic pressure; RAP: right atrial pressure; MPAP: mean pulmonary arterial pressure; MSQ: mean 
systemic flow rate; LVEDV; LV end diastolic volume; RVEDV: RV end diastolic volume. * indicates 
maximum ventricular volume.  
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restrictions ranged in cross-sectional area from 35.6mm2 to 77.7mm2(equivalent diameters of 6.73mm 
to 9.94mm) and were designed for quick placement around the RVAD outflow graft (Figure 2.4). Left 
and right pump speeds were set to those values determined for mode 1 before the smallest restriction 
was placed around the RVAD outflow graft. RVAD speed was then increased to restore PAP and RVAD 
flow (RVADQ) to their baseline values. This procedure was repeated for each restriction, thereby 
characterising the relationship between RVAD outflow graft diameter and pump speed. 
 
 
  
In the third experiment, the effects of dynamic PVR changes with modes 1 and 3 were then evaluated. 
Biventricular HF condition 3 was simulated in the MCL with a PVR of 100 dynes.s.cm-5, LVAD speed 
set at 2200 RPM, RVAD speed set at 2150 RPM (close to LVAD speed), and an initial RVAD outflow 
restriction of 7.77 mm. The PVR was increased to 200 dynes.s.cm-5 in a stepwise manner and the RVAD 
speed was altered until RVADQ was restored to the baseline condition. The test was then repeated but 
with changes in RVAD outflow restriction instead of speed, and for final PVR values of 300, 400, and 
500 dynes.s.cm-5. 
2.4.2 In-Vivo Evaluation 
Ethics approval was obtained from the Queensland University of Technology Animal Ethics Committee 
prior to experimentation (Approval Number 1100001052). One female sheep was used. After induction 
of general anaesthesia, the animal was intubated with a cuffed endotracheal tube and ventilation 
Figure 2.4: Example of a printed restriction used for dynamic variation of RVAD outflow graft diameter. The 
restriction consisted of two pieces (left) that combined around the graft (right) to reduce cross sectional area 
(middle). 
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commenced at 12 breaths/min. The animal was heparinised until an ACT > 480 s was achieved, at 
which point baseline arterial pressures and flow rates were recorded.  
After a median sternotomy, two VentrAssists were implanted without cardiopulmonary bypass. The 
LVAD was implanted first, with the inflow cannula inserted in the left ventricular apex and secured 
using the VentrAssist sewing ring. The outflow cannula was connected to the ascending aorta with an 
end-to-side anastomosis. Both LVAD and RVAD outflow grafts (Gelweave, Terumo Cardiovascular 
Systems, Ann Arbor, MI) were approximately 30 cm long and 12 mm diameter. The pump was placed 
in an abdominal pocket. After implantation, the pump was switched on and speed set to restore arterial 
pressures to baseline.  
After haemodynamics stabilised, the RVAD was implanted. The outflow graft was sutured to the 
pulmonary artery (PA) using an end-to-side anastomosis. An incision was then made in the RV free 
wall, and the inflow cannula was inserted and fed through the tricuspid valve into the right atrium (RA). 
This removed the risk of the interventricular septum occluding the tip of the inflow cannula. Based on 
previous work, the difference between RVAD inflow cannulation in-vitro and in-vivo isn't expected to 
affect the comparison between the in-vitro and in-vivo experiments [64]. 
The cannula was then secured using a purse-string suture, and the pump was switched on. The heart 
was then fibrillated, so there was no ejection through the semilunar valves. This greatly simplified the 
experiment. Left and right pump speeds were individually manipulated to maintain suitable systemic 
and pulmonary haemodynamics (MAP > 60mmHg, PAP ~ 20 mmHg, MSQ> 4 L.min-1).  
After haemodynamics settled, evaluation of the steady state performance of all three modes was 
performed, similar to the first in-vitro experiment. In the first experiment, only one contractility 
condition was assessed due to difficulties in maintaining consistent haemodynamics. Then, the 
relationship between RVAD outflow cannula restriction size and RVAD speed was characterised as per 
the second in-vitro experiment. The effect of transient increases in PVR were also evaluated in-vivo, 
but in a more simplified manner than performed in the third-vitro experiment. Step changes in PVR 
were achieved by tying a felt strip around the PA distal to the anastomosis site. The strip was manually 
tightened to increase PVR, and released to restore the condition to baseline. It is difficult to perform 
repeatable changes in PVR in-vivo, so in-vivo assessment of the relationship between RVAD speed and 
PVR changes was purely qualitative. 
At the end of the experiment, the animal was euthanized using sodium pentobarbitone (295mg/mL at 
0.5 mL/kg). The pumps and outflow cannulae were then explanted and examined for signs of thrombus 
formation.  
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2.4.3 Data Acquisition 
In-vitro systemic and pulmonary flow rates were measured using magnetic flow meters (IFC010, 
KROHNE, Sweden). VAD flow rates were measured using ultrasonic flow probes (TS410-10PXL, 
Transonic Systems, NY, USA). Systemic and pulmonary pressures were monitored throughout using 
pressure transducers (PX181B-015C5V, Omega Engineering, Connecticut, USA). The MCL and 
VentrAssist breakout box were interfaced to a computer using dSPACE hardware (DS1103, dSPACE, 
MI, USA). All signals were sampled at 100 Hz. 
In-vivo, a Swan-Ganz catheter (Swan-GanzCCOmbo, Edwards Lifesciences, Irvine, California, USA) 
was inserted prior to RVAD placement via the external left jugular vein to monitor pulmonary arterial 
pressure. Systemic arterial pressure was monitored via cannulation of the facial artery. Central venous 
pressure (CVP) was monitored at the jugular vein. Left and right VAD flows were recorded using flow 
probes (TS420-10PXL, Transonic Systems, NY, USA). Left and right atrial pressure were measured 
using indwelling catheters, and pump outflow pressures were measured using fluid-filled lines that were 
attached to tubing connectors at the pump outlet. Total pulmonary and systemic flow rates were 
measured by placing flow probes (MC20PAU and MC16PAU, Transonic Systems, NY, USA) around 
the pulmonary artery and ascending aorta respectively. Probes were placed downstream of the 
anastomoses in order to measure the combined flow produced by the pump and the ventricle.   
2.5 Results 
The MAP, LAP and MSQ for each resistance level, heart contractility and operating mode evaluated 
in-vitro are shown in Figure 2.5. Mode 1 resulted in LAP below 25mmHg for all levels of contractility 
and resistance. However, suitable MAP was only attainable during vasodilation; resulting in a flow rate 
above 7 L.min-1.  
Mode 2 resulted in high LAP for all cases except for mild left ventricular failure (LVF)/severe right 
ventricular failure (RVF) with vasodilation. The lower resistance of the pulmonary circulation lowered 
the differential pressure across the right pump, allowing more pulmonary flow than desired. The 
resulting fluid shift increased LAP. The combination of stronger LV contractility and vasodilation 
relieved this congestion. 
In mode 3, restricting the RVAD outflow diameter to 6.5mm enabled both pumps to be operated at the 
same speed without elevating LAP. In addition, MAP was kept below 100mmHg and MSQ less than 6 
L.min-1. Even though the RVAD was operated at the same speed as in mode 2, the reduced RVAD 
diameter increased RVAD outflow cannula resistance, thus increasing the total effective pulmonary 
vascular resistance. The right pump was therefore able to produce flows below 6 L.min-1. 
In contrast to the in-vitro results, all 3 modes were achievable in-vivo with expected levels of LAP, 
MAP and MSQ (Table 2.2). The main difference between in-vitro and in-vivo results was that the 
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unrestricted RVAD outflow graft resistance was much higher in-vivo than in-vitro (observed to be 
between 20 and 40 dynes.s.cm-5 compared to 510 dynes.s.cm-5 in-vivo). The increased resistance was 
due to longer grafts, different material, formation of thrombus evenly along the outflow graft 
(discovered after post mortem examination) and additional resistance caused by the PA anastomosis. 
Increased resistance acted like a diameter restriction by increasing effective PVR, enabling the right 
pump to be operated at its design speed.  
 
  
0
50
100
150
M
A
P
 (
m
m
H
g
)
Mode 1
0
20
40
60
M
L
A
P
 (
m
m
H
g
)
L M H
0
5
10
M
S
Q
 (
L
.m
in
-1
)
Resistance
0
50
100
150
Mode 2
 
 
0
20
40
60
L M H
0
5
10
Resistance
0
50
100
150
Mode 3
0
20
40
60
L M H
0
5
10
Resistance
Mild LVF/Severe RVF Severe LVF/Mild RVF Severe LVF/Severe RVF Upper Limit
Figure 2.5: In-Vitro haemodynamics for three operating modes of dual left ventricular assist devices for different pulmonary 
and systemic vascular resistances (PVR and SVR) and contractilities. MAP: mean aortic pressure; LAP: left atrial pressure; 
MSQ: mean systemic flow; L: low resistance (PVR=40 dynes.s.cm-5 and SVR=600 dynes.s.cm-5); M: medium resistance 
(PVR=100 dynes.s.cm-5 and SVR=1200 dynes.s.cm-5); H: high resistance (PVR=160 dynes.s.cm-5 and SVR=1800dynes.s.cm-5). 
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Operating 
Mode 
LVAD Speed 
(RPM) 
RVAD 
Speed 
(RPM) 
Restriction 
Diameter 
(mm) 
MAP 
(mmHg) 
PAP 
(mmHg) 
LAP 
(mmHg) 
MSQ 
(L.min-1) 
Routflow (dynes.s.cm-5) 
1 2300 1800 None 85 18 9.0 5.5 510 
2 2300 2300 None 83 18 9.0 6.0 514 
3 2300 2300 8.1 81 17 8.0 6.0 1143 
 
Figure 2.6 shows that the RVAD speed required to maintain RVADQ at 5 L.min-1 increased 
exponentially with decreasing RVAD outflow diameter, both in-vitro and in-vivo, due to the 
progressive increase in afterload. The speeds required for each level of restriction were higher in-vivo 
than those observed in the MCL, again due to higher RVAD outflow graft resistance. 
 
 
During in-vitro simulations of elevated PVR, increased speed or outflow graft diameter were required 
to maintain pulmonary flow rate at 5 L.min-1 (Table 2.3). This indicated that dynamic adjustments of 
pump speed or banding diameter may be beneficial to overcome elevated PVR, even transiently as 
occurs in a Valsalva manoeuvre. There was no change in required outflow diameter between 100 and 
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Table 2.2: Haemodynamics observed during in-vivo evaluation of three operating modes for dual left ventricular assist devices. 
LVAD: left ventricular assist device; RVAD: right ventricular assist device; MAP: mean aortic pressure; PAP; mean pulmonary 
arterial pressure; LAP: mean left atrial pressure; MSQ: mean systemic flow rate; Routflow: resistance along the RVAD outflow 
cannula. 
Figure 2.6: RVAD speed vs. equivalent outflow graft diameter for both in-vivo and in-vitro results. RVAD - 
Right ventricular assist device, MCL - Mock Circulation Loop. 
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200 dynes.s.cm-5 because the next largest banding diameter was too large, increasing RVAD flow above 
5 L.min-1.  
 
Mode 1 
PVR (dynes.s.cm-5) RVAD Speed (RPM) 
100 1400 
200 1500 
300 1600 
400 1650 
500 1750 
Mode 3 (Fixed RVAD speed 2150 RPM) 
PVR (dynes.s.cm-5) Outflow Graft Diameter (mm) 
100 7.77 
200 7.77* 
300 7.93 
400 8.10 
500 8.42 
Mode 3 (Fixed Outflow Graft Ø (7.77mm)) 
PVR (dynes.s.cm-5) RVAD Speed (RPM) 
100 2150 
200 2250 
300 2300 
400 2350 
500 2400 
 
The simplified version of the third experiment in-vivo showed that a change in pump speed was required 
to overcome increased PVR. Figure 2.7 shows an example of the speed changes required to overcome 
an increase in PVR, simulated in-vivo through restriction of the PA at approximately five seconds. After 
the increase in PVR from 375 to 425 dynes.s.cm-5, the RVADQ reduced from 4.5 to 3.2 L.min-1, before 
increasing slightly to 3.75 L.min-1 at 35 seconds. This may have been as a result of the tie around the 
PA slipping slightly. After 40 seconds, the RVAD speed was increased manually until the flow rate was 
restored to baseline levels (approximately 60 seconds). 
  
Table 2.3: Changes in outflow graft diameter (fixed RVAD 
speed) or RVAD speed (fixed outflow graft diameter) for modes 
1 and 3 required to maintain normal pulmonary flow at various 
levels of pulmonary vascular resistance (PVR). *the next size of 
restriction produced flow rates greater than 5 L.min-1, so 
restriction was left unchanged. 
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Figure 2.7: Pulmonary vascular resistance (PVR) (top), cardiac output (middle) and right ventricular assist device 
(RVAD) speed (bottom) during a restriction of the pulmonary artery. 
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2.6 Discussion 
Krabatsch et al. (2011) [17] highlighted three primary challenges when using a HeartWare HVAD as 
an RVAD. These included reducing the output of the RVAD to prevent pulmonary congestion; 
shortening the inflow cannula to prevent septal obstruction; and finding an appropriate inflow 
cannulation site in the RV. Whilst the last two issues are pump and patient specific, the first challenge 
is applicable to all patients receiving dual LVAD therapy. 
In our study, operating the right pump at a lower speed than the left pump (mode 1) reduced right pump 
output and therefore the likelihood of pulmonary congestion. Strueber et al. (2010)[47] used this mode 
to operate dual HVADs, setting the RVAD speed close to the design speed (2000 RPM) and the LVAD 
at an elevated 3600 RPM to mitigate pulmonary congestion. The authors achieved a suitable flow rate 
of 4.5-5 L.min-1 however the high LVAD speed indicates excess energy input into the system. Our in-
vivo experience was more similar to that of Saito et al. [19] who implanted dual Jarvik 2000 devices. 
They operated the LVAD at the design speed and the right pump at a speed lower than the minimum 
set by the manufacturer. It must be noted, however, that operating the device at a low speed limits the 
capacity to reduce pump speed in the event of RV suction. Additionally, hydrodynamically levitated 
impellers rely on sufficient speed to create a fluid film and thus may become unstable at these lower 
speeds. Whilst this issue is negated in mechanically/pivot supported impellers, the ensuing reductions 
in outflow pressure also potentially reduces the washout through the small impeller/casing clearances 
in the device, which in turn may increase the risk of thrombosis [65]. These results indicate that mode 
1 is a suitable option for dual LVAD operation. However, there is a trade-off between obtaining normal 
haemodynamics and avoiding impeller instability and thrombus risk.  
There are no reports of using mode 2 clinically, however it has been attempted in-vivo using dual Jarvik 
2000 devices[67], [68]. These studies report similar results to those seen in our in-vivo trials, with 
thrombus formation in the RVAD outflow graft. In our study, this thrombus formation increased the 
outflow resistance by partially occluding the flow, effectively acting as a diameter restriction. This may 
have prevented pulmonary congestion or RV suction. Our in-vitro results, however, showed that without 
any restriction (thrombus or otherwise), mode 2 causes elevated LAP due to the lower right pump 
afterload. A moderate level of LV contractility can relieve theses high LAPs, which may explain how 
the HeartWare HVAD can be used for supporting isolated RV failure without causing pulmonary 
congestion [66]. 
Mode 3 artificially increases RVAD afterload via a reduction in the diameter of the right pump outflow 
graft, thus enabling the right pump to be operated at its design speed. In this study, the outflow diameter 
required to operate the RVAD at the same speed as the LVAD was between 6.5 and 7.8 mm in-vitro 
and 8.1mm in-vivo. These values are higher than the 5mm reported previously [17], [48], but are close 
to the 7mm suggested by Krabatsch et al. for patients with elevated PVR to maintain LV filling [16]. 
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Elevated PVR was observed in our in-vivo trials (>400 dynes.s.cm-5), possibly due to mechanical 
ventilation, which explains the need for a larger outflow diameter. Another point of difference between 
in-vitro and in-vivo experiments that may account for the different RVAD resistance is the different 
outflow graft materials. 
Pulmonary vascular resistance increases transiently during straining, falls rapidly during extubation 
[18], and gradually recovers in hypertensive patients who undertake successful VAD therapy. Therefore 
it is important to determine what changes are required to either RVAD speed or banding diameter to 
accommodate for variations in PVR. After a step increase in PVR in-vitro, RVAD flow and LV filling 
reduced. Increased pump speed or outflow graft diameter were required to restore cardiac output and 
LAP. It can be inferred that the opposite is true for transient reductions in PVR. Whilst speed changes 
can be performed by the clinician, restrictions are difficult to adjust without reoperation because the 
outflow diameter is fixed. An implantable, transcutaneously adjustable restriction device, such as the 
FloWatch PAB suggested by Timms et al.(2011) [73], would be useful in this scenario. Clinicians could 
perform speed adjustments for small, acute changes in VAD flow, and adjust the RVAD outflow 
restriction after long-term PVR changes.  
Ideally, both speed and restriction should be adjustable. Alternatively, a fixed restriction could be 
chosen which allows for sufficient increases and decreases in RBP speed to cope with variations in 
PVR. Ideally, the fixed restriction would allow the device to normally operate approximately halfway 
between minimum and maximum speeds. This would ensure that there is reserve available to lower 
speed during low PVR to prevent RV suction, and to increase speed during high PVR or exercise to 
prevent LV suction.  
The results from this chapter clearly indicate that speed changes are necessary to maintain a suitable 
flow rate in response to changes in PVR if the banding is to remain constant. The use of a physiological 
control system, as opposed to clinical input, to control RVAD speed based on patient state would greatly 
benefit active patients by transiently changing speed in response to PVR changes.  
2.7 Limitations and Future Work 
There were a number of limitations with both the in-vitro and in-vivo experiments. Firstly, the MCL 
did not replicate any autoregulatory mechanisms beyond the Frank-Starling response. These 
autoregulatory mechanisms were potentially compromised in the in-vivo studies due to anaesthesia. 
Secondly, VentrAssist rotary LVADs were used both in-vitro and in-vivo. The VentrAssist was too 
large to be used as an RVAD, and had to be positioned outside the chest cavity. Additionally, the long 
VentrAssist inflow cannula was not ideal for RVAD support, as it had to be pushed through the RV 
wall, across the tricuspid valve and into the RA. Smaller pumps should be utilised for future long-term 
studies. Thirdly, the PVR changes induced in-vivo by tying a band around the PA were not necessarily 
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physiological. Future work should investigate whether pharmacological changes in PVR are more 
physiological and repeatable. Fourthly, only one animal experiment was performed, in which the heart 
was fibrillated. More than one animal is required to confirm the results presented in this thesis. Future 
work could involve investigating the degree that a functioning ventricle can assist with flow balancing. 
Finally, only PVR changes were performed in-vitro and in-vivo, which established the need for RVAD 
speed control. Whilst it can be inferred that changes in SVR would require changes in LVAD speed, 
experimental evidence is required to verify this assumption. This is addressed in the next chapter, in 
which an evaluation framework to assess rotary LVAD physiological control system performance is 
discussed.  
2.8 Conclusions and Summary 
This investigation characterised three modes of operation when using dual LVADs as a biventricular 
support system. The RVAD can be operated at a lower speed than the LVAD, however this may require 
operating the pump at a speed lower than recommended by the manufacturer, resulting in potential 
impeller instability and suboptimal washout within the device. Attempting to operate both pumps at the 
same speed is only possible in patients with high PVR, high LV contractility, or high RVAD outflow 
cannula resistance. However, if the RVAD outflow cannula is restricted to a diameter between 6.5 and 
8.1 mm, suitable steady-state haemodynamics can be achieved while maintaining impeller stability and 
optimal device washout. RVAD speed adjustments or outflow diameter changes can accommodate for 
long term or transient variations in PVR, however the latter requires the use of an adjustable restriction 
mechanism. Due to the variable nature of heart contractility between patients and the time-varying 
nature of a patient's PVR, physiological control of dual rotary LVADs could be advantageous to ensure 
suitable cardiac outputs at all times. 
This chapter highlighted that whilst the methods used clinically to operate dual rotary LVADs can 
provide stable steady-state haemodynamics, speed adjustments are required after changes in the 
circulatory system. The remainder of this thesis describes the development of such a control system, 
with the next chapter devoted to the description of the evaluation framework.  
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3 Control Evaluation Framework 
The previous chapter highlighted that the three current modes of operation for dual rotary LVADs are 
sufficient to maintain steady state resting haemodynamics, provided that careful monitoring is provided 
by the clinician to prevent pulmonary oedema or ventricular suction. However, the dynamic nature of 
the circulatory system means that frequent changes in the speeds of both pumps may be required. A 
physiological control system that can automatically adjust pump speed in response to changes in the 
circulatory system may offer some benefit by reducing the patient's reliance in clinical input. The rest 
of this thesis will describe the development of a physiological control system for dual rotary LVADs.  
In order to develop a suitable physiological control system for dual rotary LVADs, an evaluation 
framework must first be established. This can then be used to assess the performance of such a control 
system. This framework encompasses the testing apparatus used to evaluate the control system, the 
experimental protocols used to test the control system, and the metrics used to quantify the performance 
of a physiological control system.  
This chapter describes the development of an evaluation framework for the testing of the control 
systems described in Chapters 4 and 5. It begins with a literature review, summarising all of the 
previously used methods for evaluation of physiological control systems. Following this is a description 
of the testing protocol that was used throughout this thesis to evaluate physiological control systems in-
vitro. Then there is a description of the performance metrics used to quantify the performance of control 
systems evaluated throughout this thesis. Finally, both the patient scenarios and the performance metrics 
were validated against patient data presented in the literature. 
The significance of the work in this chapter is that it presents a novel method of evaluating physiological 
control systems. It involves simulations of a series of common patient scenarios which enables the 
results to be analysed from both a clinical and engineering perspective. Also, the figures of merit 
presented in this chapter can be used to quantitatively compare control system performance. This is 
significant because currently there is no consistent method of assessing controllers, making it difficult 
to directly compare control systems from literature. 
3.1 Aim 
The aim of this chapter is to develop an evaluation framework for testing of physiological control 
systems. The specific objectives devised to meet this aim are: 
 Review the literature regarding evaluation of physiological control systems. 
 Design a series of automated test scenarios in the mock circulation loop that represent common 
patient activities.  
 Propose a set of evaluation metrics for control performance that will be used in later chapters. 
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 Perform validation of both the patient scenarios and performance metrics.  
3.2 Literature Review 
In this section, the different evaluation techniques previously used to assess control system performance 
and the performance metrics used to quantify performance are discussed. A number of databases (Wiley 
Online Library, ScienceDirect and Google Scholar) were searched for articles related to the 
development of physiological control systems for pulsatile and rotary LVADs, BiVADs and TAHs. The 
search produced 62 peer reviewed publications. Each article was reviewed and the evaluation 
techniques, facilitation of the techniques and figures of merit were noted. Publications that did not 
discuss any control evaluation were then excluded from the search results.  
3.2.1 Evaluation techniques 
The two main functions of a feedback loop are set point tracking and regulation of the set point in the 
presence of disturbances to the system. Evaluation of physiological control system performance 
therefore should involve a disturbance to the plant and/or a variation in the set point. Investigators have 
previously employed a number of different evaluation techniques in order to meet this requirement. 
This section describes the different techniques used by authors to evaluate performance of their control 
systems. The popularity of these different methods is shown in Table 3.1, with each technique described 
in detail in the following subsections. 
Evaluation Technique Number of Controllers References 
Circulatory System Variation 
Preload 13 [80]–[92] 
Afterload 20 
[80], [81], [84], [86]–[88], 
[91]–[104] 
Contractility 4 [81], [83], [91], [105] 
Control System Variation 
Switch On 5 [86], [87], [106], [107] 
Target 5 [101], [108]–[111] 
Patient Scenarios 
Exercise 8 
[91], [96], [106], [109], 
[112]–[115] 
Suction 2 [116], [117] 
 
3.2.1.1 Circulatory System Variation 
Control systems for rotary VADs should adjust pump speed to accommodate variations in the 
circulatory system. It follows then that evaluation could involve some variation of the circulatory 
system. The most common circulatory system variations performed are step or ramp changes in preload, 
afterload and contractility. 
Table 3.1: Popularity of different evaluation techniques for rotary VAD control system assessment. 
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3.2.1.1.1 Preload 
Changes in preload can be used to measure the preload sensitivity of a control system. The preload 
sensitivity of a healthy LV is between 0.19 and 0.24 L/min/mmHg [51], which enables it to adjust 
ventricular output to be proportional to venous return. Preload sensitivity of a VAD-assisted ventricle 
should be in this range in order to avoid ventricular suction, hence the importance of performing step 
changes in preload. 
Preload changes have been performed by a number of investigators, however the facilitation of this 
change varies between authors. In in-silico studies, Moscato and colleagues simulated an instantaneous 
depletion and subsequent reinfusion of 0.45 L of blood [91]. Choi et al. (2001) reduced PVR from 
133.33 to 26.67 dynes.s.cm-5 to reduce LV preload [80]. As Waters et al. [92] and Arndt et al. [83] 
lumped right heart and pulmonary circulatory elements together as a single pressure source, LV preload 
was changed simply by adjusting the value of this pressure source. Gwak and colleagues (2007, 2011) 
did not use a traditional lumped parameter model for evaluation, so these investigators empirically 
varied preload by changing the horizontal and vertical offset of their cost function for control 
optimisation [86], [87]. However, these variations in cost function were not validated against clinical 
data.  
In MCL studies, Gwak et al. (2005) [85] used a hand-operated valve between the ventricle and pump 
inlet to control pump inlet flow in a left-side-only MCL. This is not a realistic scenario, because it 
simultaneously lowers pump inlet pressure whilst increasing ventricular preload. Gaddum and 
colleagues (2012) [89] increased circulatory volume in a biventricular MCL by shifting fluid from the 
systemic venous compliance chamber into the right atrium, increasing both left and right ventricular 
preloads. However the volume of fluid shift was not reported. 
From these papers, it is clear that changes in preload are not consistent between authors. This makes it 
difficult to quantitatively compare controller performance directly from literature. Another observation 
is that changes in preload are more precisely facilitated in-silico than in-vitro, due to the use of hand 
valves in-vitro. The inclusion of electronically controlled valves in a MCL may improve the precision 
and repeatability of preload changes in-vitro.  
3.2.1.1.2 Afterload 
The most common method for control system assessment is to perform a step change in afterload. The 
native heart is considered to be afterload-insensitive, which ensures that cardiac output is maintained 
regardless of the arterial pressure. The VAD-assisted ventricle should also be afterload insensitive in 
order to obtain similar behaviour, hence the importance of performing this test. 
Afterload changes are facilitated by adjusting the systemic arterial resistance in both numerical models 
and mock circulation loops. However, the magnitude, sign (i.e. increase or decrease) and duration of 
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this change differ between authors. In-silico, Wu et al. (2003) decreased total peripheral resistance by 
approximately 1333 dynes.s.cm-5 linearly over a 10 second period [93]. Moscato et al. (2010) reduced 
SVR from 1600 to 933.33 dynes.s.cm-5 in a step wise manner [91]. Choi and colleagues (2001) 
increased SVR from 1333 to 1600 dynes.s.cm-5, again using a step wise approach[80]. Ferreira et al. 
(2009) performed a step increase in SVR from 1333.33 to 2400 dynes.s.cm-5. Waters et al. (1999) 
performed step reductions in SVR, ranging in size from 1 to 50% of the original value of 1280 
dynes.s.cm-5[92]. Simaan et al. (2009) performed a ramp increase in SVR from 1333 to 2666 
dynes.s.cm-5 over a 5 second period[99]. Like their preload changes, Gwak and colleagues (2007, 2011) 
adjusted their cost functions empirically to mimic afterload changes [86], [87]. Both Faragallah et al. 
(2012) and Wang et al. (2012) halved systemic vascular resistance in a step wise manner from 1333 to 
667 dynes.s.cm-5[103], [104]. Interestingly, no clinical justification is provided for any of these changes, 
so the clinical relevance of the magnitude, sign and duration of these changes is unknown. Whilst no 
justification is presented for choosing step changes over ramp changes, step changes could be 
considered as a worst-case scenario. 
Afterload changes in-vitro are not as precise or repeatable as those performed in-silico, as they are 
primarily implemented by manually adjusting valves. Systemic vascular resistance was adjusted using 
clamp valves by Choi et al. (2001) [80], Gwak and colleagues (2005) [85], Nishida and colleagues 
(1996)[97], Kosaka et al. (2003) [118] and Endo et al. (2002) [119]. It appears that these investigators 
did not attempt to control the SVR change to any specific value. Ohuchi et al. (2001) dropped the MAP 
from 100 to 40mmHg, although no description was given as to how this was facilitated [98]. More 
recently, Casas et al. (2007) performed pseudo random changes in SVR using a servo valve [120], 
indicating that controlled changes in SVR are possible. Khalil and colleagues (2008) attempted more 
controlled changes in SVR by manually adjusting clamp valves to increase SVR from 1440 to 1760 
dynes.s.cm-5 and to increase PVR from 160 to 800 dynes.s.cm-5. However, this SVR range was quite 
small compared to that observed clinically. Additionally, the accuracy and repeatability of manually 
adjusting clamp valves was not presented and may be quite low. 
Changes in afterload in-vivo and in the clinic can be performed pharmacologically or mechanically. 
Beppu et al. (1997) increased afterload by gradually clamping the ascending aorta[108]. Nishida et al. 
(1996) similarly clamped the ascending aorta during clinical evaluation of their rotary pump control 
system for CPB [97]. Olegario et al. (2003) pharmacologically changed afterload by injecting 10mg of 
methoxamine hydrochloride [117]. Nishimura (1997) also used vasodilators and vasoconstrictors to 
adjust vascular resistance, however no details about drugs and dosage were provided [121]. Like the 
manual changes in the MCL, these changes are not as precise as those made in the numerical model.  
Assessing control system performance by changing the afterload is the most common form of 
assessment. However, like preload changes, the facilitation of changes in afterload are not consistent 
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between authors, which makes it difficult to compare control systems directly from literature. Afterload 
changes are more precise and repeatable in-silico than in-vitro and in-vivo. This is primarily due to the 
use of hand-operated valves in MCLs and clamps/drugs in-vivo, which introduce human error. The 
incorporation of electropneumatic valves along with methods of accurately measuring vascular 
resistances should improve repeatability and precision of this type of test in-vitro. The only way to 
ensure precision and repeatability in-vivo is with experienced anaesthetists and other clinical staff. 
3.2.1.1.3 Contractility 
Changes in contractility are used to assess the response of a control system to ventricles that are 
recovering (increased contractility) or failing (decreased contractility). Additionally, changes in patient 
activity may also affect residual heart contractility. As changes in contractility are a regular occurrence 
physiological control systems must be able to respond accordingly to them. 
Both Moscato et al. (2010) [91] and Arndt et al. (2007) [83] used step changes in contractility to assess 
their controllers in an in-silico environment, in an attempt to simulate an exercise state. These changes 
were implemented simply as changes in the ESPVR. In in-vitro simulations, Wu et al. (2007) [116] 
evaluated their controller using three different depressed values of LV contractility, facilitated by 
adjusting the output of the pneumatic control unit for their silicone ventricle. However no transitions 
between contractilities were performed. Endo et al. (2002) performed step changes in contractility at 
two minute intervals[119]. These changes were facilitated easily because a pulsatile pump was used as 
a model for the ventricle, which could be easily controlled to a specific contractility. In-vivo, Endo and 
colleagues (2000) induced global ischemia by clamping the base of the ascending aorta, reducing 
contractility for preliminary controller evaluation[122]. 
A step change in contractility could represent a transition from rest to exercise, or a sudden myocardial 
infarction. Simulating different contractilities as separate experiments simulates different patients and 
can be used to assess the control system's ability to accommodate inter-patient variability. However, 
like the other circulatory system variations there is no consistency between authors with respect to the 
magnitude, size and implementation of these variations.  
3.2.1.2 Control System Variation 
Making adjustments to the circulatory system can be difficult, especially in-vivo or in clinic. In contrast, 
characterising control system performance by adjusting controller settings is easy to perform regardless 
of the evaluation apparatus used. The two main methods of control system variation are switching on 
the controller and performing a step change in the target signal. 
3.2.1.2.1 Switching on Controller 
When physiological control systems are eventually utilised in clinic, it is more than likely that the pump 
will first be operated in constant speed mode. Operation will then be switched to physiological control 
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at the clinician's discretion after the patient has stabilised. Therefore, the behaviour of the control system 
during initial start-up should be known, and for this reason it has previously been used as an evaluation 
technique. 
Giridharan et al. (2002) attempted to characterise this response by switching on the pump and control 
system at the same time, however the dynamic behaviour of the pump somewhat masked the effect of 
the control system [123]. A better approach was used by Choi et al. (2001), who switched on their 
control system after operating at a constant speed during in-vivo evaluation [80]. Gwak and colleagues 
(2007,2011) and Chang et al. (2010) evaluated their controllers in the same manner as Choi et al., but 
using a numerical model instead of an in-vivo model [86], [87], [124]. 
This technique is repeatable and can be performed easily regardless of the evaluation environment. 
However, evaluation should not be limited to just switching on the controller, as it does not give the 
users enough knowledge about the controller's interaction with the native circulatory system. 
3.2.1.2.2 Step Change in Target 
The conventional evaluation of control system performance is the step response test, from which time-
domain characteristics such as rise time, settling time and overshoot can be measured (Figure 3.1). The 
step response test involves performing a step-wise change in the target signal for the controller. This is 
different from switching the controller on, as it isolates the effect of the control system from pump 
dynamics.  
Alomari et al. (2011) used step changes in 
the target signal to assess their inlet-
pressure controller[110]. Whilst it enabled 
time-domain evaluation, the authors 
neglected to highlight the effect of these 
step changes on the circulation. 
Additionally, while their controller did 
have a fast response time, the authors did 
not discuss whether these time-domain 
characteristics would be suitable for the 
human circulatory system. Saeed et al. 
(2010) varied the target flow of their 
constant-flow control system during in-
vivo evaluation, and also measured the 
effect on LAP, CVP and total flow[126]. However, only steady-state results were obtained and no time 
domain analysis was reported.  
 
Figure 3.1: Some of the characteristics that can be obtained 
using a step response test [125]. 
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Step response tests enable easy time-domain characterisation of a control system. However, suitable 
values for time-domain characteristics must be defined by the author for the results to be relevant. This 
requires knowledge of the transient characteristics of the human circulatory system in order to create a 
clinical context. Another downside of the step response test is that it can only be used for systems that 
rely on a fixed target value. Step response tests are difficult to perform on systems with varying target 
value, such as those presented in [91], [127], [128]. Finally, whilst tracking experiments are easy to 
perform, they cannot replace plant disturbances, as they do not provide an indication of how the control 
system will respond to common patient scenarios.  
3.2.1.3 Patient Scenarios 
The aforementioned evaluation techniques involve changes in single variables, either circulatory system 
or controller parameters. Changes in single variables are easy to perform and can provide time-domain 
characterisation of VAD physiological control systems as well as a low-level understanding of how 
these systems interact with the circulatory system. However, in practise it is rare that a circulatory 
parameter changes in isolation because of the complex nature of the circulatory system. Therefore, 
single parameter changes are not necessarily reflective of what happens during common patient 
scenarios. Evaluating the performance of a control system during a typical patient scenario results in a 
more clinically relevant assessment. The two main scenarios previously used for evaluation are exercise 
and ventricular suction. 
3.2.1.3.1 Exercise 
The most commonly simulated patient scenario for controller evaluation is exercise, and has been 
simulated in-silico and in-vitro. However, as shown in Table 3.2, differences arise as to how exercise 
has been simulated. This variation is due to the differences between evaluation apparatuses as well as 
the lack of a specific reference case for validation. However, from these papers, a state of exercise can 
be characterised by a decrease in SVR, and an increase in HR, venous return (due to increased action 
of the muscle pump) and contractility, all of which contribute to increased flow and arterial pressure. 
Interestingly, some investigators initiate exercise as a step change whereas others use a linear change 
in parameters over a ten second period (although no justification is given for this time scale). The step 
change could be considered as a worst-case scenario, and if the controller can be shown to handle this 
it could theoretically handle slower transitions to exercise, which are more realistic. 
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Author Apparatus 
Resting HR 
(BPM) 
Exercise HR 
(BPM) 
Transition Other 
Giridharan NM 60 135 Start SVR ↓ 33% 
Giridharan MCL 60 100 Step None 
Wu NM 60 60 Ramp 
SVR ↓ 35-50% 
Activate muscle pump 
Moscato NM 60 60 Step SVC ↑ 
Karantonis NM 
70 
80 
85 
90 
150 
135 
120 
110 
Ramp 
LVC ↑50% 
RVC ↑25% 
SVR ↓ 50% 
Ferreria NM 75 90 Step SVR ↓ 20% 
Bullister MCL 60 99 Step None 
Lim NM 60 95 Ramp 
SVR ↓ 50% 
SVC fluid shift 500mL. 
 
Exercise evaluation has also occurred in-vivo and in clinical evaluation of some controllers. Nakamura 
et al. exercised calves using treadmill tests, increasing the speed of the treadmill over 3 minute intervals, 
when evaluating pulsatile TAH control systems[129]. In the landmark clinical evaluation of their 
control system, Vollkron et al. [84] and Schima et al. [130] performed ergometric exercise of LVAD 
patients, monitoring electrocardiograms, CVP, RAP, LAP, PAP, AoP, LVAD flow and RV cardiac 
output. Assuming that the animal or patient is stable, functional and mobile, exercise based evaluation 
is simple to perform. However, instrumentation of the subject is difficult. Additionally, like all in-vivo 
and clinical evaluation it is an expensive and risky undertaking. The inter-patient variation means that 
a large number of patients must be evaluated in order to obtain statistical significance. 
3.2.1.3.2 Induced Suction 
Some investigators deliberately induced a state of ventricular suction in order to assess their control 
system's ability to mitigate this hazardous state. Wu et al. (2007), achieved this in-silico by initialising 
the pump speed at maximum level, causing suction, before switching the control system on [116]. For 
evaluation of RVAD component of a dual LVAD control system, Olegario et al. (2003) induced LV 
suction in-vitro and in-vivo by increasing the LVAD speed by 700 RPM[117]. Using this as a method 
of control system assessment requires accurate replication of ventricular suction, which is made 
complicated by the complex nature of rotary VAD-induced suction [56]. 
3.2.2 Combination of Evaluation Techniques 
The previous section highlighted that there are a number of different evaluation techniques used by 
investigators to assess different aspects of physiological control system performance, with step changes 
Table 3.2: Different methods of simulating an exercise condition using numerical models (NM) and mock circulation 
loops (MCLs) for the purpose of evaluating control systems. SVR - systemic vascular resistance; LVC - left 
ventricular contractility; RVC - right ventricular contractility; SVC - systemic venous compliance. 
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in afterload being the most common. One observation from this review is that investigators tend to only 
use only one or two of these techniques to characterise control system performance (Table 3.3). Only 
one author, Moscato et al. (2010)[91], evaluated their system using four different evaluation techniques. 
This trend of minimal evaluation is a current deficiency of control system evaluation. Only subjecting 
controllers to one type of test means that not all aspects of controller performance are characterised. 
Additionally, this minimal evaluation makes it difficult to directly compare control system performance 
from the literature. Consequently, if the early in-silico or in-vitro evaluation is not thorough enough, 
progression to in-vivo and clinical evaluation becomes difficult. Therefore, control systems should be 
subject to a number of different evaluation techniques in order to facilitate comparison and to 
thoroughly characterise the effect of the control system on the circulatory system. 
Number of tests 
used to quantify performance 
Number of controllers 
assessed in this manner 
1 20 
2 12 
3 3 
4 1 
 
3.2.3 Performance Comparisons 
The previous sections highlighted that one of the shortcomings of current evaluation methods was the 
tendency to subject systems to a single evaluation technique. Another shortcoming is the lack of 
comparisons with other physiological control systems, simulated healthy patients and/or VAD 
supported patients at constant speed during evaluation. Table 3.4 shows that the majority of control 
systems presented in literature are assessed in isolation. The end result of this isolated evaluation is that 
there is no point of comparison for all of these different control systems. Consequently, there is no way 
to directly compare control system performance from the literature. To improve upon this, investigators 
should subject other control systems to their evaluation framework.  
Benchmark Type Number of controllers 
Constant Speed 6 
Healthy LV 4 
Other Controller 6 
None (Isolated 
Evaluation) 
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Table 3.3: Number of evaluation techniques that control systems 
are subjected to in order to characterise control system 
performance. 
Table 3.4 Types of benchmarks used for performance 
comparisons during control system evaluation 
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3.2.4 Summary of Literature Review 
The purpose of the literature review was to identify evaluation techniques used by other authors in order 
to develop an evaluation framework for the control system evaluation used in this thesis. Evaluation 
techniques involve performing either single changes in variables or simulation of a patient scenario. 
Step changes in single variables, such as preload, afterload and contractility, allow for low-level 
characterisation of control system performance. However, these single variable changes are not 
reflective of what actually happens to the circulatory system during common patient scenarios. Patient 
scenarios, including exercise and deliberate induction of suction, are simulated because they are more 
reflective of scenarios that happen in clinic. They can also be induced easily in-vivo and in clinic, which 
makes in-silico and in-vitro results can be more easily validated. However, there has been no consistent 
method of simulating exercise. 
One observation from the literature is that most investigators have only evaluated their control system 
by subjecting it to one or two evaluation techniques. Evaluation using more than two techniques would 
result in more through testing, the end result being a more robust control system. Additionally, most 
investigators evaluate their control system in isolation, without comparison to other physiological 
control system. Given the volume of VAD physiological control systems presented in the literature over 
the last two decades, a high-quality evaluation framework should involve quantitative comparisons to 
previous work. Therefore, a suitable evaluation framework must first be developed which can be used 
to quantitatively compare control systems previously presented in literature across a number of different 
patient scenarios.  
3.3 Hypothesis 
The main hypothesis of this chapter was to develop a repeatable evaluation framework for the 
assessment of VAD physiological control systems that quantifies their performance across a number of 
common patient scenarios. 
3.4 Methods 
An evaluation protocol for the assessment of control systems was developed. This section describes the 
selection of a testing apparatus, improvements made to this apparatus, descriptions of the testing 
scenarios used for evaluation, descriptions of the figures of merit used for performance evaluation and 
the validation procedure used for both scenarios and the figures of merit. 
3.4.1 Testing Apparatus Selection 
The testing apparatuses commonly used for control system evaluation were described in Chapter 1. Of 
these apparatuses, an MCL was chosen as the main evaluation apparatus for this thesis for a number of 
reasons. Firstly, using real VADs ensures that evaluation incorporates real-world limitations such as 
pump speed limits, turbulent flow and uncertain viscous flow behaviour in the pump. Whilst these can 
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be modelled numerically, their inclusion increases computation time of numerical models. Using an 
MCL for evaluation ensures the most realistic performance characterisation without resorting to the 
expense or risk of in-vivo or clinical trials. Secondly, most control system development occurs initially 
in the in-silico environment, and as such some evaluation is already performed in that environment. 
Controllers must be assessed in a different environment to remove biases associated with the 
developmental environment. Thirdly, the difficulties involved in modelling a pump in-silico would add 
unnecessary delays to the experiment, especially if pumps are already available for bench top testing. 
The MCL designed and constructed by Timms and colleagues [74], [131] (described in section 2.4.1) 
was used for a number of reasons. Firstly, it is one of the only five-element Windkessel MCLs available 
worldwide. Five-element Windkessel models incorporate elements of characteristic resistance, arterial 
compliance, peripheral resistance, inertial component and venous compliance. Inclusion of these 
elements ensures accurate replication of ventricular and arterial pressure waveforms (Figure 3.2), 
making this apparatus appropriate for control system evaluation. Secondly, the MCL was designed by 
first developing a computer simulation of the loop. Pipe diameters and lengths were optimised within 
the simulation in order to replicate haemodynamics accurately [75]. Finally, this MCL is a biventricular 
MCL, making it suitable for evaluation of control systems for rotary BiVADs. In contrast, many other 
MCLs used for control system evaluation are left-sided only loops which makes them unsuitable for 
this thesis.  
 
3.4.2 Rotary Ventricular Assist Devices 
In order to evaluate control systems for dual rotary pumps, two rotary LVADs were required. Two ex-
vivo VentrAssist LVADs were donated by Professor Robert Salamonsen from the Alfred Hospital, 
enabling two devices to be used free-of-charge. While these devices are no longer used in clinic, they 
are still third-generation implantable centrifugal rotary LVADs and as such can be used to represent 
modern devices such as the HeartWare HVAD. It could be argued that the results in this thesis would 
be more clinically relevant if the experiments used a clinically available centrifugal pump. However, 
Figure 3.2: Comparison of systemic pressure traces between a natural (a), computer simulated (b) and that produced 
by an MCL (c). LVP - left ventricle pressure; LAP - left atrial pressure; AoP - aortic pressure; MAP - mean aortic 
pressure. [74] 
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the control objectives that are described in the next chapter are almost all pump-independent. Giridharan 
and Skliar established this by testing their control system using both axial and centrifugal pumps [106]. 
This means that the choice of pump does not have as much impact on performance as the selection of 
the control objective. 
With the assistance of Professor Nigel Lovell from University of New South Wales and Dr Peter Ayre 
(Thorvascular Pty Ltd), these pumps were interfaced with the dSPACE 1103 data acquisition system, 
enabling both measurement and control of pump parameters. The VentrAssist LVAD DC motor uses a 
constant voltage source and a pulse width modulation (PWM) signal to control the current. The higher 
the duty cycle of the PWM signal, the higher the motor current and therefore the higher the pump speed. 
Using this information, a new PI speed controller was developed in the Matlab/Simulink environment 
(The Mathworks, Natick, MA), which was more responsive than the default speed controller available 
clinically. Additionally, access to the PWM duty cycle enabled all control systems developed in this 
thesis to directly control pump PWM duty cycle, rather than pump speed. This minimised the 
complexity of controllers developed in this thesis. 
3.4.3 Evaluation Techniques 
Patient scenarios were used to evaluate the control systems in this thesis, because they provide a clinical 
context for controller evaluation. The most common scenario from the literature was exercise, so this 
scenario was also utilised in this thesis. Two other scenarios, a postural change and a Valsalva 
manoeuvre, were also simulated. These two scenarios are commonly performed by discharged patients, 
with the Valsalva manoeuvre representing straining that occurs during lifting or defecation. Therefore, 
knowing the response of a physiological control system to these scenarios would be of significant value 
to patients and caregivers. 
3.4.3.1 Postural Change 
Changes in posture cause fluid shifts in the circulatory system. For example, moving from a lying to 
standing position causes fluid to move from the thorax into the lower limbs. This will result in a 
temporary reduction in venous return to the right atrium. The reason for simulating a transition from 
lying to standing is that the reduced venous return to the RA increases the risk of suction in the RV. It 
also increases the risk of suction in the LV, since a reduction RV inflow will eventually cause a 
reduction in LV inflow. Simulating this drop in venous return enables evaluation of a control system's 
preload sensitivity and therefore their ability to avoid suction. 
 
Fluid shifts between the thorax and lower limbs were simulated by shifting 300 mL of fluid from the 
circulation into the systemic venous compliance (SVC) chamber. The SVC chamber is a realistic 
approximation of lower limb venous circulation because 60% of all venous blood lies in the veins of 
 51 
 
the lower limbs. After shifting the fluid, the new state was held for 60 seconds, which allowed enough 
time for MCL haemodynamics to settle. The fluid was then shifted back into circulation. 
Fluid shifting in the MCL was controlled by adjusting the air pressure in the SVC chamber. Reducing 
air pressure allows fluid to move into the SVC and decreases mean circulatory pressure (MCP) 
(emptying the MCL), whilst increasing air pressure moves fluid out of the SVC and increases MCP 
(filling the MCL). 
This fluid shift was initially facilitated using manual ball 
valves (Figure 3.3). As described in the literature review 
of this chapter, the use of manual valves results in low 
repeatability, which lowers the quality of evaluation using 
volume changes. To improve repeatability, these manual 
valves were replaced with a combination of two normally 
closed (NC) solenoids and a high-pressure manual 
regulator, using the configuration shown in Figure 3.4. 
Filling and emptying were facilitated using the switching 
shown in Table 3.5.  
 
SV1
AC
SV2
HPMR SVC
 
 
 
 
 
 
 
  
 
Figure 3.3: Ball valves used to lower (large 
valve) and raise (small valve) circulatory 
volume in the MCL 
Figure 3.4: Solenoid valve configuration for filling and emptying. AC - 
compressed air supply; HPMR - high pressure manual regulatory; SV - 
solenoid valve; SVC - systemic venous compliance chamber. 
Table 3.5: Solenoid valve settings for filling and emptying the MCL. 
Mode Solenoid Valve 1 Solenoid Valve 2 
Filling Open Closed 
Emptying Closed Open 
Hold Closed Closed 
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Accurate fluid shifts were facilitated using closed loop control. The weight of fluid in the SVC was 
continuously measured using a digital scale (BW 4-20 Indicator, @Weight Pty Ltd, Melbourne, 
Australia). Fluid shifts were then automated using the control logic shown in Figure 3.5. The control 
logic was implemented using Simulink. 
3.4.3.2 Valsalva manoeuvre 
The Valsalva manoeuvre describes forced exhalation against a closed glottis. It is a simple action that 
can be performed easily by patients, and is sometimes used to assess heart function [132]. It is also 
representative of the straining that occurs during lifting, sneezing, coughing and defecation. The 
Valsalva manoeuvre has been shown to sharply reduce LV venous return. Therefore, evaluation of a 
control system's performance to this scenario is necessary to ensure the controller response is 
appropriate. 
 
 
Figure 3.5: Control logic for controlled shifts of fluid in the MCL. 
START
END
IS 
Volume Change Limit 
> 0
Add fluid to Circulation
SV1 = Open
SV2 = Closed
Remove Fluid 
From Circulation
SV1 = Closed
SV2 = Open
Yes
Yes
No
IS 
|Volume Change| < |Volume 
Change Limit|
No
Stop Fluid Shift
SV1 = Closed
SV2 = Closed
Begin measuring 
volume change 
(fluid shift in/out of MCL)
 53 
 
The Valsalva manoeuvre consists of four phases (Figure 3.6). The first phase, intrathoracic 
compression, compresses the heart chambers and augments output to the periphery. It also causes 
reduced diastolic filling and therefore reduced LV stroke volume. According to Lu and colleagues [133] 
this phase lasts for 1-2 heartbeats. The reduced LV output leads to the reduction in arterial pressure seen 
in Phase 2. The baroreflex (particular the sympathetic stimulation of venous tone and contractility) is 
then responsible for restoring arterial pressure. Phase 3, release of the Valsalva, is marked by a drop in 
arterial pressure, due to the sudden reduction in intracardiac pressure and stroke volume. Phase 4 
describes the overshoot and recovery of the arterial pressure caused by the baroreflex. 
 
 
 
 
From the previous description of the Valsalva manoeuvre, some simulation of breathing was required 
to be implemented in the MCL prior to implementing this scenario. Variation of intrathoracic pressure 
caused by breathing changes the external pressure on the ventricles, which results in changes to preload. 
Unfortunately, the MCL chambers were constructed from rigid polyvinyl chloride, making it impossible 
to apply an external compressive pressure. Therefore, breathing was simulated by pressurising the air 
in the pulmonary venous compliance (PVC) chamber, which pushed fluid from the PVC chamber into 
the left ventricle. This simulated the compression of the pulmonary capillaries that occurs during 
breathing, which squeezes additional fluid into the left atrium.  
This mechanism was implemented using a 
compressed air supply, high pressure 
manual regulator (ITV2030-012BS5, SMC 
Pneumatics, Tokyo, Japan), a 3/2 NC 
solenoid valve (VT325-035DLS, SMC 
Pneumatics, Tokyo, Japan) and a 2/2 NC 
Figure 3.6: Arterial pressure and heart rate during a Valsalva manoeuvre, 
simulated using a numerical model of the cardiovascular and pulmonary 
systems [133]. The four phases are noted here. 
Table 3.6: Solenoid valve inputs required for each breathing 
state 
Breathing State 3/2 Valve 2/2 Valve 
Inhalation ON ON 
Exhalation OFF ON 
Hold ON or OFF OFF 
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solenoid valve (VX2360-04-5D1, SMC Pneumatics, Tokyo, Japan) as per Figure 3.7. The configuration 
of solenoid valves enabled three states of operation: inhalation, exhalation and a hold mode (Table 3.6). 
Breathing was facilitated by switching the 2/2 valve ON and alternating the 3/2 valve between the ON 
and OFF positions. The default breathing rate was set at 10 breaths per minute. This pneumatic 
configuration was installed alongside the other MCL pneumatics. The manual regulator was adjusted 
until an inhalation of 3 seconds pushed most of the fluid out of the PVC chamber. 
HPMR 3/2 SV 2/2 SV
AC
PVC
 
 
 
Simulation of the Valsalva manoeuvre was simplified by only incorporating the changes in intrathoracic 
pressure and stroke volume. To replicate the increase in intrathoracic pressure (Phase 1), an inhalation 
was performed. Then the pulmonary venous compliance chamber (PVC), normally open to atmosphere 
to simulate the high compliance of the pulmonary circulation, was closed to atmosphere. This increased 
the LV diastolic filling and therefore the arterial pressure. The drop in LV diastolic filling and therefore 
arterial pressure (Phase 2) was simulated by increasing the PVR from 100 to 350 dynes.s.cm-5 two 
seconds after phase 1. To release the Valsalva manoeuvre, the PAC chamber was reopened to 
atmosphere (Phase 3) and PVR restored to the normal value of 100 dynes.s.cm-5 two seconds after the 
PAC was reopened (Phase 4).  
 
The baroreflex is an important factor in the shapes of the of the arterial pressure waveforms during the 
Valsalva manoeuvre. However, a baroreflex simulation was omitted from the MCL for a number of 
reasons. The first reason was that in the situation in which dual LVADs are required, the reflex is either 
Figure 3.7: Pneumatic setup required for simulation of breathing in the MCL. AC 
- compressed air supply; HPMR - high pressure manual regulator; SV - solenoid 
valve; PVC - pulmonary venous compliance chamber. 
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absent or severely limited in its action due to pre-existing cardiovascular disease or the implantation 
procedure. This means that even if a reflex was able to be simulated in the MCL, its inclusion is not 
necessary relevant. Secondly, omission of the reflex should still produce realistic results, since it is the 
changes in intrathoracic pressure during the Valsalva manoeuvre (and consequently LV end-diastolic 
volume) that are of most concern, since reduced LV filling may result in LV suction. A baroreflex was 
not necessary to change preload in the MCL. Finally, incorporation of the baroreflex introduces another 
control loop into the system, increasing system complexity and may result in the masking of the 
behaviour of the physiological control systems. One effect of the omission of the baroreflex was that 
the heart rate did not vary during the Valsalva manoeuvre. 
3.4.3.3 Exercise 
Exercise encompasses any patient activity more intense than a resting state, requiring a higher cardiac 
output than rest. Discharged rotary VAD patients may exhibit slightly improved exercise performance 
a number of months after implantation compared to unsupported chronic HF patients and are therefore 
more active [134]. Salamonsen and colleagues found that the larger the pump flow increase in exercise 
the greater the patient's exercise capacity [135]. Therefore, a control system that can increase pump 
flow in exercise without draining the ventricles may be beneficial for patients. It was for this reason 
that an exercise scenario was chosen as part of the framework. 
Further modifications to the MCL were required in order to increase cardiac output during exercise. 
Firstly, in a collaboration with Dr Shaun Gregory, the ventricular contraction mechanism was modified 
in order to better mimic the Frank-Starling behaviour of each ventricle. This mechanism was described 
in detail in section 2.4.1. 
The second MCL modification ensured that increases in heart rate resulted in increased contractility. 
One limitation of the Timms' MCL was that increasing the heart rate resulted in less time to 
pneumatically compress the ventricles in systole and less time for the ventricles to passively fill in 
diastole. The result was that increasing the heart rate actually decreased cardiac output, which is the 
opposite of what happens in a normal heart. To compensate, the regulator voltage was increased in 
proportion to the increase in heart rate, effectively introducing the force-frequency relationship present 
in the native heart into the MCL. Equation (2.1) was modified to incorporate heart rate, producing 
Equation (3.1). 
 
𝑉𝑟𝑒𝑔 =  {𝑉𝑃
𝑉𝑃(𝑡). 𝐾𝑠𝑡𝑎𝑟𝑙𝑖𝑛𝑔(𝑡). 𝐾𝑣𝑒𝑛 ;  𝐻𝑅 ≤ 60
(𝑡). 𝐾𝑠𝑡𝑎𝑟𝑙𝑖𝑛𝑔(𝑡). (𝐾𝑣𝑒𝑛 + (𝐻𝑅 − 60)𝐾𝐻𝑅) ;  60 < 𝐻𝑅 < 90 
𝑉𝑃(𝑡). 𝐾𝑠𝑡𝑎𝑟𝑙𝑖𝑛𝑔(𝑡). (𝐾𝑣𝑒𝑛 + 30𝐾𝐻𝑅) ;  𝐻𝑅 ≥ 90
 (3.1) 
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HR is the heart rate (BPM) and KHR (min) is another contractility constant which affects the sensitivity 
of the contractility to heart rate. Values of KHR for LV and RV for three different contractility conditions 
are given in Appendix A. 
Finally, a variable systolic period was introduced into the MCL. The Timms' MCL initially required the 
user to set the percentage of time spent in systole during the cardiac cycle, and this was kept constant 
regardless of heart rate. However, the percentage of time spent in systole actually increases as heart rate 
increases [136]. Therefore, to more accurately represent states of exercise, this variation was 
incorporated into the MCL.  
Systolic period was adjusted using the relationship 
defined by Vollkron and colleagues [136], shown in 
Figure 3.8 . Data were extracted from this figure using 
DataThief (B.Tummers, http://datathief.org) and 
imported into Matlab (The Mathworks, Natick, MA, 
USA). The relative time spent in systole (systolic ratio) 
during each heart beat was calculated for each heart rate. 
Linear regression was the used to quantify the 
relationship between HR (in BPM) and the systolic ratio 
(Equation (3.2)). 
 𝑆𝑦𝑠𝑡𝑜𝑙𝑖𝑐𝑅𝑎𝑡𝑖𝑜 = 𝐾𝑆𝐷 . 𝐻𝑅 + 𝑐𝑆𝐷 (3.2) 
 
The constants KSD and cSD were 0.0029 min and 0.2123 respectively, producing an R2 value of 0.9963. 
Systolic time (in seconds), Tsys, was then determined by multiplying the ratio by the heart period 
(Equation (3.3)).  
 
𝑇𝑠𝑦𝑠 =
60. 𝑆𝑦𝑠𝑡𝑜𝑙𝑖𝑐𝑅𝑎𝑡𝑖𝑜 
𝐻𝑅
 (3.3) 
 
As highlighted in the literature review, exercise has been simulated in a number of different ways by 
other investigators. However, in each of these previous simulations, the primary haemodynamic 
characteristics of exercise were an increase in cardiac output and arterial pressure [20]. For this 
evaluation framework, cardiac output was increased by increasing the heart rate from 60 to 80 BPM, 
decreasing the SVR from 1300 to 800 dynes.s.cm-5 and decreasing the PVR from 100 to 40 dynes.s.cm-
5. The heart rate was only increased to 80 BPM because further heart rate increases did not increase 
 
Figure 3.8: The effect of heart frequency on the 
duration of systolic and diastolic phases [136]. 
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cardiac output. This was a limitation of this MCL. Replication of the muscle pump effects was achieved 
by shifting 700mL of fluid from the SVC into the RA, further augmenting cardiac output increases. N 
During simulations of healthy ventricles, left and right ventricular contractility were increased by 
varying 𝐾𝑠𝑚1 from 0.387 to 0.403 for the LV and 0.199 to 0.256 for the RV, which increased both 
cardiac output and arterial pressure. However, exercise capacity is greatly reduced in heart failure, due 
to reduced contractile strength of the myocardium[20]. It was therefore assumed that in simulations of 
HF in the MCL, there was no capacity for the failed ventricles to further increase their output via 
sympathetic stimulation. Therefore, for simulations of HF patients exercising, Ksm1 was not increased 
beyond the resting values. An atrial kick was also included to assist in shifting fluid across the 
atrioventricular valves. Atrial contraction was implemented in a manner similar to the ventricles, as 
described in [74]. The contractility (as represented by the maximum current sent to the electropneumatic 
regulators during systole) of the atria was varied manually until the atrial and ventricular pressures 
equalized at the end of ventricular diastole. 
3.4.3.4 Combined Test Bed 
The three patient scenarios were combined sequentially to produce a single test bed for control system 
evaluation. Combining each scenario provides a more complete story than each scenario alone. For 
example, after a scenario, if a control system that does not stabilise pump speed fast enough then it may 
affect its performance in the next scenario.  
Beginning with a resting condition, each scenario was simulated consecutively. The loop was returned 
to a resting state between each scenario. A summary of the timing of the combined test bed, and the 
MCL settings that were adjusted for each event is given in Table 3.7.  
Scenario Simulation  
Time (s) 
Name 
PVR 
(dynes.s.cm-5) 
SVR 
(dynes.s.cm-5) 
HR 
(BPM) 
Circulation fluid shift 
1 0 Rest 100 1300 60 -- 
2 60 Postural Change 100 1300 60 RV -> SVC (300mL) 
3 120 Rest 100 1300 60 SVC -> RV (300mL) 
4 180 Valsalva 350 1300 60 PVC -> LV (100mL) 
5 240 Rest 100 1300 60 LV -> PVC (100mL) 
6 300 Exercise 40 800 80 SVC -> RV (700mL) 
7 360 Rest 100 1300 60 RV -> SVC (700mL) 
3.4.4 Figures of Merit 
As highlighted in the literature review, there is no consistent method of quantifying of the performance 
of physiological control systems for rotary VADs. It is essential to quantify control performance to 
provide a measurable point of comparison with other control systems during evaluation. Four different 
figures of merit (FOMs) were created in order to quantify four aspects of control system performance.  
Table 3.7 Settings for each patient scenario simulated in the MCL. PVR - pulmonary vascular resistance; SVR - systemic 
vascular resistance; HR - heart rate; RV - right ventricle; SVC - systemic venous compliance chamber; PVC - pulmonary 
venous compliance chamber; LV - left ventricle. 
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Firstly, the control system's ability to maintain appropriate resting haemodynamics was assessed by 
measuring the steady state mean aortic pressure, mean pulmonary arterial pressure and mean pulmonary 
and systemic flow during all resting states (Scenarios 1, 3, 5 and 7). In order to maintain appropriate 
end-organ perfusion as well as patient comfort, these parameters must remain within certain ranges. 
These ranges (Table 3.8) were selected after review of physiological textbooks and discussions with 
clinical staff at The Prince Charles Hospital.  
Variable Range 
Mean aortic pressure 60-120 mmHg 
Mean pulmonary arterial pressure 15-25mmHg. 
Mean pulmonary flow rate 4.5-6 L.min-1 
Mean systemic flow rate 4.5-6 L.min-1 
 
A single performance metric, FOMREST was used to quantify how well these 4 variables remained within 
these ranges (Equation (3.4)) 
 
𝐹𝑂𝑀𝑅𝐸𝑆𝑇 =
∑ (𝑇𝑖𝑆𝑎𝑓𝑒 − 𝑇𝑖𝑈𝑛𝑠𝑎𝑓𝑒)
𝑖=𝑁
𝑖=1
𝑁. 𝑇
 × 100% (3.4) 
 
Where TiSafe and Tiunsafe represent the time (in seconds) spent by the ith variable in the safe and unsafe 
ranges respectively, N is the number of such variables (in this case N = 4) and T represents the total 
length of the simulation (in seconds). FOMREST was calculated only during the resting scenarios, as 
pressures and flow may temporarily vary outside of these ranges safely during common patient 
scenarios. 
Secondly, the control systems must not cause pulmonary or system venous congestion. Pulmonary 
congestion is especially harmful, as it causes oedema fluid to overwhelm the capacity of the interstitial 
space and flood the airways and alveoli [137]. Pulmonary and systemic congestion is prevented by 
maintaining LAP and RAP below the threshold of 25mmHg respectively [137], [138]. Maintaining 
pressures at 15mmHg was advised by Boston, Antaki and Simaan (2003) in order to improve the safety 
margin [59]. Therefore, we defined two regions for safe LAP and RAP operation. Atrial pressures below 
15 mmHg were considered "good", between 15 and 25mmHg "average" and above 25mmHg was 
considered "Poor". To quantify congestion avoidance performance, Equation (3.5) was used. 
 
𝐹𝑂𝑀𝐶𝑂𝑁𝐺 =
(𝑇𝐺𝑜𝑜𝑑 −  𝑇𝑃𝑜𝑜𝑟)
𝑇
 × 100% (3.5) 
Table 3.8: Appropriate ranges for control systems during rest to 
ensure end-organ perfusion. 
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Where TGood is the time (in seconds) spent in the "Good" range, Tpoor the time (in seconds) spent in the 
"Poor" range and T the total length of the simulation (in seconds). Spending significant time in the 
"Good" range results in a high positive score, whilst excessive time in the "Poor" region results in a 
negative score. "Average" performance results a score around zero. This score was calculated separately 
for systemic and pulmonary circulations. 
Thirdly, as fewer suction events indicated better control system performance, the number of suction 
events were recorded as FOMSUC. Suction events were simulated in the same manner as Lim [139], who 
defined the resistance between LV and pump inlet as a variable resistance Rsuc. Under normal operation, 
Rsuc is set to zero. When the LV volume below a threshold, Rsuc increased exponentially, based on the 
difference between ventricular volume and a threshold. This approach was found to match the suction 
observed in the author's animal experiments than other approaches. Therefore, this approach was 
adopted for use in this MCL. Variable inflow cannula resistance in the LV and RV was achieved using 
socket valves (VMP025.03X.71, Alb. Klein Ohio, Plain City, OH) installed between the ventricles and 
VAD inlet ports. These valves were used to set the inflow cannula resistance as a function of ventricular 
volume, adapting the relationship used by Lim [139]. This relationship is described by Equation (3.6). 
 
𝑅𝑠𝑢𝑐 =  {
𝑘𝑠1(𝑒
𝑘𝑠2(𝑉𝑙𝑣−𝑉𝑡ℎ)) 𝑉𝑙𝑣 < 𝑉𝑡ℎ
 0  𝑉𝑙𝑣  ≥ 𝑉𝑡ℎ
 (3.6) 
 
Values for the constants ks1 and ks2 were selected the same as presented by Lim and colleagues (0.5 
mmHg.s.mL-1 and -1.3 mL-1 respectively). The volume threshold Vth was set at 30mL, which was the 
minimum volume achievable in the MCL that enabled normal ventricle contractile behaviour.  
A suction event was defined as closing of the suction solenoid valves, and was measured as events per 
second (Equation (3.7)). 
 
𝐹𝑂𝑀𝑆𝑈𝐶  =
𝑁
𝑇
 (3.7) 
 
N represents the total number of suction events and T the total simulation time in seconds. FOMSUC was 
calculated separately for left and right ventricles. 
Fourthly, the exercise performance was assessed by measuring the steady state LVAD, RVAD, systemic 
and pulmonary flow rates. An increase in total flow is desired during exercise, which would 
theoretically deliver more oxygen to the exercising muscles. It is also desirable that the increase in flow 
be primarily due to an increase in pump flow in order to reduce unnecessary strain on the ventricles. 
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With this in mind, FOMEX (described in Equation (3.8)) was used to quantify the effective increase in 
flow during exercise. 
 
𝐹𝑂𝑀𝐸𝑋 =  (𝑄𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ − 𝑄𝑟𝑒𝑠𝑡̅̅ ̅̅ ̅̅ ̅)
 
{
(𝑄𝑉𝐴𝐷𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅)
(𝑄𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ )
}
 
(3.8) 
 
Where 𝑄𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ and 𝑄𝑉𝐴𝐷𝑒𝑥𝑒𝑟𝑐𝑖𝑠𝑒
̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅  represent the mean total and pump flows respectively during the 
whole duration of the exercise scenario (scenario 6), and 𝑄𝑟𝑒𝑠𝑡̅̅ ̅̅ ̅̅ ̅ and 𝑄𝑉𝐴𝐷𝑟𝑒𝑠𝑡
̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ represent the mean resting 
total and pump flows respectively. This FOM primarily rewards increases in total flow due to increases 
in pump flow. It also rewards controllers that increase flow quickly, as the mean exercise flow is 
calculated over the duration of the whole exercise scenario. (Note that whilst the other three FOMs are 
expressed as a percentage, FOMEX is expressed in L.min-1) 
3.4.5 Validation and Repeatability Assessment 
In order to use the test beds and FOMs, validation was required. The following section describes the 
validation methods used. 
3.4.5.1 Patient Scenarios 
Ten iterations of patient scenarios were simulated for two heart conditions (healthy and mild left 
ventricular failure), and both accuracy and repeatability were measured. Accuracy was assessed by 
measuring the steady state mean ± standard deviation of systemic and pulmonary arterial pressure and 
flow and left and right atrial pressures for all scenarios across all the tests and comparing these values 
to those presented in literature. Steady state was defined as the final ten seconds of each of the seven 
stages outlined in Table 3.7. Additionally, arterial pressure waveforms during the Valsalva manoeuvre 
were compared to those presented by Lu and colleagues, who simulated the Valsalva manoeuvre with 
and without a validated baroreflex in a numerical model [133]. 
Transient repeatability was assessed by calculating the correlation coefficients of key haemodynamic 
parameters (aortic, pulmonary arterial, left and right atrial pressures and systemic and pulmonary flow 
rates) between each of the ten iterations for each heart condition. The null hypothesis was that there was 
no correlation between any of the simulations. A p-value less than 0.05 was considered significant to 
reject the null hypothesis.  
3.4.5.2 Figures of Merit 
Validation of the four FOMs involved determining the range of values for each one. Some of the ranges 
could be inferred, while others had to be determined experimentally. 
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Validation of FOMREST and FOMCONG was performed by simulating 3 patient scenarios for three 
different heart conditions and obtaining the maximum and minimum values for each FOM. The VAD 
was not in place for these simulations. The best-case scenario was considered to be a healthy simulated 
patient. As the loop was previously validated using human data, simulation of a healthy patient was 
considered a realistic representation of human cardiovascular behaviour. Simulations of mild and severe 
left heart failure patients were used establish baselines for the worst-case scenarios. 
Validation of FOMsuc was not required, because this metric only counts the number of times the suction 
valves close during a simulation. The best-case value for FOMsuc was considered to be zero, while there 
would be no upper limit. 
Validation of FOMEX involved measuring the increase in flow rate during the simulation of the healthy 
patient exercising, and using this as the upper limit. The lower limit was considered to be zero, 
indicating no contribution from the VAD during exercise. 
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3.4.6 Results 
3.4.6.1 Test Bed Validation 
Accuracy of the test bed simulation was assessed by comparing steady state haemodynamics with those 
observed in literature. For the healthy simulation, resting MAP, mean pulmonary arterial pressure 
(MPAP), MSQ and mean pulmonary flow rate (MPQ) were all within suitable ranges given in literature 
(Table 3.9). However, LAP and RAP were higher than these ranges at rest. All resting haemodynamics 
were similar across the four resting scenarios, indicating that the initial condition was able to be restored 
before the next patient scenario was simulated. 
The changes in postural change for all variables were different to those reported in literature. MAP 
dropped by 8mmHg, whereas it should not have changed at all. The other parameters all fell, however 
these reductions were not as large as those reported in literature. In the Valsalva manoeuvre, the flow 
rate decreased and the pulmonary arterial pressures all increased, although these changes were not as 
high in magnitude as those reported in literature. However, the MAP, which was meant to stay constant, 
fell nearly ten percent. The aortic pressure waveforms produced during the Valsalva manoeuvre were 
compared with those generated by Lu and colleague, who simulated the Valsalva manoeuvre without 
the baroreflex (Figure 3.9). Whilst the time scales are different, it is obvious that the behaviour of 
arterial pressure is similar, and the 4 phases can be clearly identified. 
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Figure 3.9: Aortic pressure during a simulated Valsalva manoeuvre, produced in the MCL (Top) and 
from a numerical model (bottom) produced obtained from literature [133]. Both simulations were 
performed without a baroreflex present. 
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During exercise, the MPAP, MLAP, MRAP and flows all increased, similar to that observed in 
literature. However, the MAP was unchanged. The MCL was able to revert back to the initial resting 
condition between scenarios, with all haemodynamics returning to within three percent of their initial 
values. However, the final resting state produced haemodynamics between five and ten percent lower 
than the initial values. 
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Parameter 
Rest 1 
Postural Change 
(% Change) 
Rest 2 
(% Change) 
Valsalva 
(% Change) 
Rest 3 
(% Change) 
Exercise 
(% Change) 
Rest 4 
(% Change) 
MCL Literature MCL Literature MCL Literature MCL Literature 
MAP 95±2.2mmHg 100 mmHg [77], [140] -8.6±0.3 1[141] -1.3±0.5 -15.8±0.6 0 -2±0.5 -0.5±4.5 19-40[140], [141] -5.5±0.7 
MPAP 16±0.8 mmHg 15 mmHg [77] -9.6±0.3 -33[141] -1.6±0.3 51.4±3 252 -1±0.5 12.7±4.6 67[141] -6.6±1.4 
LAP 10±0.7 mmHg 1-5 mmHg [77] -10.6±0.4 -111[141] -1.9±0.4 -24.2±0.6 - - -2.8±0.6 33.9±6.2 61[141] -6.3±2.1 
RAP 8±0.6 mmHg 
-5 -0 mmHg [77] 
 
-21.6±2 -157[141] -2.7±1.3 11.6±3.1 - - -2±1.5 57.9±11.1 33[141] -9±7.4 
MSQ 4.9±0.1L.min-1 4.9-5.6 L.min-1 [77] -7.3±0.2 -21[141] -1.2±0.4 -18.5±0.5 -53.13 -1.9±0.5 74.7±7.6 60-76[140], [141] -5.2±0.4 
MPQ 4.8±0.1 L.min-1 4.9-5.6 L.min-1[77] -7.5±0.4 -21[141] -1±0.5 -18.9±0.6 -53.13 -1.6±0.6 78±8.6 60-76[140], [141] -5.1±0.5 
 
Parameter 
Rest 1 
(% Change) 
Postural Change 
(% Change) 
Rest 2 
(% Change) 
Valsalva 
(% Change) 
Rest 3 
(% Change) 
Exercise 
(% Change) 
Rest 4 
(% Change) 
MCL Literature MCL Literature MCL Literature MCL Literature 
MAP 72.3±8.4 mmHg 
80-87 mmHg [140], 
[142], [143] 
-7.4±0.6 0 [141] -1.3±0.3 -11±0.6 - - -1.7±0.2 3.2±0.4 0-32[140]–[143] -5±0.7 
MPAP 18.5±0.2 mmHg 
15.9-31 mmHg 
[140]–[144] 
-
11.2±0.2 
-15 - -
49[141], 
[144], [145] 
-2±0.3 35.9±0.8 - - -1.9±0.2 23.1±1 
54-71[140], [142], 
[143] 
-7.9±0.3 
LAP 13.4±0.1 mmHg 
11-19 mmHg [141]–
[143] 
-
13.1±0.3 
-74 [141] -2.2±0.5 -25.1±0.5 - - -3.2±0.3 39.5±1.2 63-94[142], [143] -8.6±0.3 
RAP 6.7±0.2 mmHg 
4-8 mmHg [141]–
[143] 
-
25.1±1.5 
-105[141] -4.2±0.4 15.9±1.3 - - -3.6±0.6 48.4±4.8 
63-175[141]–
[143] 
-14.9±5.3 
MSQ 4±0L.min-1 
3.5-4.56 L.min-
1[140]–[143] 
-5.5±0.7 -12.5[141] -0.9±0.5 -13.7±0.6 - - -1.4±0.2 83.2±1.1 60-88[141]–[143] -3.9±0.8 
MPQ 4±0 L.min-1 
3.5-4.5 L.min-
16[140]–[143] 
-6.1±1.1 -12.5[141] -1.1±0.6 -14.2±0.4 - - -1.2±0.7 86.3±0.8 60-88[141]–[143] -4.3±0.5 
 
 
Table 3.9: Steady state haemodynamics in all scenarios for simulated healthy patients in the MCL 
Table 3.10: Steady state haemodynamics in all scenarios for simulated mild left heart failure patients in the MCL 
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For the mild left heart failure condition, all resting parameters except for MAP were within the ranges 
specified in literature (Table 3.10). Specifically, the LAP, PAP and RAP were elevated and MSQ and 
MPQ reduced compared to their healthy values, due to reduced LV function. MAP was lower than 
literature values, due to the lack of a baroreflex. 
Like the healthy simulations, the haemodynamic changes for simulated mild left heart failure (MLHF) 
patients during the postural change simulation were of a smaller magnitude that those reported in 
literature. The main differences between MCL and literature observations were the left and right atrial 
pressures (-13% and -25% in the MCL and -74% and -105% from literature).  
Validation of the Valsalva manoeuvre with MLHF was more complicated than the healthy case due to 
the fact the Lu and colleagues did not simulate a MLHF case without the baroreflex. Therefore, 
validation was performed using data from patients whose baroreflex was present. Figure 3.10 shows 
that there was a distinct difference in the systemic arterial pressure waveform for the mild LHF 
condition generated in the MCL compared to mild and severe heart failure waveforms from patients. 
There was no overshoot of arterial pressure during Phase 2, nor was there large variation in MAP in 
phases 2 and 4. This was primarily due to the lack of a baroreflex. Between heart failure and healthy 
simulations, the only similarity was that the percentage change in LAP was similar. This was to be 
expected, as the change in PVR was consistently 350 dynes.s.cm-5. 
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In exercise, all variables increased, however only the flow rate increases were similar to literature. All 
other increases were below reported values. The total cardiac output during exercise was lower with 
lower LV contractility, due to reduced functional capacity of the ventricle (Figure 3.11, left). This led 
to higher LAP in exercise, as the weakened LV was not able to respond accordingly to increased venous 
return (Figure 3.11, right).  
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Figure 3.10: Arterial pressure trace during a simulated Valsalva manoeuvre of a patient with mild left 
hear failure (LHF) in the MCL (top), arterial pressure traces of patients with mild LHF (middle) and 
severe LHF (bottom) [146]. 
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For assessment of transient repeatability, correlation coefficients were calculated between all of the ten 
tests. For the sake of readability, these coefficients are presented in Appendix B. All tests correlated 
positively with one another for all signals, indicating a high level of repeatability. Figure 3.12 shows 
the beat-to-beat mean LAP trace for all ten healthy simulations, and is a typical example of the 
differences between tests. From this figure, the only haemodynamic difference between signals was a 
vertical offset. This was due to small differences in initial priming volume of the MCL. 
 
 
3.4.6.2 FOM Validation 
Table 3.12 shows the FOMs determined for all of the heart conditions evaluated. The FOMREST and 
FOMCONG scores for the healthy simulation were near-perfect, indicating that the four key 
0 60 120 180 240 300 360 420
6
8
10
12
14
16
Time (s)
L
ef
t 
A
tr
ia
l 
P
re
ss
u
re
 (
m
m
H
g
)
 
 
1 2 3 4 5 6 7 8 9 10
REST REST
POSTURAL
CHANGE REST VALSALVA EXERCISEREST
  
Figure 3.11: Total cardiac output (left) and left atrial pressure (right) during rest and exercise in the MCL 
simulations for two different heart conditions. 
Figure 3.12: Left atrial pressure vs. time for 10 simulations of the test bed, showing the strong correlation between all 
signals. 
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haemodynamics remained within safe regions. The scores for FOMREST fell with decreasing heart 
failure, due to the reduced flow rate and higher LAP caused by the reduced ventricular contractility. 
The severe heart failure simulation produced an FOMREST score of -45.9%, which indicates that 3 of the 
4 variables were outside of the safe ranges for the whole duration of the scenario.  
FOMCONG -Left score for mild LHF was lower than that of the healthy simulation (83.4 vs. 94.6%), 
reflective of the increased LV volume caused by reduced heart contractility. This score decreased even 
further to 9% with severe heart failure, indicating that the LAP was between 15 and 25mmHg for nearly 
the entire simulation. The FOMCONG -right score was unchanged with decreasing LV functionality, due 
to the unchanged RV contractility.  
During the exercise in the healthy simulation, the 
cardiac output increased by 3.62 L/min, a suitable 
benchmark for the LV-assisted conditions. The 
heart failure conditions all resulted in higher 
increases in flow than the healthy test. This was 
due to higher stroke volume caused by greater 
LAPs. Despite this, the total cardiac output in 
exercise with heart failure was lower than that of 
the healthy simulation, due to the lower cardiac 
output during rest. 
 
Table 3.11 shows the range and standard deviation of each of the FOMs based on the baseline conditions 
simulated in the MCL. 
Table 3.11: Range of FOMs 
 Worst Best 
FOMREST (%) 2.7.±0.1 96.9±0.3 
FOMCONG (%) 
Left 9.8±2.4 94.6±0.4 
Right 9.8±2.4 95.1±1.2 
FOMSUC (s-1) 
Left - - 0 
Right - - 0 
FOMEX 
(L.min-1) 
Left 0 3.56±0.25 
Right 0 3.62 ±0.28 
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Heart Condition FOMREST 
FOMCONG FOMSUC FOMEX Left FOMEX Right 
L R L R CO (L/min) VAD (L/min) 
FOM 
(L/min) 
CO (L/min) VAD (L/min) FOM 
Healthy 95.3±0.5 94.6±0.4 95.1±1.2 -- -- 3.56±0.25 N/A 3.56±0.25 3.62 ±0.28 N/A 3.62 ±0.28 
MLHF 6.28±0.9 83.4±1.2 93.0±0.2 -- -- 3.66±0.03 N/A 3.66±0.03 3.88±0.03 N/A 3.88±0.03 
SLHF -45.9±0.2 9.8±2.4 96.7±.1 -- -- 4.13±0.06 N/A 4.13±0.06 4.31±0.07 N/A 4.31±0.07 
 
 
 
 
 
 
  
 
 
 
 
Table 3.12: Figures of merit for three different unassisted left heart failure conditions in the mock circulation loop.  
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3.5 Discussion 
The aim of this chapter was to simulate a repeatable sequence of patient scenarios for the purpose of 
quantitative comparison of VAD physiological control systems. This chapter described an attempt to 
simulate three common patient scenarios in a five-element Windkessel MCL: postural change, Valsalva 
manoeuvre and exercise. All three scenarios were simulated for healthy and left heart failure conditions, 
and haemodynamics were compared to values reported in literature to assess accuracy.  
All three scenarios simulated produced haemodynamics that were only somewhat similar to those 
presented in literature. A major reason for this was that there was no baroreflex in the mock circulation 
loop. Therefore, vascular resistance was controlled to be constant throughout each scenario. The change 
in MAP brought about by the change in posture would theoretically activate the baroreflex and cause 
increased heart rate, contractility, venous tone and systemic vascular resistance in order to restore MAP 
whilst maintaining cardiac output. As all of these elements were unchanged in the MCL, the reduction 
in MAP during the postural change and Valsalva manoeuvre was an expected result. 
In all three scenarios, some of the haemodynamic changes were not as large in magnitude as those 
reported in literature. However, with the exception of MAP, all haemodynamic changes were in the 
correct direction. In the postural change, the atrial pressures did not fall as much as reported in literature 
due to their not being enough volume removed from the loop during the study. However, we found that 
rapid removal of fluid amounts larger than the 300 mL in this study transiently emptied the right atrium, 
causing temporary cessation of RV contractility, before the fluid redistributed. Slower fluid shifts may 
prevent this from occurring, enabling a larger volume of fluid to be shifted. This would require 
replacement of the solenoid valves used to control filling and emptying with electropneumatic 
regulators to enable more controlled fluid shifts.  
In the exercise scenario, the MCL simulation had a similar increase in flow compared to literature, but 
the rises in pressure were not as high as those reported in literature. This may have been caused by not 
enough fluid being shifted from the SVC into the circulatory system.  
Even though the simulated scenarios did not produce as large a variation in haemodynamics as reported 
in literature, it can be argued that these scenarios can still be used to assess control system performance. 
The simulated postural change, for example, reduced preload to the RV, which translated into reduced 
LV preload a few heart beats later. In the healthy simulation, the ventricles instantaneously 
accommodated for the reduced preload by reducing its output via the Frank-Starling mechanism. 
Normally the baroreflex would then activate a few seconds later. The few seconds before the baroreflex 
activates is a low ventricle volume state, and therefore a high risk for suction. Physiological controllers 
should mimic the initial Frank-Starling response of the ventricle by reducing pump flow and preventing 
suction. Therefore, the simulated postural change is still a valid test case for control performance 
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assessment. As for the Valsalva manoeuvre, this scenario caused lower LV volume but higher RV 
volume. This is a particularly valid test case for dual LVAD control, as the left pump would have to 
decrease speed and the right pump increase speed to accommodate.  
Scenarios were simulated with a high degree of repeatability, as indicated by the high correlation 
between results. This was primarily due to the use of electronically-controlled pneumatic regulators, 
solenoid valves, pressure, flow and volume sensors which enabled precise control of resistance and 
circulatory volume. This is superior to other MCLs, as discussed in the literature review of this chapter, 
which adjusted preload and afterload using ball valves that were operated manually. This highlights that 
the MCL and test beds is precise enough for comparing VAD physiological control systems, and is a 
significant contribution of this thesis..  
The pressure offset (as per Figure 3.12) between simulations were primarily caused by small differences 
in initial volume for each test. The loop was filled manually with fluid until the mean circulatory filling 
pressure was between 8 and 9mmHg. This small difference in pressure is enough to cause this variation 
between tests. This limitation could be overcome in the future by improving the active control of loop 
filling volume to ensure that the same volume of fluid is added each time. To compensate this 
shortcoming in the remainder of this thesis, extra care was given to ensure that the MCP prior to the 
beginning of each test was restored back to 8.5mmHg, and that all pressure transducers were correctly 
offset prior to each test.  
In order to be able to quickly compare different control systems, quantitative performance metrics are 
required. In this chapter, metrics were proposed that covered four aspects of control system 
performance. These metrics were validated by using them to quantify the performance of unsupported 
left ventricles with three different levels of contractility. The results from this chapter provided context 
for each of the four performance metrics. Ideally, controllers evaluated later in this thesis could be 
considered “good” if their metrics are similar to those produced by the healthy heart. Conversely, “bad” 
controllers are those with scores close to those produced by the MLHF and SLHF simulations.  
Based on the high repeatability of these tests, control testing in this thesis will only be performed once. 
It was assumed that the sample standard deviations measured for each FOM in this chapter are similar 
to the true standard deviations. Based on this assumption, the largest standard deviation for each FOM 
will be used as the standard deviation for all controller results presented later in this thesis, and will 
therefore be used to determine if the differences between results are significant.  
There are a number of disadvantages to using the performance metrics presented in this chapter. Firstly, 
these FOMs are quite complex in their derivation and may not be easily understood at first glance by 
clinicians or engineers. Context is required in order for the reader to understand, for example, the 
relevance of a FOMREST score of 6%. Another shortcoming was that FOMREST lumped together 4 
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different haemodynamic signals together into one metric. It is not possible to determine which of the 4 
signals are responsible for a poorly-performing result without further investigation into the resulting 
waveforms. However, the purpose of these metrics is not to provide detailed and thorough insight into 
control behaviour. Rather, the objective of these metrics is to quickly rank the performance of 
physiological control systems with respect to their ability to maintain resting haemodynamics, prevent 
congestion, avoid suction and increase flow during exercise. This will enable investigators to subject a 
number of control systems to the same evaluation protocol and then quickly determine which controllers 
are most appropriate and which should be disregarded. Further characterisation of control system 
performance could then be performed by the investigator at their discretion. 
3.6 Limitations and Future Work 
There were a number of limitations in this study. The first was that while a MCL offers numerous 
advantages over a NM, it is not as customisable. Secondly, whilst the pressure and flow sensors were 
correctly offset to zero at the start of each simulation, calibration was not performed as frequently. 
Future work should incorporate sensor recalibration on a regular basis. Thirdly, the model of ventricular 
suction was not validated due to time constraints. Given that a previously validated suction model was 
used (albeit in a numerical model), it was assumed that it would give a similar response in the MCL. 
However, the use of pneumatic regulators and a different volume threshold may have modified the 
suction behaviour. Future work should incorporate validation of this suction mechanism. 
3.7 Conclusion and Summary 
This chapter described the evaluation framework that can be used to assess the performance of 
physiological control systems for rotary VADs. This framework involved the simulation of three 
common patient scenarios in a mock circulation loop, and the creation of performance metrics to 
provide quantifiable information about control system performance. The scenarios were validated 
against haemodynamic data presented in the literature, and it was found that perfect replication of 
haemodynamics was difficult without implementation of a baroreflex. However, the scenarios are still 
useful for evaluation of control systems because they subject the systems to preload and afterload 
changes similar to those observed in clinic. The performance metrics were validated using simulations 
of healthy and heart failure patients, and will enable fast ranking of controller performance. However, 
they are not easily understood at first glance and as such may not be useable beyond quick comparison 
of control systems. 
The purpose of this chapter was to describe the development and validation of a testing protocol for 
evaluation of control systems. In the context of this thesis, this protocol is essential to the development 
of any control systems for both single and dual rotary LVADs. It enabled thorough and quantifiable 
evaluation of control systems, which aids in identifying shortcomings and furthers development. This 
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protocol will be used in Chapter 4 in order to compare a number of LVAD control systems, and in 
Chapter 5 to assess the final dual LVAD control system.  
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4 LVAD Control System Development 
The previous chapter outlined the evaluation framework that was required prior to the development of 
a dual LVAD control system. The next two chapters discuss the development of this system. 
One method of developing a control system for dual LVADs is to adapt one of the many LVAD control 
systems previously reported. In order to select a suitable system for adaptation, a review of previously 
proposed control methods and their efficacy is required. However, as outlined in the previous chapter, 
direct comparison of controllers from the literature is difficult due to the inconsistent nature of 
evaluation. The aim of this chapter was to therefore experimentally compare the performance of a 
number of rotary LVAD physiological control systems. The results of this comparison will determine 
the most suitable LVAD control strategy, which may then be adapted for use in a BiVAD system.  
The significance of this chapter is that it presents, for the first time, a thorough and quantitative 
comparison of a number of different rotary LVAD control systems previously presented in literature. 
Since the evaluation techniques for physiological control systems differs between authors, the 
controllers that are worth further investigation can only be speculated. The definitive results in this 
chapter provide a starting point for development of a control system for dual LVADs. Furthermore, 
results from this chapter can provide both clinicians and engineers with relevant information about the 
performance of well-known physiological control systems. 
The chapter begins with a literature review, which summarises the previous work. A number of control 
systems from literature were then selected and implemented. Each control system was then subject to 
the test bed outlined in the previous chapter, and their performance measured using the figures of merit 
described in the previous section.  
This chapter uses some information and descriptions from three publications. The first manuscript 
entitled "Evaluation of a morphological filter in mean cardiac output determination: application to left 
ventricular assist devices.” was published in the scientific journal Medical and Biological Engineering 
and Computing (Volume 51 Issue 8, 891 – 899). The filter described in that publication was used to 
pre-process feedback signals. This publication is included in   
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Appendix E. The second manuscript, “Starling-like Flow Control of a Left Ventricular Assist Device; 
In Vitro Validation”, was published in Artificial Organs (38 (3), E46-56). This was a standalone 
evaluation of one of the control systems compared in this chapter, and I was the second author on this 
paper. The third publication, “Comparison of Linear and Non-Linear control of Flow and Pressure in a 
Rotary Left Ventricular Assist Device”, was submitted to the scientific journal "Medical and Biological 
Computing and Engineering" and at the time of the submission of this thesis is currently under review. 
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4.1 Aim 
The aim of this chapter is to experimentally compare a number of control systems from literature and 
determine the best performing LVAD control system to be adapted into a BiVAD controller. The 
specific objectives devised to complete this aim are: 
 Review the literature of physiological control systems. 
 Identify suitable control systems for evaluation. 
 Compare control systems using the framework established in the previous chapter. 
 Select one or more control systems for development into a dual LVAD control system. 
4.2 Literature Review 
Development of a physiological control system for a rotary LVAD required detailed knowledge of the 
work previously done in this field. This section presents a review of literature on these topics and 
discusses the gaps in the field. 
4.2.1 Structure of a physiological control system 
Pump speed is conventionally adjusted by a clinician, which is referred to as an operator-in-the-loop 
approach (Figure 4.1). Clinicians make adjustments to pump speed based on observations of patient and 
pump parameters, including haemodynamic and biochemical markers. A physiological control system 
involves careful selection of objective and implementation that can remove the clinician out of the loop, 
which reduces patient dependence on clinical staff. 
 
 
A physiological control system can be broken down into two components: a control objective and an 
implementation (Figure 4.2). The objective encompasses the selection of the controlled variable 
(usually one or more parameters from the pump or circulation) and the selection of the desired set point 
for this variable. Effectively the control objective describes the "physiological" aspect of physiological 
control, and should be based on strategies used by clinicians when operating LVADs manually. The 
implementation involves taking these clinically-based objectives and implementing some method to 
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Figure 4.1: Conventional pump operation, using a clinician-in-the-loop 
 77 
 
automate pump speed changes. Effectively the implementation section could be considered as the 
"control" aspect of physiological control.  
 
 
4.2.2 Control Implementation 
Automatic control has been integrated into numerous engineering applications, such as temperature 
control and cruise control for automobiles. A number of control theories and techniques are used across 
all of these applications. These theories and techniques are well understood. Most control objectives 
are independent of controller implementation, with the exception being those objectives that require 
optimisation of some function. This section is a brief summary of some of the more common 
implementations used for physiological control of rotary LVADs.  
4.2.2.1 Proportional, Integral and Derivative Control 
Perhaps one of the most popular control techniques is proportional-integral-derivative (PID) control. 
This linear control technique matches plant output to a target input by combining the raw, integral and 
derivative of the error signal (with respect to time) between target and measured plant output. The 
transfer function of a PID controller is shown in Equation (4.1). 
 
𝐺(𝑠) = 𝐾𝑝 +
𝐾𝑖
𝑠
+  𝐾𝑑𝑠 (4.1) 
The transient response of the system is affected by adjusting the three PID gains. Either Kd or Ki may 
be set to zero to produce a proportional-integral (PI) or proportional-derivative (PD) controller 
respectively. Numerous approaches are used for tuning PID gains, including analytical, heuristic, 
frequency response, optimisation and adaptive tuning methods [147]. For further information, the reader 
is directed to [148]. 
4.2.2.2 Fuzzy Logic 
Fuzzy logic (FL) control is a non-linear control technique that is an implementation of the natural multi-
variable logic that human beings perform every day. This control technique is suitable for plants that 
have unknown and/or complex characteristics that are difficult to model [149]. Briefly, FL control uses 
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Figure 4.2: General structure of a physiological control system for a rotary LVAD and its interaction with the human 
body 
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FL theory to implement the linguistic control laws that govern human decision making. Input and output 
variables are defined and sets of linguistically labelled classes are used to describe the range of possible 
values. An example of a set of labelled classes to describe a controller error signal could be {"Negative", 
"Zero", "Positive"}. Fuzzification is the process of acquiring discrete input values and converting them 
into degrees of membership of one or more of these classes. A set of fuzzy rules is then defined which 
dictates the changes in output with changes in input. An example of a rule is "If error is Negative, 
controller output is Positive". After the fuzzification step, fuzzy inferencing is used to evaluate all of 
the fuzzy rules with respect to the degrees of membership to the fuzzy sets. Each fuzzy output now 
obtains a value corresponding to the degree that output action should be applied. For further detail, the 
reader is directed to [149], [150]. 
4.2.2.3 Extremum Seeking Control 
Extremum seeking control, or ESC, adjusts control output (u) to reach the optimal point of some cost 
function l. This cost function may be related to some desired performance objective of the system that 
may be unknown and/or time varying. ESC can be thought of as a real-time optimisation algorithm for 
control purposes. The advantage of ESC is that it does not require a priori knowledge of the cost 
function, and can also be used for time-varying cost functions. A variation of ESC, slope-seeking 
control (SSC) maintains operation at a precise slope on this cost-function. Further details of the 
implementation of the ESC algorithms can be found in [82], [86].  
4.2.3 Control Objectives 
Physiological control systems automatically adjust pump speed in response to changes in one or more 
haemodynamic or pump variables in order to satisfy some clinical objective. This section presents a 
literature review of the different control objectives for rotary LVADs. 
4.2.3.1 Differential Pressure 
The differential pressure (ΔP) across a rotary blood pump refers to the difference in fluid pressure 
between the outlet and the inlet of the pump. The ΔP, or head (H), generated across a rotary pump 
depends upon the speed of the impeller and the flow rate of fluid through the device. The relationship 
between these three variables is commonly presented using an H-Q curve (Figure 4.3). 
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The justification for 
controlling ΔP, 
according to 
Giridharan and Skliar 
(2003) is that the native 
ventricle maintains a 
constant differential 
between the pulmonary 
veins and the aorta, and 
therefore the pump's 
control system should 
do likewise [152]. 
Waters and colleagues 
(1999) were the first to 
propose maintaining ΔP constant as a control strategy, and used proportional-integral (PI) control to 
maintain ΔP at 110mmHg [92]. Controller gains were chosen based on root locus analysis of the 
system's stability. The gains were selected such that any oscillation of ΔP caused by residual 
contractility did not result in oscillatory pump speed. Evaluation was performed using a lumped-
parameter numerical model. The control system was subject to step changes in filling pressure (± 
50mmHg) and systemic vascular resistance (1-50%), and the time taken for ΔP to return to the set-point 
was measured as a figure of merit. The settling time was found to be approximately 10 seconds.  
The most significant investigations into ΔP control were performed by Giridharan and colleagues [106], 
[112], [123], [153]–[155]. These authors extended on the previous work by evaluating ΔP control of 
both axial and centrifugal pumps. Initially the authors used fixed gain PI control, with gains determined 
using an exhaustive numerical search in order to minimise the controller error and pump speed 
oscillations[123]. These gains resulted in a settling time of 30 seconds. The authors later used gain 
scheduling to reduce pump speed oscillations, but without any improvements in settling time [154]. 
Evaluation was performed by simulating a state of exercise using both a NM and an MCL, and 
comparisons were made with a pump operating at constant speed as well as a simulated healthy LV. 
During exercise simulations in-silico, ΔP control increased pump speed and restored cardiac output to 
a similar level as the healthy ventricle. In-vitro tests showed a similar response, however\ the controller 
was implemented with user-in-the-loop in-vitro, with the investigators manually changing pump speed 
to meet the control objective. Thus practical implementation of this algorithm has not been investigated. 
Giridharan and colleagues extended the concept of ΔP control into maintaining the differential between 
the pulmonary vein and aorta (ΔPaopv) constant[156]. The intention of the authors was to remove the 
systolic portion of LVP, and therefore truly maintain the difference between heart preload and afterload 
 
Figure 4.3: Example of a H-Q, showing the relationship between speed, flow and 
pressure in the HeartWare HVAD [151]. 
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to be constant. Another significant benefit of this approach is that this pressure difference is maintained 
regardless of cannula resistance. The authors used a mock circulation loop to assess the steady state 
validity of this control variable. Manual changes in pump speed were used. Qualitative comparisons 
were made with an unsupported LV, constant speed control and ΔP control, using a healthy LV, failing 
LV and asystolic LV. The authors concluded that ΔPaopv control was able to consistently restore the 
steady state flow rate close to the baseline values during rest and exercise states, regardless of heart 
condition.  
Maintaining ΔP constant increases the afterload and preload sensitivity of the pump equally. Therefore, 
independent changes in either of these variables will result in a corresponding change in pump flow, 
which may be advantageous. However, there are two disadvantages to this approach. Firstly, 
simultaneous changes in afterload and preload may not be accommodated for by the control system. 
Secondly, the native ventricle is preload sensitive but highly afterload insensitive. Therefore, making 
the LVAD-supported LV equally sensitive to both makes the system behave less like the native 
ventricle, potentially increasing the risk of hazardous events like ventricular suction. Whilst the exercise 
performance has been thoroughly assessed, the ability of this control system to avoid and/or handle 
suction has not been assessed at all. 
4.2.3.2 Aortic pressure 
Aortic pressure (AoP) is normally maintained by the baroreflex, which adjusts vascular resistance, 
venous tone, heart rate and contractility [133]. However, this mechanism may be diminished in heart 
failure, partly due to reduced ventricular contractility. Adjusting pump speed to maintain AoP would 
be able to compensate for a reduced baroreflex mechanism. This approach was proposed by Wu and 
colleagues as a primary control objective [93], [113], [116]. The authors identified that solely 
maintaining AoP constant without knowledge of the venous return may result in suction events, so they 
included constant ΔP control as a secondary objective. The reasoning behind this is that if afterload and 
pump differential pressure are constant, then by extension LVAD inlet pressure must be constant as 
well, which helps to avoid suction. The authors evaluated their system using both a NM and a MCL, 
with different evaluation protocols in each. In the NM evaluation, the authors performed a series of step 
changes in SVR, and then simulated a transition from rest to exercise. Exercise was simulated by 
increasing RV contractility and decreasing SVR. In the MCL, only changes in contractility were used 
to disturb the system. The authors assessed the performance of AoP control by comparing the changes 
in arterial pressure, total flow and left atrial pressure during each scenario obtained using their algorithm 
with those obtain from simulating healthy and chronic heart failure patients undergoing the same 
scenarios. The system exhibited settling times between 2 and 5 seconds for all disturbances, and was 
able to recover from suction in the MCL. This approach requires estimation or measurement of two 
pressures in order to prevent suction and maintain perfusion. This control strategy appears to be quite 
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beneficial; however its performance has only been compared to a healthy left ventricle and has not to 
compared to any other system 
4.2.3.3 Constant Preload 
One of the aims of physiological control of a rotary LVAD is to avoid ventricular suction.  
Control of LV end-diastolic pressure (LVEDP), or preload, to a set point is the most direct method of 
avoiding suction because it would maintain a constant level of fluid in the ventricle. Bullister et al. 
(2001, 2002) developed a control strategy based around maintaining LVEDP to a set point, and they 
utilised their own custom-made pressure sensor to measure LVEDP for feedback [115], [157]. The set 
point selection was automatically optimized to ensure that AoP remained at an appropriate level, whilst 
ensuring LVEDP remained within safe ranges. Integral control was used to implement this objective, 
whilst the addition of ventricular collapse and retrograde flow detection algorithms as outer control 
loops enhanced the safety of this control system. No details were given about the latter components. 
The authors assessed the controller using a Donovan MCL[158]. Time-domain performance was 
assessed by starting with constant speed operation and then switching the control system on. 
Haemodynamic performance was assessed by simulating an exercise condition through an increase in 
heart rate. The controller’s performance was assessed by observing the changes in LVEDP and arterial 
pressure during exercise. No comparison was performed with any other control system. The authors 
found that their system was able to reach the target LVEDP within 10 seconds. The control system was 
also found to automatically adjust the target LVEDP during increases in heart rate to ensure increased 
perfusion pressure during increased activity. No assessment of suction avoidance was performed, and 
no comparison was made to any other system. 
More recently, Alomari et al.(2011) proposed sensorless control of inlet pressure to a constant value 
[110]. The authors used a dead-beat control algorithm, which used an autoregressive exogenous (ARX) 
model of the system to determine the required pump output in the shortest possible time. Evaluation 
was performed using an ARX model of pump and circulatory system. Assessment involved using square 
waves of various amplitudes, frequencies, means and duty cycles as the set point and calculating the 
maximum and minimum error between target and measured inlet pressure. Errors were kept between ± 
0.92mmHg by the controller. The response time of the control system was rapid, with a nearly 
instantaneous rise time. However this system was not compared to anything else and its ability to 
respond to realistic patient scenarios was not assessed. 
Maintaining pump preload constant could be a suitable approach for preventing suction. However, no 
authors have confirmed this assumption in their evaluations, nor has it been compared to other control 
systems. Additionally, selection of an appropriate set point for end-diastolic pressure is difficult because 
the LVEDP is not constant in the native human heart. Such a system would rely heavily on the user's 
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clinical experience. Finally, no pressure sensors are commercially available for use in rotary blood 
pumps (although some are in development) making practical implementation difficult [159], [160]. 
4.2.3.4 Pulsatility Control 
Provided that the ventricle has some residual contractility, all haemodynamic signals will exhibit a 
sinusoidal-like characteristic, referred to as pulsatility (PIx). The native Frank-Starling mechanism 
means that the strength of residual contraction (hence the amplitude of pulsatility) depends upon the 
left ventricular end-diastolic volume. This is shown in Figure 4.4, in which the pulsatility of the flow 
signal is shown to decrease as preload decreased due to an increase in pump speed. Therefore, pulsatility 
can be used as a surrogate for preload, negating the need for a pressure sensor on the pump inlet.  
 
 
Choi et al. (2001) was the first to develop a control system whose aim was to maintain a constant level 
of pulsatility [80]. The authors implemented this algorithm using both fuzzy logic (FLC) and 
proportional-integral-derivative (PID) control. The authors defined pulsatility of flow (expressed in 
L.min-1) as per Equation (4.2). 
 𝑃𝑢𝑙𝑠𝑎𝑡𝑖𝑙𝑖𝑡𝑦(𝑡) = 𝐿𝑃(|𝐻𝑃(𝑄𝐿𝑉𝐴𝐷(𝑡))|) (4.2) 
Where HP and LP are 3rd-order Butterworth high-pass and low-pass filters with cut-off frequencies of 
0.5 and 0.25 Hz respectively. Evaluation was performed in a NM, MCL and in a single acute animal 
experiment. Haemodynamic performance was evaluated using PVR and SVR step changes in the NM, 
SVR step changes in the MCL, and simply switching on the control system in the animal. Each test 
began with the pump operating at constant speed (the minimum pump speed), before switching the 
control system on. The response of the LVAD flow, atrial pressures and arterial pressure to changes in 
preload and afterload was observed. A qualitative comparison of time-domain performance was 
performed with PID control, in which the control system was switched on and the PIx was monitored 
for undesirable characteristics (oscillations, slow settling time). 
In the numerical model, the authors showed that their algorithm restored atrial pressures (6 – 8mmHg) 
and arterial pressures (90 – 120mmHg) at rest. The algorithm also increased pump flow during increased 
Figure 4.4: LVAD speed (a), flow (b) and flow pulsatility (c) during a speed ramp test [80]. 
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venous return and increased afterload. The controller settling time was between 35 and 40 seconds, as 
interpolated from the graphs. Finally, the authors found that fixed-gain PID control performance was 
affected by contractility, whilst the FLC performance was not, suggesting that FLC is the preferred 
method of control implementation. This paper is the only comparison of PID and FLC implementation 
techniques for rotary LVAD control in the literature. The investigators also found that different set 
points were required for NM, MCL and animal studies [80].  
One of the shortcomings of maintaining a constant PIx is that PIx is not a monotonic function of pump 
speed, as shown in Figure 4.4. PIx decreases as speed increases until suction occurs, at which point PIx 
increases again. Therefore there are two speeds that can produce the same PIx, and one of these solutions 
is in a state of suction. To overcome this, Choi and colleagues (2005) found that the ratio between flow 
and pressure pulsatility (PIratio) changed significantly during ventricular suction, but was relatively 
constant when there was no suction regardless of the base level of residual contractility [95]. Thus they 
evaluated a new control objective that maintained the PIratio at a level just before suction occurs.  
This control system was implemented using fuzzy logic control and evaluated using a NM. The system 
was subject to step changes in preload, afterload and ESPVR, and its performance was compared to that 
of a PIx control system. They found that the PIratio objective was able to avoid suctions in all scenarios 
tested, whereas using the PIx objective resulted in suction events when the ESPVR decreased. 
Endo and colleagues (2002) investigated the use of motor current pulsatility to detect and avoid 
ventricular suction [119]. Current pulsatility was calculated as the difference between maximum and 
minimum divided by the beat-to-beat mean current every cardiac cycle and referred to as the index of 
current amplitude (ICA). The authors developed a controller that maintained ICA at 0.18, which was 
found to be always below the point of suction (Figure 4.5). The authors used a proportional controller 
which adjusted the speed in 50 RPM increments every 3 seconds. Evaluation was performed by 
subjecting the control system to changes in afterload and contractility in a MCL and observing the 
convergence time. The controller took 1 minute to converge to a new pump speed with each parameter 
change. Unlike flow pulsatility used by Choi et al., this sensorless feedback variable appears to be 
independent of changes in contractility. It still requires input by a clinician for the target ICA, which is 
not necessarily a concept easily understood by clinicians.  
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Using the pulsatility of an easily obtainable signal as a surrogate for preload is feasible and may be able 
to prevent suction. However, as the relationship between contractility and pulsatility differs between 
patients, the selection of an appropriate set point is difficult, and may require individual patient 
calibration. Additionally, the method of calculating pulsatility differs between authors. 
4.2.3.5 Constant Flow 
Clinicians may wish to treat their patient by operating the pump at a constant flow rate in order to ensure 
end organ perfusion. As outlined earlier, the flow rate through a rotary pump depends primarily on the 
speed and differential pressure across the pump. Changes in both preload and afterload can vary pump 
flow. A constant flow control algorithm adjusts pump speed to maintain a constant flow. 
Constant flow control algorithms have been proposed for automatic control of rotary pumps used for 
cardio-pulmonary bypass (CPB) and for extracorporeal membranous oxygenation (ECMO) [94], [97]. 
Constant flow is suitable for these applications, as the patient is immobile and thus there is little 
variation in cardiac demand. Lim and colleagues (2011) proposed a method of controlling LVAD flow 
to a sinusoidal set point using non-invasive measurements [109]. It was implemented using deadbeat 
control, and assessed using a NM. Evaluation involved performing a step change in target flow, as well 
as simulating an exercise condition. The authors showed that this control approach could track target 
flow within ± 0.5L.min-1, and that the controller could maintain flow rate in the exercise case. However, 
this required a manual increase in the target flow rate. This limits the application of this control system 
for active patients. 
Figure 4.5: Index of current amplitude (ICA), or current pulsatility, with increased 
pump speed. t corresponds to cessation of aortic valve flow and s corresponds to the 
point at which suction occurred[119]. 
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4.2.3.6 Frank-Starling Control of Pump Flow 
The demand for blood flow varies depending on patient activity and heart condition, thus the set point 
in a flow controller must vary. The native ventricle varies flow automatically with preload due to the 
Frank-Starling mechanism; however this mechanism is diminished in failed ventricles. Therefore, direct 
mimicry of this mechanism using a physiological control system should improve preload sensitivity. 
Maslen and colleagues (1998) were the first to propose a physiological control system that mimicked 
the Frank-Starling mechanism of the native ventricle[161]. This system was designed to vary pump 
flow rate in response to preload by adjusting the pump speed, forcing the pump to exhibit a flow-preload 
response similar to that shown in Figure 4.6. However, no implementation or evaluation of this 
controller was presented. 
 
 
Salamonsen and colleagues (2012) described a Frank-Starling like control system that sets a target flow 
rate as a function of preload [127]. This controller used flow pulsatility (difference between maximum 
and minimum flow rate each cardiac cycle) as a surrogate for preload which eliminated the need for an 
implantable pressure sensor. The authors suggested that the relationship between beat-to-beat mean 
flow and flow amplitude should be maintained linear using a physiological control system (Figure 4.7). 
The paper explained the theory underlying such a controller but did not present evaluation of the control 
system in any format.  
Figure 4.6: An example of the flow vs. preload response exhibited by the native ventricle that could be mimicked 
using physiological control [161]. 
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The authors highlighted that 
tracking a variable target flow 
rate is difficult, because the 
initial target flow rate post-
disturbance is an over or 
underestimate of the final value 
of flow, especially with a steep 
relationship between target flow 
and pulsatility. This could result 
in a hyper sensitive control 
system that spends excessive 
time hunting for steady state. The authors proposed that after a system disturbance, the control system 
should predict the steady-state target flow rate and adjust speed to meet that, rather than using the 
instantaneous target flow rate determined using the linear relationship between flow and pulsatility. To 
implement this, the investigators proposed that the target flow rate should be determined using an arc 
drawn from the operating point to the target control line, rather than simply moving vertically from the 
operating point to the target control line. Two different arcs were proposed, one with its centre at the 
origin of the Cartesian plane and the other with its centre along the control line (Figure 4.8). However, 
as this was a theoretical paper, comparison of these approaches was not performed. One shortcoming 
of Salamonsen's approach is that flow amplitude is dependent on systolic pressure generated by the 
ventricle. This pressure varies not only with preload but also with changes in the inotropic state of the 
heart, such as those caused by changes in patient activity or with recovery or worsening of the baseline 
heart condition (Figure 4.7). Therefore, changes in activity or heart condition may be misinterpreted as 
preload changes, causing the control system to behave incorrectly. 
 
 
 
Figure 4.7: Starling-like relationship between mean flow (QVAD) vs. flow 
pulsatility (QVAD,PULS) for different levels of contractility [127]. 
Figure 4.8: Calculation of steady state target flow rate using an arc centred about the control line (left) and 
about the origin of the Cartesian plane (right). OP - operating point; CL - control line; QVAD - pump flow; 
QVAD,PULS - pump flow amplitude. 
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Gaddum and colleagues (2014) recently assessed the aforementioned control system in a mock 
circulation loop [128]. The target flow was calculated using the radial about the origin method (Figure 
4.8, right).  Evaluation consisted of step increases in filling pressure (to assess preload sensitivity), step 
decrease in PVR (to assess suction avoidance) and a simulated exercise state.  The Starling-like control 
system was shown to have a higher preload sensitivity, better avoid suction and produce higher flow 
rates during exercise than constant speed control. However, this system was not compared to any other 
physiological control system, and the radial about the control line methodology was not assessed.  
The flow control system developed by Moscato et al. automatically varied flow rate using a linear 
relationship between LVP and target flow[91]. The justification for this approach is that, assuming that 
the LVAD provides all flow during mechanical support, the afterload impedance that the LV sees can 
be approximated as the ratio of QLVAD and LVP. Maintaining constant afterload impedance therefore 
ensures that target QLVAD varies linearly with LVP, which itself is a function of LVEDP, inadvertently 
mimicking the Starling relationship between flow and preload. 
Proportional-integral control was used to implement this algorithm. For the feedback variables, QLVAD 
was measured, and LVP was estimated using an extended Kalman filter utilising QLVAD, AoP and pump 
rotational speed as inputs. The authors evaluated this control system using a NM by perturbing the 
model in a number of ways, including exercise simulations, increased contractility, step changes in 
blood volume and step changes in afterload. During each disturbance, the authors compared the changes 
in afterload impedance as well as the changes in flow with changes in LVP for a controlled LVAD and 
for a LVAD operating at constant speed.  
The authors found that maintaining constant afterload impedance improved the overall preload 
sensitivity of the LVAD system – the flow automatically varied with LVP, avoiding suction situations 
that otherwise occurred during constant speed operation. During the various scenarios, the maximum 
variation in afterload impedance with the constant speed controller was shown to be 26.3%, whereas 
there was no variation with the control system. The authors suggested that maintaining this impedance 
constant enabled controlled training of the ventricle and may lead to recovery of the ventricle. Long-
term in-vivo testing is required to determine if this is the case. The settling time of the control system 
was approximately seven seconds. These investigators did not report any difficulties using a variable 
target flow rate, however the use of the Kalman filter may have damped the response of preload. 
Additionally, a pressure sensor is still required for AoP in order to estimate the LVP. Finally, another 
shortcoming of this study was that this controller was not compared with any other control systems. 
A control system that mimics the native Frank-Starling relationship is the most direct way to improve 
preload sensitivity. Despite this, little work has been completed on this field, with no comparisons 
performed with other controllers. It is unknown whether LVEDP or pulsatility would be a more suitable 
measure of preload in this control system. 
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4.2.3.7 Flow Control Based on Systemic Vascular Resistance 
Faragallah and colleagues (2012) [103] developed a control system that set the target flow rate based 
on the systemic vascular resistance. The SVR was estimated in real time using a 6th order NM, using 
11 iterations of a Fibonacci optimisation sequence. This estimated SVR was then substituted into a 
model of a healthy unsupported patient to determine the required cardiac output. A second Fibonacci 
optimisation operation (10 iterations) was then used to adjust pump current until desired pump flow 
was reached. Evaluation was performed using a NM by reducing SVR by 50%, and comparing the 
steady state values of flow and motor current before and after the disturbance. The controller increased 
motor current to increase flow from 9.224 L/min to 11.912 L/min. Basing pump flow rate on a model 
of a healthy patient is a logical approach to this problem. However no comparison was performed with 
other controllers and no time domain performance was characterised. Additionally, the flow rates were 
much higher than the resting cardiac output of 5 L/min. No mention was made of the time it takes to 
complete each iteration of the Fibonacci optimisation, so the time-domain performance of this approach 
is unknown. 
Wang and colleagues (2012) [104] extended the aforementioned concept by incorporating a suction 
detector, which interrupted the SVR control logic if suction was detected. Evaluation also involved a 
step change in SVR in the same NM as above. The suction detector correctly classified suction in 98.1% 
of cases. The rise time of the system was approximately 10 seconds, with a settling time between 15 
and 20 seconds. Further evaluation of this system in a different evaluation environment is required to 
ensure that other haemodynamic pressures, including LAP and AoP, are not adversely affected.  
4.2.3.8 First and Second Derivatives of Pump Parameters 
Baloa et al. (2000) established that as pump speed increases, mean pump flow increases at a decreasing 
rate before reaching a plateau (or even decreasing) after suction occurs [111]. This can be seen in the 
top graph of Figure 4.9, which shows how the rate of change of pump flow rate with pump speed starts 
as a positive value, decreases to zero just before 12 kRPM (reportedly the point of suction), and becomes 
slightly negative. The rate of change of this curve is shown in the bottom graph of Figure 4.9, which 
falls below zero at the point of suction. Minimum flow and pulsatility of ΔP also exhibit similar 
behaviour [86], [87].  
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Researchers at the University of Pittsburgh were the first to develop control algorithms based around 
utilising the first derivative of the minimum flow each cardiac cycle (QLVADmin) with respect to pump 
speed as the feedback variable. The algorithm was first described by Chen et al. (2005) [162] , with 
further evaluation performed by Simaan et al (2009) [99]. These authors showed that the first derivative 
of QLVADmin with respect to pump speed is positive when not in suction, and rapidly falls to a negative 
value when suction occurs (Figure 4.10). By maintaining this slope at zero, suction is avoided whilst 
providing the maximum amount of flow.  
Figure 4.9: Pump flow (a) and first derivative of pump flow with respect to pump speed (b) during a speed ramp 
[111]. The first derivative of pump flow falls below zero just prior to the point of suction at 12 kRPM, which 
may be useful as an indicator of suction. 
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The speed signal was updated using an integral controller, with the speed update rule shown in Equation 
(4.3).  
 
𝜔(𝑘 + 1) = 𝜔(𝑘) +  𝑐.
𝑑𝑄𝐿𝑉𝐴𝐷𝑚𝑖𝑛
𝑑𝜔
 (4.3) 
 
Where ω is pump rotational speed (RPM), k is the update sample, QLVADmin is the minimum pump speed 
each cardiac cycle (L.min-1) and c (min2.L-1) is the gain parameter used to control the rate of speed 
adjustment. Evaluation was performed using a NM. The perturbations were step changes in SVR, and 
its performance was compared to that of a controller that maintains maximum possible flow rate in 
[162], and ΔP control in [99]. The authors were primarily interested in comparing the control systems’ 
ability to avoid suction. When comparing with ΔP control, the authors compared the steady state flow 
and arterial pressure at three levels of resistance. The authors also added noise to the flow signal to 
determine if noise impacted on the controller’s ability to avoid ventricular suction. Suction frequency 
and severity were measured using two indices. The first was ρ, which was a percentage of the total time 
T (seconds) that the pump speed exceeded the speed at which suction was known to occur (Equation 
(4.4)). 
 
𝜌 =
∑ ∆𝑡𝑖
𝑖=𝐼
𝑖=1
𝑇
× 100 (4.4) 
 
Figure 4.10: LVAD speed (top) and flow (bottom) during an in-vivo experiment, showing the change in minimum 
flow as suction occurs[99]. 
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Where Δti (seconds) is the ith interval over which pump speed exceeded suction speed, and I is the 
number of such intervals. The second index η measures the percentage average speed penetration into 
suction (Equation (4.5)). 
 
𝜂 =
𝜔𝑠̅̅ ̅ − 𝜔𝑠
𝜔𝑠
 × 100 (4.5) 
Where ωs is the suction speed (RPM), and 𝜔𝑠̅̅ ̅ is the average speed over the intervals where suction 
occurs and is calculated using Equation (4.6). 
 
𝜔𝑠 =  
∑ ∫ 𝜔(𝑡)𝑑𝑡∆𝑡𝑖
𝑖=𝐼
𝑖=1
∑ ∆𝑡𝑖
𝑖=𝐼
𝑖=1
 (4.6) 
 
The authors found that QLVADmin control algorithm avoided suction when the SVR increased by 50%. 
Interpolation from the figures in the paper revealed a settling time for pump speed of approximately 10 
- 15 seconds using the noise-free signal. The main difference between QLVADmin and ΔP control was that 
QLVADmin control produced slightly higher arterial pressures and total flow rate for each level of 
resistance, which shows that this algorithm provides greater unloading of the ventricle. No comparison 
was made between the transient responses of these two controllers. Finally, the authors showed that the 
addition of noise (SNR < 20) into the feedback signal increased the number of and severity of suction 
events. Thus, the main disadvantage of this algorithm is that it relies on a high-fidelity flow probe or 
accurate noise-free estimation algorithms in order to measure the minimum LVAD flow.  
Gwak (2007) used extremum seeking control (ESC) and slope seeking control (SSC) instead of integral 
control to adjust the pump speed until the peak of minimum flow vs. pump speed curve was reached[86]. 
This controller was evaluated using a NM by switching the controller on and observing the transient 
behaviour. The author found that the controller overshot the peak and did not return, resulting in 
sustained ventricular suction. This was because the cost function (i.e. slope of the minimum flow vs. 
pump speed curve) was not monotonically decreasing in the numerical model, making it difficult to 
locate the peak. To overcome this, the author replaced the entire NM with a cost-function obtained in-
vivo. The transient response of both ESC and SSC was measured after switching on the controller. The 
ability to accommodate different patient scenarios was also evaluated, with the scenario variations 
simulated by changes in the shape of the in-vivo cost function. Overall, ESC exhibited more overshoot 
and oscillations than SSC. Slope seeking control was more stable than ESC, indicating that it is easier 
to maintain the first derivative close to (but not equal to) zero. Both options had settling times of 120-
150 seconds. Both ESC and SSC systems using minimum flow were able to reduce pump speed to avoid 
ventricular suction. However, the settling times were long. Additionally, the replacement of a valid 
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numerical model with a cost function is a gross simplification of the circulatory system, and the 
variations in the cost functions were not validated against different patient scenarios, limiting the value 
of this study. The author also highlighted that SSC was preferable to ESC because the peak point of the 
cost function was close to the point of suction. As SSC kept the pumps speed just below the peak point, 
it operated with a large safety margin. However, determination of the optimal slope for each patient was 
not discussed. 
A solution proposed both by Arndt et al. (2008,2010) and Gwak et al. (2011) to determine the optimal 
slope for a ΔP pulsatility vs. pump speed curve (Figure 4.11, top) was to use ESC to operate at the 
minimum of the first derivative of this curve i.e. locating where the second derivative is zero (Figure 
4.11, bottom) [82], [83], [87]. Gwak and colleagues [87] compared this approach using ΔP pulsatility 
and minimum pump flow approaches, using a simplified NM for evaluation (previously described in 
[86]). Assessment involved switching the controllers on and measuring time until convergence. 
Variations in circulatory conditions were facilitated by adjusting the cost function used for the plant 
model. The authors found that ΔP pulsatility had a shorter settling time than using the minimum pump 
flow (300 vs. 1200 seconds). No evaluation was made against realistic patient scenarios, however, this 
controller is anticipated to be too slow to handle sudden changes in patient condition.  
The controller developed by 
Arndt and colleagues (2008, 
2010) was more complicated 
than that developed by Gwak et 
al. (2011). The controller had 
two modes of operation: partial 
assist and full assist (FA). In 
partial assist mode, the first 
derivative of pulsatility of ΔP 
(GPI) was kept constant at -
2mmHg, at which point the aortic 
valve remained open. In FA 
mode, ESC was used to maintain 
the pump speed at the minimum 
of the GPI vs. speed curve. 
Implementation consisted of a cascaded control loop. The outer loop was responsible for maintaining 
GPI at a set point (for partial assist mode) or at the minimum (FA mode). The output of the outer loop 
was a desired pulsatility index, which was used as the input for the inner loop. The inner loop controlled 
pump speed to maintain the desired PI. The inner loop was tuned using internal model control to produce 
robust stability and performance for varying plant gains. The outer loop was controlled using integral 
 
Figure 4.11: Pulsatility vs. Speed curves (A) and gradient of the pulsatility 
vs. speed curves (B) for three levels of preload[83]. 
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control, with the gain set at 1. Evaluation was performed using a LV-only NM, which simulated the 
pulmonary circulation with a single pressure source. The controller was subject to step changes in 
preload, transitions between FA and partial assist and sudden changes in contractility. Performance 
metrics included observing the settling time, the number of suction events that occurred and time to 
resolve suction events and restore normal operation. The response time of the inner loop was fast, with 
the PI restored to its initial value within 25 seconds, although this was reduced to 15 with the 
implementation of dedicated suction avoidance strategies[83]. The outer loop was much slower, with 
the system taking 500 seconds to switch from FA to partial assist mode. Settling time after switching 
on the outer loop was 2500 seconds. The authors argue that the long settling times for the outer loop 
are suitable because the inner loop is fast enough to avoid suction events, and that changes in the target 
GPI will mainly occur with changes in patient parameters, which happen over a long time scale. No 
comparison was performed with any other control system, nor was the controller evaluated outside of 
the in-silico environment.  
4.2.3.9 Suction Avoidance 
Ferriera, Boston and Antaki (2009) describe a method of control that relied on maintaining the pump 
speed as high as possible without inducing suction[96]. Discriminant analysis was used to combine 8 
suction indicators into two discriminant scores, which represented whether the LV was in a state of no 
suction, moderate suction or severe suction. Fuzzy logic was then used to adjust pump speed based on 
these scores. Pump speed modifications were kept within ±5% of the current speed. Evaluation was 
performed using an LV-only NM. The controller was subjected to two simulated scenarios with three 
different levels of contractility. Exercise was simulated by performing step reductions in SVR and step 
increases in HR, and hypertension was simulated by a step increase in SVR. The settling time of the 
controller after switching on was approximately 110 seconds, and it reduced speed within 30 seconds 
of a suction event. The controller appeared quite conservative, but the maximum allowable speed 
change could be adjusted by the clinician to improve responsiveness. Interestingly, the pump speed 
actually decreased in exercise, which is the opposite of what is expected to occur. This indicates that 
the exercise simulation did not incorporate any increase in preload.  
Numerous investigators have proposed algorithms for detecting and classifying ventricular suction 
events [55], [163]–[168]. However, as these systems do not adjust pump speed based on the detection 
of suction, they do not satisfy the definition of a physiological control system and as such will not be 
discussed here. 
4.2.3.10 Motor Current 
Pump motor current is attractive for use as a feedback control variable because it can be obtained non-
invasively, without the need for implanting different sensors. Nishimura and colleagues (1997) [121] 
controlled a centrifugal blood pump at a constant motor current, which increased pump speed when ΔP 
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rose. Evaluation was performed in-vivo using nine adult male sheep. Constant speed operation was used 
for two sheep and constant current control was used in seven sheep. In the sheep with current control, 
rotational speed corresponded positively with ΔP and inversely correlated with pump flow. Current 
control reduced the amount of flow fluctuations over a thirty minute period whilst sheep were upright 
in a cage. Maintaining a constant flow by way of current control is good for bypass applications. 
However, some flow variation is required to avoid ventricular suction and accommodate variations in 
cardiac demand. 
4.2.3.11 Multi-objective Control 
Multi-objective control (MOC) strategies involve combining two or more control objectives into a 
single controller. Gwak et al. (2005) proved the feasibility of MOC by combining a suction prevention 
controller with a venous-return matching controller [85]. The suction prevention controller first 
determined the ratio between the powers of the first and second harmonic (HSI), which was found to 
decrease during suction, and kept this to a constant value. The venous return controller (VRI) 
maintained the first derivative of pump flow with respect to speed close to zero. Final speed output of 
the control system was the weighted average of two separate PI controllers. Evaluation was performed 
using a LV-only MCL. The system's response time was assessed by performing step changes in preload 
and afterload, facilitated by manual adjustments of needle valves. The two components of this MOC 
strategy were tested separately before being combined. Individually the VRI had rise times of 10-15 
seconds, whilst the combined controller had a rise time of 30-35 seconds. HSI control did not change 
the pump speed at all on its own. When combined, the VRI controller saturated to the upper limit whilst 
the HSI controller reached a low pump speed. The weighted average of the two prevented excessive 
pump flow.  
One of the most successful MOC strategies was proposed by Vollkron and colleagues (2005) [84]. This 
system consists of four logical units that interacted to adjust flow with cardiac demand as well as 
alleviate suction events (Figure 4.12).  
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The closed loop controller adjusted pump speed based on four different control objectives: maintaining 
a desired flow rate (set based on HR), maintaining a desired flow pulsatility, ensuring a minimal 
acceptable flow and limiting pump power to a preset maximum. Each objective was weighted using 
gains, and combination was performed using minimum and maximum operations (Figure 4.13). 
An integral controller was used to adjust pump speed. Evaluation was performed in a MCL and in a 
clinical study. In the MCL, the 
controller was subjected to step changes 
in HR, aortic pressure, LV pressure, LA 
pressure, systemic flow and stroke 
volume. However, no evaluation results 
were presented.  
In the clinic, 15 patients were tested in 
as many as 4 different settings, 
including the intensive care unit, 
standard ward, rehabilitation bicycling, 
and spiroergometry. The controller was compared to constant speed operation. The controller remained 
stable across HR from 100 to 220 BPM. There was a significant increase in pump flow during exercise 
with the control system compared to manual operation. Patients reported subjective improvements in 
comfort with the automatic control system. This system is the only rotary LVAD physiological control 
system to have undergone clinical evaluation. It is a landmark study which highlights the benefits that 
physiological control can offer rotary LVAD patients. However, the controller gains and settings were 
not mentioned in any of their publications. 
Figure 4.12: Multi-objective control proposed by Vollkron et al. (2005) [84] 
 
Figure 4.13: Closed loop control using four different control 
strategies [84] 
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More recently, Karantonis and colleagues (2010) proposed a MOC system that relied on the input from 
an accelerometer combined with HR as an indicator of patient activity level [169]. This formed part of 
a 6-level hierarchical controller, which meets the following objectives (in order) 
1. Pump power must remain below a certain 
threshold. 
2. A minimum pump flow must always be achieved 
3. Upon detection of ventricular suction, pump speed 
must be reduced. 
4. A minimum pulsatility must always be achieved. 
5. Peak ΔP must remain within a specified range. 
6. Speed to be controlled according to ALI. 
No mention was made as to how the objectives were implemented or combined. Evaluation was 
performed using a NM. A transition from rest to exercise was simulated by slowly ramping LV and RV 
contractility, HR and SVR over a 55 second period. This was performed for three different levels of 
contractility. Cardiac output was measured before and after exercise, and speed pulsatility was used as 
a measure of suction avoidance. The MOC was compared to constant ΔP, constant PI and constant 
speed control systems. The results showed that whilst ΔP control produced the highest increase in flow 
during exercise, it also produced the lowest PI which suggests it has the highest risk of suction. In 
contrast, the MOC increased pump flow whilst still avoiding ventricular suction. This paper highlights 
the benefits of combining objectives. However, the accelerometer input was only simulated. 
Additionally, the final pump speed depended on heart contractility, with lower speeds observed with 
weaker hearts. This is the opposite of what is expected in clinic. Since there was no assessment of 
control using solely the accelerometer signal, its benefit is unknown.  
Kosaka and colleagues (2003) investigated controlling pump speed to keep both pump flow and 
differential pressure within ±20% of an operating point. They also incorporated a suction handling 
component, which sharply drops pump speed if an adverse event is detected. In-vitro analysis revealed 
that this approach could maintain pump flow during increases in afterload. However, it took the 
controller 50 seconds to recover from a state of suction, which seems like an excessive amount of time.  
Multi-objective control systems are a feasible approach to combining the benefits of two or more control 
systems, simultaneously addressing shortcomings of individual control strategies. However, the more 
systems that are incorporated into a MOC, the more complex the final control system is. Careful 
consideration must be given to the switching between different control systems. Of the MOCs presented 
in this literature review, only Gwak et al. [85] and Vollkron et al. [84] gave details as to how they 
managed the interaction between the different objectives. 
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4.2.4 Summary of Literature Review 
In summary, physiological control systems consist of two components: a control objective, which 
compares feedback from the VAD and/or patient to some set points, and the control implementation, 
which automatically adjusts pump speed in order to meet the control objective. The two main control 
implementations, PID and FL control, have been widely used in VAD control yet only compared in one 
study. Extremum seeking control is only applicable for control objectives that involving finding the 
minimum of some variable.  
A number of different control objectives have been presented in literature that range in complexity from 
single variable control systems to multi-objective approaches. Some of these control systems may be 
suitable for adaptation into controllers for dual LVADs as BiVADs. However, experimental comparison 
is required to more thoroughly evaluate these control systems. Multi-objective control systems combine 
the benefits of a number of different control objectives into one system. However, these systems are 
complex and little detail is given in the literature regarding the combination of these algorithms. A 
simpler control algorithm that behaves in a physiological way similar to the native heart and that 
naturally avoids hazardous states would be more preferable than a complex MOC. Finally, 
physiological control systems can either use implantable sensors to measure pressure and/or flow, or 
estimate these values using pump parameters. The accuracy of estimation algorithms may have some 
effect on controller performance.  
The main finding from this review is that while there has been a significant volume of research into the 
field of LVAD control, it is difficult to determine the "best" performing control systems by direct 
examination of the literature. Therefore, there is no simple way to determine which algorithms would 
be best for adaptation into BiVAD control. The remainder of this chapter will describe the evaluation 
of a number of controllers from literature, in order to determine the most suitable candidates for rotary 
BiVAD control.  
4.3 Hypothesis 
The main hypothesis of this chapter is to evaluate a number of LVAD physiological control systems in 
a thorough and proper manner in order to determine the most suitable control system  
4.4 Methods 
4.4.1 Control Algorithms 
Control systems selected for comparison included most of the systems previously described in the 
literature review and some of their variations, as listed in Table 4.1. These systems were chosen based 
on their popularity in the literature, and the fact that enough information was provided in their respective 
publications to implement them in the evaluation framework.  
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All controllers were implemented using Simulink 
(The Mathworks, Natick, MA). For each system, 
PI control was used. Gains were tuned using an 
optimisation procedure with the intention of 
giving all control systems the same dynamic 
response. This approach ensured that differences 
in control system performance were solely due to 
differences in strategy, not due to differences in 
tuning or PI gains. The optimisation procedure is 
described in detail in Appendix D. 
With the exception of the ΔP and Starling-like controllers, all of the aforementioned controllers had 
only one configuration and thus implementation was simple. Two configurations of the ΔP controller 
was evaluated. The first, ΔP, was the original concept proposed by Giridharan, and used the difference 
in pressure between the inlet and outlet of the pump. The second, ΔPaolv, was a modified version that 
utilised the pressure difference between the LV and aorta, thereby including the pressure drop across 
the cannulae as well. The Starling-like control system proposed by Salamonsen and colleagues had two 
different methods of calculating a target flow rate (Figure 4.8) - radial about a control line (RACL) or 
radial about the x-intercept (RAXI). These two methods are described in further detail in Appendix C, 
and both were evaluated in this study. Additionally, the original description of Starling-like control of 
an LVAD by Maslen and colleagues [161] used preload or LAP to set a target flow rate. To evaluate 
this original approach, pulsatility was substituted with LVEDP in Salamonsen's approach, and both 
RACL and RAXI methods were evaluated. Therefore, four different configurations of the Starling-like 
control system were evaluated in this study.   
Finally, it was assumed that all of the control systems were implemented using pressure and flow 
sensors where necessary, as opposed to using estimation techniques. This assumption was made in order 
to only compare the efficacy of the control objectives in isolation. Estimation algorithms increase the 
complexity of control systems and may mask elements of the control objective's behaviour. 
4.4.2 Signal Conditioning 
All signals were filtered in order to remove the native heartbeat. Without removal of the heartbeat, the 
control signal sent to the pump would unnecessarily oscillate at the same frequency. This extra 
controller effort may result in increased power consumption, leading to shorter battery life.  
Filtering of signals for select frequency removal is traditionally performed using a linear filter. These 
filters require a trade-off between response time and stop-band attenuation. The higher the attenuation, 
generally the slower the response time of the filter. For LVAD control applications, the signal should 
be free of artefacts caused by the heartbeat but also be responsive enough to accommodate for sudden 
Table 4.1: Control systems compared using the testing 
protocol developed in Chapter 3 
Strategy Author 
Constant ΔP Giridharan 
Constant Afterload Impedance Moscato 
Starling-like control Salamonsen 
Constant QLVAD Casas 
Constant LVEDP Bullister/AlOmari 
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changes in state, caused by coughing, sneezing or postural changes. As an alternative to linear filters, a 
non-linear morphological filter (MF) was developed to obtain the mean beat-to-beat signal for control 
purposes. 
A full description and evaluation of the morphological is presented in Appendix E, and can also be 
found in [170]. Briefly, the filter involved firstly performing real time morphological opening and 
closing on the signal x (t) using a flat structuring element B. These processes yielded the beat-to-beat 
minimum and maximum of the signal respectively. The mean was then determined as a weighted 
average of the maximum and minimum. (Equation (4.7)). 
 𝑦(𝑡) = 𝑤. (𝑥(𝑡) • 𝑩) + (1 − 𝑤). (𝑥(𝑡) ∘ 𝑩) (4.7) 
Where the symbols • and ∘ denote morphological closing and opening respectively, and 0 <w < 1, which 
can be adjusted to accommodate different waveform shapes. For pressure and flow signals, w was set 
at 0.33, based on the clinically standard equation for calculating MAP from systolic and diastolic 
pressures. 
4.4.3 Evaluation 
Evaluation was performed using the framework outlined in the previous chapter. A severe left heart 
failure condition was simulated in the MCL and the ventricle supported using a VentrAssist LVAD. 
Initial pump speed was set at 2300 RPM, which restored all systemic haemodynamics to the same values 
as those in the healthy simulations presented in Chapter 3. For each control system, the target variable 
and other controller settings were selected in order to produce the same initial pump speed of 2300 
RPM. The controller gains, target variables and other controller settings are summarised in Table 4.2. 
Note that a butterworth filter was utilised for Moscato et al.’s control system, because it was difficult 
to make this controller work using the MF. 
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Controller Target Variable/Control Parameters Value KP KI Filter 
ΔP Pump Differential Pressure 100 mmHg 18 RPM.mmHg-1 21 RPM.mmHg-1.s-1 MF 
ΔPaolv LV-Aorta Differential Pressure 75 mmHg 16 RPM.mmHg-1 14 RPM.mmHg-1.s-1 MF 
Moscato Afterload Impedance 0.5 mmHg.mL.s-1 59 RPM.min.L-1 81 RPM.min.L-1 BW 
Constant Flow Pump Flow 4.25 L.min-1 0.06 PWM.min.L-1 0.04 PWM.min.L-1 MF 
Constant LVEDP Left Ventricular End-diastolic pressure 5.75 mmHg 0.06 PWM.mmHg-1 0.04 PWM.mmHg-1 MF 
Starling Preload RACL 
Ksc1 
Ksc2 
a 
0.447 
0.894 L.min-1.mmHg-1 
5.5 mmHg 
0.06 PWM.min.L-1 0.04 PWM.min.L-1 MF 
Starling Preload RAXI 
Ksc 
a 
2 L.min-1.mmHg-1 
5.5 mmHg 
0.06 PWM.min.L-1 0.04 PWM.min.L-1 MF 
Starling Pulsatility RACL 
Ksc1 
Ksc2 
a 
0.447 
0.894 
5.5 L.min-1 
0.06 PWM.min.L-1 0.04 PWM.min.L-1 MF 
Starling Pulsatility RAXI 
Ksc 
a 
2 
5.5 L.min-1 
0.06 PWM.min.L-1 0.04 PWM.min.L-1 MF 
 
Table 4.2: Summary of all control system settings used in this study. 
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Each control system, as well as constant speed control was subject to the sequence of patient scenarios 
presented in Chapter 3. Pressure and flow transducers were all re-zeroed and the MCP restored to 
8.5mmHg prior to the evaluation of each controller. Figures of merit were calculated for each control 
system and compared. As no repetition was performed, differences in figures of merit were considered 
significant if they were greater than the maximum standard deviation determined in Chapter 3. These 
deviations are presented in Table 4.3.  The controllers that produced the best performance across all 
four performance metrics were then selected for further development into a dual LVAD control system, 
as discussed in Chapter 5. 
 
  FOMREST 
 FOMCONG  FOMSUC -L  FOMSUC -R  FOMEX 
L R s-1 s-1 Left 
Deviation ±0.6 ±2.4 ±1.2 -- -- ±6.4 
 
4.5 Results 
Controller FOMREST (%) 
FOMCONG (%) FOMSUC FOMEX (L/min) 
L R (s-1) 
Total Flow 
Increase 
Pump Flow 
Increase 
Score 
Constant Flow 95.71 87.66 95.42 0.32 1.95 0.21 1.22 
Constant LVEDP 93.55 97.76 93.78 0.09 3.5 2.94 2.93 
Constant Speed 97.38 86.42 94.95 0.12 2.48 1.62 2.14 
Constant ΔPaolv 96.56 99.67 94.64 0.74 3.43 2.63 2.81 
Constant ΔP 96.99 87.77 96.20 0.08 2.58 2.03 2.09 
Afterload Impedance 95.63 89.20 95.32 0.25 2.64 1.89 2.1 
Starling (preload) 
RACL 
93.65 99.09 93.66 0.00 3.54 3.1 3.05 
Starling (preload) 
RAXI 
92.37 97.97 93.75 0.02 3.47 3.03 2.97 
Starling (pulsatility) 
RACL 
91.17 95.72 93.47 0.52 3.37 1.37 2.25 
Starling (pulsatility) 
RAXI 
93.45 94.60 93.40 0.46 3.69 2.85 3.27 
 
  
Table 4.3: Deviations of figures of merit as determined in Chapter 3 
Table 4.4: FOMs for each LVAD control system evaluated in the evaluation framework 
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The four FOMs for each controller tested are shown in Table 4.4. All controllers exhibited similarly 
good behaviour at rest, as reflected by the high FOMREST scores. There were some small differences in 
FOMREST scores which were greater than the maximum standard deviation (0.6%) observed in Chapter 
3, indicating that they were significant. The range of FOMREST was 91.17% (Starling (pulsatility) 
RACL) to 97.38% (Constant Speed), which was close to the healthy heart simulation (95.3%) and much 
higher than the untreated heart failure simulations (6.28% and -45.9% for MHF and SHF respectively). 
There was a distinct difference between FOMCONG scores for the left atrium between controllers. Only 
constant LAP, constant ΔPaolv, and all of the Starling-like controllers produced an FOMCONG-Left score 
equal to or greater than that of the healthy LV (94.6%). The other controllers produced FOMCONG-Left 
scores between 86.42 and 89.2%, significantly lower than the aforementioned controllers and only 
slightly better than the MLHF simulation (83.4%). The response of each control system to exercise had 
the most effect on FOMCONG -L. Constant LVEDP control, ΔPaolv and all of the Starling controllers 
increased pump speed from 2300 RPM to above 2700 RPM during exercise, which maintained LAP 
below 15mmHg, hence the good FOMCONG -L scores (Figure 4.14). The other controllers did not 
increase speed sufficiently to relieve LAP, as reflected by their reduced FOMCONG -L. All of the 
FOMCONG -R scores were high and similar to those produced in the unassisted LHF simulations, 
indicating that the controllers had no negative effects on RAP. 
  
  
The main difference between control system performances was with regards to suction handling and 
avoidance. Only one controller (Starling Preload RACL) completely avoided all states of suction. This 
controller successfully reduced flow sufficiently quickly in response to the drops in preload caused by 
the postural change and Valsalva manoeuvre. Only Starling Preload RAXI, constant ΔP and constant 
Pin had less than 0.1 events per second. The suction events produced by these controllers were shorter 
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Figure 4.14: Mean LAP (left) and pump speeds (right) during exercise for the different control systems. 
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and less severe than the others, indicating that these controllers could recover quickly from suction 
events. 
Sustained, unresolvable suction was observed with some of the controllers that controlled flow rate. If 
flow rate did not drop sufficiently quickly in response to changes in preload, suction occurred. These 
suction events caused further reduction in flow rate. This resulted in a positive error between the target 
flow rate set by the flow controllers and the measured flow rate, to which the controller responded by 
further increasing pump speed. This exacerbated the suction condition, further reducing flow, which led 
to further increases in pump speed (Figure 4.15). This cycle continued until pump speed reached the 
upper limit. Since these controllers could not escape suction events, suction events continued 
throughout the duration of the simulated scenarios. This may have affected the performance of these 
controllers during exercise. 
Maintaining a constant LVEDP 
caused unresolvable suction 
during the exercise scenario for 
two reasons. Firstly, LVEDP was 
significantly elevated during 
exercise, to which the controller 
responded by increasing pump 
speed. However, the target 
LVEDP was not reached even 
after reaching maximum speed. 
This led to suction events, even 
though the LAP was nearly 15mmHg. These suction events occurred just before the start of the isometric 
relaxation phase of the cardiac cycle, when the ventricular volume was low but pressure high. Once 
diastole began the suction events were relieved. However, constant LVEDP control did not cause 
suction during the low preload in the postural change and Valsalva manoeuvres.  
 
Figure 4.15: Pump flow rate and speed for the constant flow control 
system during the Valsalva manoeuvre. 
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Both differential pressure controllers caused 
suction, with better suction handling exhibited 
by ΔP control. This was because activation of 
the suction valves caused the pump inlet 
pressure to fall sharply and LV pressure to rise. 
This sharply increased ΔP each event but kept 
ΔPaolv relatively constant. Therefore, the ΔP 
controller sharply lowered pump speed with 
each suction event whilst ΔPaolv kept speed 
constant. Whilst ΔP control dropped speed with 
each suction event, effectively shortening the 
width of each event, it kept speed constant 
during preload reductions that preceded suction 
and was therefore not able to prevent suction 
from occurring (Figure 4.16).  
The exercise performance of all controllers varied significantly. The best performing control systems 
in exercise were the Starling Preload RACL, Starling Preload RAXI and Constant LVEDP control. The 
two Starling controllers increased pump speed to 2800 RPM, which increased pump flow without 
causing suction events in exercise. The constant LVEDP controller increased flow to the maximum 
speed, which resulted in suction events. However, the severity of these events was not enough to 
significantly reduce total flow. 
The worst performing controllers during exercise were those that did not sufficiently increase pump 
flow (Figure 4.17). This was due to either a small or zero increase in pump speed (for constant speed, 
afterload impedance and constant ΔP control) or by sustained severe suction from previous patient 
scenarios (Starling Pulsatility controllers).  
 
 
Figure 4.16: Pump speed during the Valsalva manoeuvre 
using ΔP control. 
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4.6 Discussion 
The key finding from this comparison of physiological control systems was that Starling control using 
preload and the RACL method was the best performing system with respect to all aspects evaluated. 
This control system not only produced suitably appropriate resting haemodynamics, but prevented any 
suction events from occurring. This was due to prompt reductions in pump speed when preload dropped, 
in combination with pump speed increases during exercise that increased flow without over-pumping. 
This is the first time a Frank-Starling control system has been evaluated with respect to three different 
patient scenarios, and the results have highlighted the advantages of this system over other types of 
control systems. Based on these findings, the Starling Preload RACL controller should be further 
investigated for use in a BiVAD system.  
However, this evaluation has also highlighted that one of the disadvantages of flow-based controllers 
is their ability to exacerbate ventricular suction conditions. Lower average pump flow caused by 
sustained ventricular suction in conjunction with a target flow that was not low enough to avoid suction 
led to the controller increasing pump speed in order to compensate what appeared to be a positive 
controller error. This exacerbated the suction condition, which may be relieved by a sustained reduction 
in pump speed, suspended controller action and/or infusion of fluid to raise the patient’s circulatory 
volume. Even though the successful Starling controller configuration avoided states of suction in this 
evaluation, the fact that it relies on control of pump flow means that it too is vulnerable to this 
phenomenon. The inclusion of a suction-detection and avoidance algorithm into the control system is 
required to prevent this from occurring.  
 
 
Figure 4.17: Systemic and pump flow rates during exercise for each of the different 
controllers. Coloured bards represent pump flow rate; white bars represent aortic valve 
flow. 
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In order to validate the results in this study, individual control system results should be compared to 
those published by the original investigators. The two differential pressure controllers presented by 
Giridharan and colleagues, ΔP and ΔPaolv, exhibited higher pump flows in exercise than constant speed 
control, with ΔPaolv producing higher flows than ΔP. These results align with those initially presented 
by Giridharan in [112], [152]. Additional findings from this study were that the differential pressure 
control strategies did not reduce pump speed sufficiently in response to a change in preload to prevent 
ventricular suction. This implies that this control approach should not be used as a primary control 
objective.  
Constant flow control was the worst performing control strategy in this evaluation. It did not drop pump 
speed to prevent suction and exacerbated suction conditions. It also produced the worst exercise 
performance. These results indicate that maintaining a constant pump flow rate at all costs is not a viable 
control objective. Casas et al. (2007) proposed that this control objective can ensure suitable end-organ 
perfusion regardless of the patient's SVR [120]. However, the results from this study suggest that the 
disadvantages of this control system greatly outweigh this potential advantage in patients with varying 
cardiac demand. 
Maintaining a constant LVEDP using an LVAD physiological control system proved to be one of the 
better performing control strategies. Bullister and colleagues did not perform any suction-avoidance 
assessment [115], so no direct comparison can be made. Maintaining a constant LVEDP effectively 
produces an infinite preload sensitivity, which supports its case as being a suitable control strategy. The 
performance of this controller was marred by the occurrence of ventricular suction during exercise, 
which occurred because the pump speed increased to the upper limit. This occurred because the LVEDP 
increased to approximately 13mmHg during exercise and was not able to return to the baseline level of 
5.75mmHg, despite maximum speed being reached. This is reflective of the fact that LVEDP is not 
rigidly fixed in a healthy patient, and it could therefore be argued that it is not physiological to do so 
with a pump. This shortcoming could be overcome by setting a different target LVEDP for exercise. 
These results indicate that this simple approach can avoid suction and increase flow during exercise and 
thus should also be considered for control of dual LVADs. 
The afterload impedance based control presented by Moscato et al. is effectively another form of 
Starling-like control in that it varies pump flow with pump preload (LVP). However of all the Starling 
controllers, this approach had the worst overall result. The changes in pump flow with venous return 
were not large enough in magnitude to prevent suction events, and the flow increase in exercise was not 
as high as the other Starling-like controllers. This may have been due to the use of LVP rather than 
LVEDP. Another reason for the poor performance was that Moscato's controller was slower to change 
pump flow rate than the other Starling controllers. This was due to the use of a 3-Windkessel model to 
calculate target flow, as well as a 3rd order Butterworth filter. The other Starling controllers used a 
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morphological filter to determine the beat-to-mean values of LVEDP and flow rate, which has been 
shown to be more responsive that Butterworth filters [170]. Another reason for the poor performance 
may have been the use of a different afterload impedance compared to the original paper (0.5 vs. 1 
mmHg.mL.s-1). However, this afterload impedance was required in order to obtain suitable initial 
resting haemodynamics in this MCL.  
4.7 Experimental Limitations and Future Work 
There were a number of limitations in this experiment which should be addressed in future experiments. 
Firstly, only a number of control systems were compared. Notable omissions included work by Arndt 
et al. [82], [83], Vollkron and colleagues [84], Choi et al. [80], [95] and Gwak et al. [86], [87]. These 
controllers were omitted because their complexity, in conjunction with insufficient detail of controller 
parameters in their published descriptions, made it difficult to implement them in this experimental 
setup within the time frame. Comparisons with these untested systems may require collaboration with 
the initial investigators in future studies. 
The second limitation of this study was that it was assumed that all feedback variables were measured 
using accurate and reliable sensors. This assumption was necessary in order to assess the efficacy of 
each control objective in isolation. Both pressure and flow sensors were required, and for long term use 
these sensors need to have high accuracy and low drift. Currently there are no commercially available 
pressure sensors that meet this criteria, although there are some in development [159], [160]. Flow 
sensors are an available alternative, as one is incorporated into the HeartAssist 5 LVAD [171]. 
Therefore, the assumption that sensors were available is not reflective of the current situation in clinic. 
Further investigation is required to determine whether the use of flow [172] and/or pressure [110] 
estimation algorithms instead of sensors affects the performance of these control systems. 
Finally, no repetition was performed of the results. The repeatability of the MCL was already 
established in the previous chapter, so it was assumed that repeating experiments in this chapter was 
redundant.  
4.8 Conclusion and Summary 
The aim of this chapter was to compare and contrast a number of physiological control systems for 
rotary LVADs in order to determine which systems could be adapted into a control system for dual 
rotary LVADs. Using the testing protocol described in the previous chapter, a thorough and detailed 
comparison of control systems was performed. It was found that Frank-Starling like control produced 
the best all-round performance, and thus was used as the basis of a dual LVAD control system in the 
next chapter. However, this control system does rely on the implantation of flow and pressure sensors, 
which are not available for long term clinical use. Additionally, some LVAD controllers were missing 
from the comparison stage due to insufficient information from the literature.  
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As the aim of this thesis was to develop a control system for dual rotary LVADs, knowledge of the 
current state of single LVAD control systems was required. Knowing which approaches worked best 
for LVAD control enabled selection of appropriate systems for further development into a BiVAD 
system. This stage streamlined the development process of the BiVAD control system described in the 
next chapter.  
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5 BiVAD Control 
The previous chapter described the comparison of a number of rotary LVAD physiological control 
systems. The result was that the Starling-like control systems produced significantly better performance 
than other control systems. The next challenge is to identify methods of modifying this LVAD controller 
into a suitable control system for dual LVAD use. 
This chapter describes the adaptation of this control mechanism into a dual LVAD control system. The 
chapter begins with a review of the literature encompassing dual LVAD control systems, which 
highlights that a number of different approaches could be used for this adaptation process. These 
different methods are assessed using the evaluation framework described in Chapter 3, which enabled 
selection of an appropriate control method.  
The significance of this chapter is that it presents a novel physiological control system for dual LVADs. 
This system is shown to be better than other dual LVAD control systems through thorough quantitative 
evaluation methods. The use of quantitative methods for evaluation as well as comparisons with other 
control systems ensure that this novel control system is an improvement upon other methods previously 
presented in literature.  
The work completed in this chapter has been published as a manuscript entitled "Physiological control 
of dual rotary pumps as a biventricular assist device using a master/slave approach" in the scientific 
journal Artificial Organs (Published Online 21st April 2014). The methods, results and discussion of 
this chapter were taken directly from that publication. The introduction was extended to provide the 
reader with more background information. The results and discussion sections were further expanded 
to include comparisons of different slave control systems 
5.1 Aim 
The aim of this chapter is to develop a control system for dual rotary LVADs based on the LVAD 
physiological control system selected at the end of Chapter 4. The specific objectives devised to meet 
this aim were as follows: 
 Review the literature regarding evaluation of physiological control systems. 
 Identify a number of possible approaches for control of dual rotary pumps in series. 
 Implement these approaches in an in-vitro testing environment. 
 Evaluate each approach using the framework established in Chapter 3. 
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5.2 Literature Review 
Prior to development of a control system for dual LVADs, knowledge of previous work was required. 
The following section is a summary of the physiological control systems for dual LVADs previously 
proposed in literature. Unlike the review in Chapter 4, this review includes both pulsatile and rotary 
pump control methods, and control methods for TAHs as well as BiVADs. This is because the issue of 
balancing left and right flow rates applies to both pulsatile and rotary blood pumps, regardless of 
whether they are used for TAH or BiVAD applications.  
5.2.1 Pulsatile Pump Control 
Most clinically available pulsatile VADs, such as the Thoratec PVAD, can operate on a fill-to-empty 
mode. In this mode of operation, the pump only ejects when the blood volume in the device reaches a 
minimum level. This ensures that the outflow of the pump matches the inflow, making the device 
preload sensitive.  When using two pulsatile pumps as a BiVAD or as a TAH, both devices are operated 
in the fill-to-empty mode, which helps to balance flows [173]. The Syncardia TAH, which consists of 
two pulsatile pumps, also operates using a similar fill-to-empty mode [174]. In addition to the 
physiological control systems used by these commercially available devices, other investigators have 
presented more complicated methods of physiological control. 
Nakamura et al. (1999) proposed control of a pneumatic TAH using mixed venous oxygen saturation 
(SVO2) [129]. Left pump flow rate was set as a linear function of SVO2 and right pump flow rate was 
set as 90% of left pump output to prevent pulmonary venous congestion and to account for bronchial 
shunt flow. This system was evaluated in-vivo by implanting a TAH into a sheep and recovering the 
animal. The animal was exercised using a treadmill, the speed of which was increased from 1 to 6 km/h 
over 6 stages of 3 minutes each. The final stage was continued until the calf collapsed. The controller 
resulted in higher pump flows during exercise compared to constant flow control, however there was 
no difference in total exercise duration. Settling time of the system was approximately 1 minute. Clearly 
SVO2 is a good indicator for cardiac demand and can be used as a guide to increase pump output. 
However in this study SVO2 was only measured every 5 seconds, which is a slow sampling rate. 
Additionally, SVO2 cannot be used as an indicator for ventricular suction. 
Previous work by Abe and colleagues investigated control of dual pulsatile pumps for both TAH and 
BiVAD applications [175], [176]. In both applications, the investigators designated one pump as the 
master and the other the slave. The control system for the master pump in both applications was based 
on 1/R control, which set the cardiac output as a function of the SVR. At each time step, the flow rate 
of the master pump was set using Equation (5.1). 
 
𝐶𝑂 = (𝐴𝑜𝑃𝑠𝑒𝑡 −  𝑅𝐴𝑃𝑠𝑒𝑡).
𝑄
(𝐴𝑜𝑃 − 𝑅𝐴𝑃)
+ 𝐶𝑃. 𝐵𝑊. (𝐴𝑜𝑃 − 𝐴𝑜𝑃𝑠𝑒𝑡) (5.1) 
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Where CO is the desired cardiac output (L.min-1), Q is the measured cardiac output (L.min-1), BW is 
the body weight of the sheep (kg), CP is an animal-specific constant (L.min-1.kg-1.mmHg-1), AoP and 
RAP the aortic and right atrial pressures respectively (mmHg) and AoPset and RAPset were the desired 
values for AoP and RAP respectively (mmHg). The CO of the master was varied by changing the beat 
rate and keeping stroke volume (SV) constant.  
For the TAH approach [175], the left pump was set as the master and the right pump the slave. The SV 
of the right pump was programmed to balance the left and right atrial pressures, using Equation (5.2). 
 𝐿𝐴𝑃 = 𝑎𝑠𝑙𝑎𝑣𝑒 . 𝑅𝐴𝑃 + 𝑏𝑠𝑙𝑎𝑣𝑒 (5.2) 
Where aslave was set to 1 and bslave (mmHg) set to the difference in static pressure head between left and 
right atria. Evaluation was performed in-vivo using 10 goats. Seven goats had their ventricles removed 
and two pulsatile pumps implanted. Three goats were instrumented but otherwise healthy and used as 
controls. Of the seven TAH animals, four had 1/R control and three used constant SV and beat rate (i.e. 
constant flow control). Animals were recovered and data recorded continuously for at least 21 days (up 
to 340), during which they undertook everyday scenarios as well as treadmill tests. There was no 
statistically significant difference in flow rates between natural heart group and 1/R group. With 1/R 
control, CO varied throughout each 24 hour period in a similar manner to normal circadian rhythm, 
with lower flow in rest and higher flows in standing and eating. Constant flow control resulted in 
elevated AoP and RAP compared to natural heart group. In exercise there were similar increases in CO 
between 1/R control and the natural heart groups, although the 1/R control group exhibited 30 second 
delay between exercise commencing and the pump flow rate changing. Clearly this approach showed 
benefits for control of dual pulsatile pumps by making them respond similar to the native heart. 
However, there was a strong dependence on sensor fidelity, with the control system no longer working 
once pressure sensors became obstructed. The delay of 30 seconds after the onset of exercise was also 
slow. No justification was presented for the choice of using the left pump as master and right pump as 
slave. 
For biventricular assistance, Abe and colleagues (2000) used a similar control scheme but set the right 
pump as master [176]. The left pump, as slave, was set to maintain LAP below 10mmHg. Driving 
pressure was updated every 2 seconds, with a new target flow rate calculated every 6 seconds. This was 
a more precise update interval than the TAH controller. After implantation, the PA was clamped off to 
produce total RV assistance, whilst the aorta was partially clamped to provide partial LV assistance. 
The authors claim that this was because the 1/R control strategy does not work when the LVAD is 
providing full assistance. The algorithm was tested in 5 goats, with support durations ranging from 13 
to 75 days. The pulse rate of the devices was compared to that of the residual ventricles, and found to 
always be higher than the native heart. However, the changes in VAD pulse rate mirrored those of the 
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native ventricle, indicating synchronicity with the native control mechanisms. Whilst flow balancing 
was achievable with this controller, there was no inherent method of avoiding RV suction. In addition, 
no comparisons were performed with other control mechanisms.  
Saito and colleagues (2003) developed a multi-objective control system for using dual undulation 
pumps as a TAH [177]. The undulation pump is a continuous-flow volume-displacement pump which 
can produce continuous flow, continuous flow with pulsatility or totally pulsatile flow. The 7 control 
objectives were (in order of priority): 
1. Controlling pump speed to a set point using PWM control of pump current. 
2. Pulsatility mode, which switches between a high and low PWM duty cycles to simulate systole and 
diastole. 
3. Anti-suction mode, which drops PWM duty cycle to the diastolic value if suction is detected in 
systole. 
4. PRD control, which maintains the product of systolic PWM and systolic/diastolic ratio (PRD) 
constant. 
5. Emergency control, which lowers the target PRD if inlet pressures fall below -20mmHg, and 
increases target PRD if inlet pressures rise above 20mmHg. 
6. LAP control, in which the left pump sets the PRD to maintain LAP constant at 4mmHg using an 
integral controller. 
7. 1/R control, as described above, for the right pump. 
The investigators kept goats alive for up to 62 days with this control system, and all suction events were 
resolved within two "beats". However, no comparison was performed with any other control mode, nor 
was any mention made of the control logic used to combine all 7 control systems.  
In summary, all of the physiological control systems for dual pulsatile pumps are master/slave style 
controllers, with one pump's control system dependant on the other. They appear to have all been 
assessed in-vivo. 
5.2.2 Rotary Pump Control Strategies 
Rotary VADs produce a continuous flow of blood, and cannot be operated in a fill-to-empty mode like 
pulsatile VADs. This makes it difficult to automatically balance flow rates. Therefore the development 
of a physiological control system is more important for dual rotary LVADs. 
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All of the aforementioned control strategies for pulsatile BiVAD and TAH were evaluated in an in-vivo 
environment and appeared offer some benefit over normal pulsatile pump operation. However, control 
of dual rotary LVADs is more challenging due to the lower preload sensitivity of rotary pumps [51]. 
There have been two types of approaches used to control dual LVADs, both of which involve separate 
control systems for each approach. In the first approach, the two control systems are completely 
independent from each other. In the second approach, one control system takes the role of master and 
the other slave, which introduces some dependency between the controllers. The following section 
summarises the different control systems for dual rotary LVADs for both TAH and BiVAD. 
5.2.2.1 Independent Control Systems 
Khalil and colleagues (2008) designed a flow-based control system for dual HeartAssist 5 pumps [102]. 
The strategy was for each pump to maintain its flow rate constant using integral control. Equations of 
pump flow were derived from first principles, and the unknown variables were determined using 
frequency analysis of the pumps in a mock circulation loop. In-vitro evaluation revealed that constant 
flow was maintained during variations in SVR and PVR. However, this control system did not consider 
any strategies for suction avoidance, nor did it incorporate any mechanism to automatically adjust flow 
during exercise. Additionally, attempting to maintain a constant flow is not a suitable approach for 
active patients, given the results presented in the previous chapter. Finally, this study assumed that there 
was no bronchial flow, which is not a clinically relevant assumption for a system that relies on 
maintaining constant pump flow rates.  
Gaddum et al. (2012) used two independent Starling-like control systems for control of dual VADs 
[89]. Each pump's control system varied its flow rate with preload, similar to those systems proposed 
by Salamonsen et al.[127] and Moscato et al. [91]. This controller was implemented with two 
independent PID controllers, with the gains tuned manually. Evaluation involved shifting fluid from the 
SVC to the RA and measuring the preload sensitivity and rise and settling times. Whilst this approach 
increased LV and RV preload sensitivity to 0.28 and 0.2 L/min/mmHg respectively, some coupling 
between the two systems was observed. Increased flow from the RVAD increased LV preload, causing 
increased LVAD flow. This in turn raised RV preload, causing further increased RVAD flow. The 
effects of the interaction are reflected in the oscillations present in the RVAD flow signal. It took nearly 
60 seconds for these oscillations to disappear (Figure 5.1). The interaction between these two 
independent control systems was more pronounced when using constant inlet pressure control, in which 
both pump speeds continuously increased and did not appear to settle. While these results are promising, 
the evaluation was simplistic and the coupling of the two pumps must be addressed before further 
implementation. 
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5.2.2.2 Master/Slave Control Systems 
Olegario and colleagues (2003) [117] extended the work of Abe and colleagues by using a master/slave 
approach for control of dual RBPs as a TAH. The left pump was set as the master, and controlled using 
1/R control previously described. The right pump was the slave, and controlled to maintain LAP 
constant. Evaluation was performed in-vitro and in-vivo using two Capiox centrifugal blood pumps 
(Terumo Corp., Tokyo, Japan). In the MCL, only the right pump slave control system was evaluated, 
with the left pump operated at constant speed. Evaluation involved inducing suction by increasing left 
pump speed by 700 RPM, and observing the right pump speed changes. It took 60 seconds for the LAP 
to recover after the left pump speed increase. Some oscillation of LAP was observed, possibly due to 
overshoot of the right pump controller.  
In-vivo, the pumps were implanted alongside the native heart and the heart stopped with electrical 
current. The MCL study was repeated first, with the left pump speed increased by 2000 RPM. The 
settling time of the slave controller was faster (approximately 10 s), however right pump speed exhibited 
Figure 5.1: Response of dual independent Starling-like control systems to an increase in right atrial pressure [89].  
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oscillatory behaviour. 1/R control was then switched on, and some right pump speed and flow 
oscillation was still present. However, arterial pressure was still maintained. In the animal study, the 
authors found that the system was able to prevent left atrial suction. However, oscillatory behaviour of 
right pump speed was present, because the RVAD controller was trying to maintain preload to a constant 
value. Preload in a healthy person is not strictly constant - it varies with circadian rhythm. Therefore, it 
is not physiological to maintain a constant LAP, which may be why the oscillatory behaviour was 
present. The inclusion of a tolerance into the controller may have eased this oscillatory behaviour 
without causing hazardous effects on the human body. Another shortcoming of this controller was that 
there was no method of avoiding RA suction. 
Endo and colleagues (2000) [122] used a master/slave control system to control two mixed-flow pumps 
as a BiVAD. The master was the left pump, and was set to maintain a constant LV preload using the 
ICA (previously described in section 4.2.3.4). The RVAD was controlled to match the LVAD flow rate. 
This strategy was implemented with the user-in-the-loop, with the operator manually adjusting pump 
speeds to meet the objectives. Evaluation was performed in-vivo using 5 piglets, and involved clamping 
the base of the aorta to develop global ischemia, then gradually recovering the heart using nitric oxide 
or defibrillation. The right pump was able to be weaned off completely as the heart recovered using this 
control strategy. However, no practical implementation of this system was discussed. Like Olegario's 
controller, there was also no method of avoiding or recovering from RV suction.  
Another master/slave control system was proposed by Siess in a patent for control of two rotary VADs 
when used as a BiVAD [178]. In this system, the LVAD was considered master and kept flow rate 
constant. The RVAD, as slave, maintained a flow rate that was 90% of the LVAD flow rate. If the 
LVAD flow rate changed, the RVAD flow would automatically change to remain 90% of the LVAD 
flow rate. However, no evaluation was presented. 
5.2.3 Summary of Literature Review 
The two main approaches to controlling dual rotary LVADs are to use two identical and independent 
control systems, or making one control system dependent on the other (commonly referred to as a 
master/slave configuration). Early work controlling dual pulsatile pumps using master/slave 
configurations was relatively successful, however this success has not yet been achieved with rotary 
pumps. This may be due to the comparatively lower preload sensitivity of rotary pumps.  
Controlling two rotary LVADs placed in a series circuit has proven challenging. The interaction 
between left and right pumps due to their inherent coupling makes selecting the control strategy 
difficult. It appears that any system that involves maintaining one or both atrial pressures or preloads 
constant has strong coupling between left and right pumps, which results in instability if not handled 
correctly. Interestingly, the successful strategies employed in dual pulsatile pump control (1/R control 
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master control and preload-matching slave control) have not yet been employed to control dual rotary 
pumps.  
Like LVAD control, evaluation of dual rotary pump control has involved simulating one patient 
scenario or circulatory system change, which is not thorough enough to characterise performance. 
Additionally, with the exception of Gaddum et al. [89], no dual LVAD control systems have been 
evaluated against other control systems.  
Given the success of the Starling-like control systems (as shown in the previous chapter), they are a 
suitable candidate for dual LVAD control. Based on the literature review, a master/slave 
implementation of the Frank-Starling system would be most appropriate in order to reduce the negative 
effects of the coupling between left and right pumps and therefore create a stable system. However, 
there are two key unknowns. Firstly, there have been a number of different slave control systems 
presented in the literature, all evaluated in different ways, making it difficult to determine the most 
appropriate slave controller for this application. Secondly, it is not obvious whether the left or right 
pump should be the master. The aim of this chapter is to investigate these two unknowns in order to 
determine the best-performing approach for control of dual rotary LVADs.  
5.3 Methods 
Controller assessment was performed using the MCL previously described in Chapter 3. A severe heart 
failure patient was simulated, and biventricular support achieved by connecting two VentrAssist 
LVADs (VentraCor, Sydney, Australia) in a BiVAD configuration. The inflow cannulation sites were 
the ventricles, while outflow cannulation site was the aorta (for left pump) and pulmonary artery (for 
right pump). The outflow graft of the RVAD was not banded, which meant that under normal conditions 
of SVR and pulmonary vascular resistance (PVR), the RVAD speed was lower than LVAD speed.  
The most successful LVAD control system from the previous chapter, preload-based Starling control 
using RACL, was adapted for use in a dual LVAD system. This adaptation involved developing a 
master/slave control system, with the Starling-like control system being used as a master. The controller 
settings for the master were the same as those outlined in Chapter 4 and in Appendix C. For reference, 
the master control system calculated the target flow rate (QVADM_target) using Equation (5.3). 
 QVADM_target = QVADM(1 − 𝐾𝑠𝑐1) + Ksc2(PinM − a) (5.3) 
Where QVADM_target is the target flow rate of the master controller (L.min-1), QVADM is the measured flow 
rate through the master pump (L.min-1), PinM the measured pump inlet pressure (mmHg), a the inlet 
pressure offset (mmHg), Ksc1 and Ksc2 (L.min-1.mmHg-1) are based on the desired preload sensitivity of 
the pump, and are set the same as described in Appendix C (0.447 and 0.894 L.min-1.mmHg-1). 
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A total of 8 different master/slave approaches were compared in this experiment (Table 5.1), with their 
results compared to constant speed operation, dual independent Starling-like controllers and dual 
constant LVEDP controllers. The 8 approaches consist of four different slave controllers, as well as 
designating either the LVAD or RVAD as the master pump. 
 
Controller 
Combination 
LVAD Control System RVAD Control System 
1 
Starling-Like 
(Master) 
Match Pressures (Slave) 
2 Match Flows (Slave) 
3 Constant Slave Preload (Slave) 
4 Constant Master Preload (Slave) 
5 Match Pressures (Slave) 
Starling-Like 
(Master) 
6 Match Flows (Slave) 
7 Constant Slave Preload (Slave) 
8 Constant Master Preload (Slave) 
 
The first slave controller (Controllers 1 and 5) varied the end-diastolic ventricular pressure of the slave 
pump (PEDS) linearly with the end diastolic pressure of the master pump (PEDM). This approach was first 
proposed by Abe and colleagues [175]. The implementation was similar to the master controller, except 
that QVAD was substituted with PEDS in order to obtain the target slave inlet pressure (PEDS_target), as per 
Equation (5.4). 
 𝑃𝐸𝐷𝑆_𝑡𝑎𝑟𝑔𝑒𝑡 = 𝑃𝐸𝐷𝑆(1 − 𝑐𝑜𝑠(𝑡𝑎𝑛
−1 𝐾𝑠𝑙𝑎𝑣𝑒)) + (𝑃𝐸𝐷𝑀 − 𝑐) 𝑠𝑖𝑛(𝑡𝑎𝑛
−1 𝐾𝑠𝑙𝑎𝑣𝑒) (5.4) 
Where PEDS_target (mmHg) is the target end-diastolic pressure for the slave pump, PEDS is the measured 
end-diastolic pressure for the slave pump (mmHg), PEDM is the measured end-diastolic pressure for the 
master pump (mmHg), c is the horizontal offset for the control line (mmHg) and Kslave (unitless) is the 
sensitivity of the controller. The constants Kslave and c were set to 2 and 7.63mmHg respectively in order 
to obtain the same resting haemodynamics described earlier in this thesis. PEDS_target was limited to the 
range 3 - 25mmHg to prevent suction and venous congestion respectively. Equations (5.3) and (5.4) are 
generic descriptions of the master/slave (MS) control system. Table 5.2 shows the actual variables used 
for left/right or right/left MS configurations. 
  
Table 5.1: Different master slave control approaches evaluated in this chapter. 
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Master/Slave Combination PEDM EDPS QVAD 
Left/Right LVEDP RVEDP QLVAD 
Right/Left RVEDP LVEDP QRVAD 
 
The second slave controller's (Controllers 2 and 6) objective was to set the flow rate of the slave VAD 
(QVADStarget) to be a fraction of the master VAD flow rate (QVADM), based on the controller proposed  by 
Siess [178]. This was implemented as per Equation (5.5). The constant α was set at 0.9 when LVAD 
was master, and 1.1 when RVAD was master. This follows the assumption made by Siess that LVAD 
flow should be 10% greater than RVAD flow. 
 QVADStarget =α. QVADM (5.5) 
The third slave controller (Controllers 3 and 7) that was evaluated maintained the preload of the slave 
controller constant and was assessed because of its simple implementation. The target preloads were 
selected in order to obtain the same base haemodynamics described earlier. These targets were 
3.5mmHg for LVAD master/RVAD slave (Controller 3), and 9.0 mmHg for RVAD master/LVAD slave 
(Controller 7). 
The fourth and final slave control system (Controllers 4 and 8) evaluated in this investigation maintained 
the preload of the master controller constant. This approach was initially proposed by Olegario and 
colleagues in 2003 [117]. The target preloads were selected in order to obtain the same base 
haemodynamics described earlier. These targets were 9.0mmHg for RVAD slave (Controller 4), and 
3.5mmHg for LVAD slave (Controller 8). 
Both master and slave control systems automatically adjusted the PWM duty cycle of their respective 
pumps each time step in order to maintain the target flow and inlet pressure respectively. For each 
pump, if the difference between measured and target value was less than 5% of the target value, no 
changes were made to the duty cycle. If the difference was greater than 5%, the duty cycle was adjusted 
using proportional-integral (PI) control. The PI gains were tuned using the same Quasi-Newtonian 
optimisation process used in the previous chapter, described in detail in Appendix D. Controller gains 
are given in Table 5.3. 
  
Table 5.2: Variables used for the two different master/slave 
configurations. EDP - End-diastolic pressure; QVAD - ventricular 
assist device flow; LVEDP - left ventricular EDP; RVEDP - right 
ventricular EDP; QLVAD - Left VAD flow rate; QRVAD - Right 
VAD flow rate. 
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Controller 
Number 
LVAD Controller RVAD Controller 
Left Pump 
Gains  
Right Pump 
Gains  
KP KI KP KI 
1 
Starling-Like 
(Master) 
Match Pressures (Slave) 0.064 0.0389 0.056 0.0215 
2 Match Flows (Slave) 0.0508 0.0498 0.0532 0.0507 
3 Constant Slave Preload (Slave) 0.0940 0.0442 0.0615 0.0108 
4 
Constant Master Preload 
(Slave) 
0.0725 0.0498 0.0953 0.0111 
5 Match Pressures (Slave) 
Starling-Like 
(Master) 
0.1137 0.0346 0.0735 0.0224 
6 Match Flows (Slave) 0.0485 0.0744 0.0461 0.0714 
7 Constant Slave Preload (Slave) 0.1108 0.0160 0.0778 0.1270 
8 
Constant Master Preload 
(Slave) 
0.0953 0.0111 0.0725 0.050 
9 Starling Control Starling Control 0.0552 0.0349 0.0938 0.03940 
10 Constant Preload Constant Preload 0.064 0.0389 0.056 0.0215 
 
As per Chapter 4, a non-linear morphological filter, which used mathematical morphology to estimate 
the beat-to-beat mean of a signal using the minimum and maximum values each cardiac cycle, was 
used to smooth all feedback signals. Further details of this filter and its derivation can be found in 
Appendix E. 
For controller evaluation, the evaluation protocol was the same as that described in Chapter 3 and used 
in Chapter 4. For comparative purposes, two different dual independent controllers (dual Frank-
Starling-like (Controller 9) and dual constant preload controllers (Controller 10)) presented by Gaddum 
et al. (2012) [89] were also evaluated. These control systems were tuned using the aforementioned 
Quasi-Newtonian optimisation method, and the controller gains are given in Table 5.3. Dual constant 
speed controllers were also evaluated, in order to provide perspective with the current mode of operation 
used in clinic. In order to represent a patient with elevated circulatory volume, evaluation of constant 
speed control was performed at both a normal mean circulatory filling pressure (MCFP) of 8mmHg, 
and a MCFP of 11mmHg [179]. Pump speeds and independent control settings were adjusted to obtain 
the same resting haemodynamics as the MS controller.  
5.4 Results 
Table 5.4 shows the four figures of merit for each combination of left/right and right/left master/slave 
combinations. From these results, only preload-matching slave controllers (1 and 5) were able to 
maintain a FOMREST score at 100%, indicating that these controllers were able to restore resting 
haemodynamics after each scenario. Of these two controllers, only the left/right combination 
maintained a high FOMCONG score, indicating that it is better at avoiding pulmonary congestion. The 
left/right combination also had the least number of suction events and the second highest FOMEX score. 
Therefore, this combination had the best all round performance.  
 
Figure 5.2 shows the performance of Controller 1 across all scenarios. The master controller varied 
target flow according to changes in preload. It decreased flow (4.8 to 3.5 L.min-1) during the postural 
Table 5.3: PI control gains for each of the dual LVAD controllers tested 
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change to prevent suction. It initially decreased flow during the Valsalva manoeuvre, but then returned 
to baseline within 15 seconds. Finally, it increased flow significantly in exercise (4.8 to 8.5 L.min-1) in 
response to increased venous return. Measured LVAD flow did not reach the target flow in exercise 
because the LVAD pump speed had reached the upper limit. Otherwise, the measured flow tracked the 
target flow accurately. The slave controller effectively maintained right ventricular end diastolic 
pressure (RVEDP) between 3 and 5 mmHg during rest, postural change and the Valsalva manoeuvre. 
During exercise, the target RVEDP increased in response to the increased venous return. Noise was 
present in both target signals, but otherwise the measured signals were stable.  
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Controller  
Number 
LVAD Controller 
RVAD 
Controller 
 FOMREST 
 FOMCONG (%)  FOMSUC (s-1)  FOMEX 
Left Right Left Right 
Left (L.min-1) Right (L.min-1) 
ΔSQ ΔLVADQ Score ΔPQ ΔRVADQ Score 
1 
Frank-Starling 
(Master) 
Preload 
Matching 
100 95.13 98.40 0.01 0.00 4.69 4.27 4.33 4.24 3.93 3.98 
2 
Flow 
Matching 
42.40 92.38 99.63 0.05 0.00 4.95 3.99 4.32 4.67 3.69 4.08 
3 
Constant RVAD 
preload 
63.11 75.56 99.86 0.07 0.06 6.54 4.43 5.19 6.51 5.75 5.94 
4 
Constant LVAD 
preload 
80.10 99.43 95.46 0.06 0.00 3.44 3.08 3.17 2.79 -0.42 1.56 
5 
Preload 
Matching 
Frank-Starling 
(Master) 
100 73.19 99.87 0.03 0.02 6.48 4.33 5.12 6.53 6.42 6.34 
6 
Flow 
Matching 
100 80.43 98.30 0.01 0.03 4.05 1.41 2.77 3.42 2.54 2.97 
7 
Constant RVAD 
preload 
93.61 77.54 99.85 0.04 0.03 6.65 4.58 5.30 6.61 6.49 6.40 
8 
Constant LVAD 
preload 
97.07 84.22 99.87 0.04 0.05 2.31 -4.21 0.21 2.25 1.42 1.91 
Table 5.4: Figures of merit for all combinations of master and slave control systems 
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Table 5.5 shows the performance metrics for the two best performing master-slave systems as well as 
the other controllers assessed for comparison. Sufficiently high arterial pressures and cardiac outputs 
were maintained during rest scenarios in all control systems and with constant speed control. The 
left/right MS control system produced fewer suction events than constant speed control (0.01 s-1 vs. 
0.15 s-1). An example of how the MS control system actively avoided suction during the Valsalva 
manoeuvre is shown in Figure 5.3. In this scenario, left ventricular (LV) venous return fell due to 
increased PVR. Constant speed control resulted in a fall in LV volume, and consequently suction events, 
because there was no decrease in LVAD flow. A similar drop in LV volume occurred with constant 
speed and high MCP (not shown), however the higher initial circulatory volume prevented suction. In 
contrast, the MS controller prevented suction by adjusting pump speeds. During reduced LV venous 
return, both the target flow rate of the master control system and the target inlet pressure of the slave 
system decreased. The LVAD speed decreased and the RVAD speed increased to match the new target 
values. The resulting reduction in LVAD speed prevented over-pumping from the LV, whilst the 
increase in RVAD speed overcame the increased PVR to assist with maintaining LV volume.  
 
 
Figure 5.2: Target and measured LVAD flow (top) and target and measured right ventricular end diastolic pressure (bottom) 
as produced by the left/right master/slave control system. 
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Controller 
 
FOMREST 
(%) 
 FOMCONG 
(%) 
 FOMSUC 
(s-1) 
 FOMEX 
(L.min-1) 
Left Right Left Right Left Right 
1 100 95.13 98.40 0.01 0 4.33 3.98 
5 100 73.19 99.87 0.04 0.02 5.12 6.34 
Constant Speed 
(Normal MCP) 
100 95.49 97.87 0.15 0 2.09 1.92 
Constant Speed 
(High MCP) 
100 95.31 91.33 0 0 2.15 1.71 
2x Independent 
(Constant EDP) 
80 77.92 99.95 0 0.01 4.91 5.53 
2 x Independent 
(Frank Starling) 
100 76.32 99.89 0.04 0.05 5.41 6.49 
 
Approximate time domain behaviour of the MS controller can be determined from Figure 5.3. All speed 
changes occurred within 2 seconds of perturbations. Both pump speeds exhibited 2% settling times of 
10 seconds. The LVAD speed exhibited minor oscillations due to residual ventricle contractility. 
Chattering was present in the RVAD speed, which was due to the small level of noise in the target 
signal.  
Table 5.5: Results from all control systems subjected to common patient scenarios 
in the mock circulation loop.  
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 (i) (ii) 
(a) 
  
(b) 
  
 
In all systems, the maximum LVEDP and RVEDP occurred during the exercise scenario (Table 5.5). 
Both independent control systems and the right/left MS system resulted in excessively high LVEDP 
during exercise, resulting in high FOMcong scores, which is indicative of pulmonary congestion. In this 
scenario, increased venous return to both ventricles caused all control systems to increase both LVAD 
and RVAD speeds. Left pump speed reached the upper limit of 3200 RPM, at which point there was no 
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Figure 5.3: (a) Pump speeds and (b) ventricular volumes for (i) constant speed operation and (ii) left/right 
master/slave control system during the simulated Valsalva Manoeuvre. LVAD - left ventricular assist device; RVAD - 
right ventricular assist device; LV - left ventricle; RV - right ventricle; 
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further capacity to unload the LV. Figure 5.4 shows that the controller strategies that caused pulmonary 
congestion kept increasing RVAD speed above 3000 RPM, because the target values for the RVAD 
control system had not yet been reached. This caused RVAD flow to exceed LVAD flow (Figure 5.5), 
which led to overfilling of the LV. In contrast, the left/right MS system adjusted RVAD speed to match 
the LVEDP and RVEDP, regardless of LVAD speed. In this case the RVAD speed remained at 2072 
RPM, preventing overfilling of the LV.  
 
 
Constant speed control did not cause high LVEDPs in any scenario. However, as shown in Figure 5.5, 
CO was lower in exercise with constant speed control compared to MS control (8.3 vs. 10 L.min-1). 
Furthermore, the contribution of pump flow to total flow with constant speed control (approximately 
73%) was lowest, whilst MS control was highest (93-97%). This indicates that MS control placed less 
strain on the ventricles than constant speed control during exercise. 
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Figure 5.4: Pump speeds at rest and at exercise for each control system. L/R - left/right master/slave; R/L - right/left 
master/slave; CS 1 - constant speed (CVP 8mmHg); CS 2 - constant speed (CVP 11 mmHg); FS - Frank-Starling 
control; CAP - constant atrial pressure control. 
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 Using the right pump as the master resulted in higher cardiac output during exercise when compared 
to the left pump (12.06 vs. 10.1 L.min-1). However, right/left MS caused more suction events across all 
scenarios. This indicates that the target flow rate set by the Starling controller was not low enough 
during low preloads. A linear relationship between flow and preload might not be suitable for RVAD 
Starling control.  
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Figure 5.5: Flow rates through LVAD, RVAD, aortic valve and pulmonary valve during exercise scenario for each 
control system. 
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5.5 Discussion 
Of the 8 different combinations of master and slave control systems evaluated in this experiment, the 
LVAD master and the preload-matching RVAD slave controller (Controller 1) had the best overall 
performance. This system was adept at reducing suction events during reduced venous return, especially 
when compared to constant speed control. This was primarily due to the slave controller's ability to 
avoid both left and right ventricle suction. It could increase speed to fill the opposite ventricle, or 
decrease speed to prevent suction of the corresponding ventricle. This is an advantage over slave 
controllers that maintain the preload of one ventricle constant [117], as this would leave the other 
ventricle vulnerable to suction. 
The successful MS slave system avoided pulmonary vascular congestion in all scenarios, which is one 
of the most difficult challenges of dual BiVAD operation [19]. Frequent speed changes that are induced 
by an automatic control system increase the likelihood of unbalancing systemic and pulmonary 
circulatory volumes. Using RVAD as slave meant that RVEDP was dependent on LVEDP. When 
LVAD pump speed reached the upper limit during exercise, the slave control system maintained the 
balance between LVEDP and RVEDP. In contrast, independent control systems increased the speed of 
both pumps to maximum levels in exercise, irrespective of the preload in the opposite ventricle. This 
resulted in the RVAD overfilling the LV. Therefore, there are clear advantages of this MS control 
system over dual independent Frank-Starling control systems.  
Previous investigations into the MS relationship between LVAD and RVAD have assumed that the 
LVAD should be the master, without providing experimental evidence [175]. In this study, we 
compared both left/right and right/left MS configurations for our system. The left/right MS combination 
produced the fewest suction events and the lowest risk of pulmonary congestion, thus verifying the 
previous assumption. The Frank-Starling relationship between RVADQ and RVEDP for the right/left 
MS system was not sensitive enough at low preloads, resulting in an increase in suction events. 
Additionally, the support capacity of the LVAD during exercise was limited once the maximum LVAD 
speed was reached. This led to excessive LVEDP which is indicative of pulmonary congestion. 
Therefore there are obvious benefits to using the LVAD as the master.  
In our study, the RVAD outflow cannula was not restricted, thus the RVAD speed was inherently lower 
than the LVAD speed. However, as outlined in Chapter 2, restriction of the RVAD outflow cannula is 
sometimes performed in clinic in order to operate the RVAD at the design speed for LVAD use [48]. 
With both pumps operating at similar speeds, it is difficult to determine which pump would reach the 
upper limit first during the simultaneous speed increases observed in exercise. However, left/right MS 
control should still work in this scenario. For instance, during exercise, if RVAD speed reached the 
upper limit first, the LV venous return will no longer increase. The LVAD Frank-Starling control 
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system, which sets flow based on preload, will then maintain LVAD flow rate in response to the stable 
venous return. Therefore, no LV suction or RV overfilling should occur. 
It is advised to keep the circulatory volume of LVAD patients higher than normal in order to reduce the 
likelihood of suction events[179]. This was confirmed in our study, as elevated MCP during constant 
speed control resulted in zero suction events. In comparison, the left/right MS control system only 
produced 6 suction events at a normal level of MCP by maintaining ventricular volume. This indicates 
that suction events can be avoided without relying on volume-loading, a clear advantage of MS over 
constant speed operation. Further experimentation in-vivo is required to verify this finding. 
5.6 Experimental Limitations and Future Work 
One of the limitations of the master/slave system is the reliance on three sensors (2 pressure and 1 flow). 
Currently there are no commercially available long-term implantable pressure sensors. However there 
are low drift sensors under development [159] which may be incorporated into LVADs in the near 
future. Flow probes are an available alternative, as one is incorporated into the design of the HeartAssist 
5 LVAD [171]. Further investigation is required to determine whether the MS system can use flow 
[172] and/or pressure [110] estimation algorithms instead of sensors. 
Another limitation of this study was that the only implementation technique investigated was dual PI 
control systems. PI controllers were used for their simplicity in their implementation and to minimise 
steady state error. Additionally, only a simple implementation was required to assess the feasibility of 
different control strategies. PID controllers may have produced a faster response, however they would 
have increased the number of variables for optimisation from 4 to 6, increasing the optimisation time. 
Additionally, PI and PID controllers are linear, while the BiVAD and circulatory system is non-linear, 
which means that they may not be the most optimal control implementation. More complex non-linear 
multivariable control approaches, such as self-organising multivariable fuzzy logic control, may offer 
some benefit. They have previously been used for control of anaesthesia [180]. Future work could 
involve investigating if there any possible benefits offered by more complex control algorithms when 
compared to simpler PI and PID control systems.  
5.7 Conclusion and Summary 
In this chapter, a novel MS control system was developed by thoroughly comparing a number of 
different master/slave controllers. The most successful controller combined a Frank-Starling like 
control system for the LVAD and a preload-matching controller for the RVAD. Under in-vitro 
evaluation, the MS system produced fewer suction events than constant speed control, did not cause 
pulmonary congestion and increased cardiac output without placing extra strain on the ventricle. This 
controller was more adept at balancing ventricular volumes than dual independent control systems. The 
LVAD was also established to be the preferred master pump instead of the RVAD, primarily due to its 
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improved ability to prevent pulmonary congestion. However, this control system relies on pressure and 
flow sensors to operate. Limitations in this experiment include only using linear PI control and only 
performing each test once. 
  
 130 
 
6 Conclusions 
The aim of this thesis was to design and evaluate a physiological control system for a dual rotary LVAD 
system operating as a BiVAD. You will recall that in the introduction, four objectives were devised to 
help meet this aim. These objectives were 
 Investigate the different operating modes of dual rotary LVADs as a BiVAD that have 
previously been presented in literature. 
 Develop an evaluation framework for in-vitro assessment of physiological control systems. 
 Develop a physiological control system for a rotary LVAD control system and evaluate using 
the evaluation framework. 
 Modify the rotary LVAD physiological control system into a BiVAD physiological control 
system and assess using the evaluation framework. 
With respect to the first objective, a review of the literature revealed that there are three different 
operating modes for dual rotary LVADs that are currently used in clinic: operating the left pump at a 
higher speed than the right pump, operating both pumps at their design speed, and restricting the outflow 
diameter of the right pump. These three modes were characterised in-vitro using a mock circulation 
loop. It was found that the RVAD can be operated at a lower speed than the LVAD, however this may 
require operating the pump at a speed lower than recommended by the manufacturer (1400-1800 RPM), 
resulting in potential impeller instability and suboptimal washout within the device. Attempting to 
operate both pumps at the same speed is only possible in patients with high PVR, high LV contractility, 
or high RVAD outflow cannula resistance. However, if the RVAD outflow cannula is restricted to a 
diameter between 6.5 and 8.1 mm, suitable steady-state haemodynamics (systemic flow rate 5 L.min-1, 
MAP 90mmHg and LAP less than 25mmHg) can be achieved while maintaining impeller stability and 
optimal device washout. RVAD speed adjustments (increase between 250 and 350 RPM for a PVR 
increase of 400 dynes.s.cm-5) or outflow diameter changes (increase of 0.65mm for the same PVR 
increase) can accommodate for long term or transient variations in PVR, however the latter requires the 
use of an adjustable restriction mechanism. Due to the variable nature of heart contractility between 
patients and the time-varying nature of a patient's PVR, physiological control of dual rotary LVADs 
could be advantageous to ensure suitable cardiac outputs at all times.  
With respect to the second objective, a new evaluation framework for the assessment of physiological 
control systems for rotary blood pumps was developed. This was required, because a review of the 
literature revealed that previous evaluation techniques have been inconsistent between authors, nor were 
they thorough enough to characterise physiological control system behaviour across a number of 
different scenarios. Additionally, this inconsistency makes comparison between different control 
systems difficult when using the literature alone. The evaluation framework developed in this thesis 
addresses the lack of thoroughness by simulating three common patient scenarios in a mock circulation 
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loop. It also involved the creation of performance metrics to provide quantifiable information about 
control system performance and to facilitate fast control system comparisons. The scenarios were 
validated against haemodynamic data presented in the literature, and it was found that perfect replication 
of haemodynamics was difficult without implementation of a baroreflex. However, the scenarios were 
still useful for evaluation of control systems because they subjected the systems to preload and afterload 
changes similar to those observed in clinic. The performance metrics were validated using simulations 
of healthy and heart failure patients, and enable fast ranking of controller performance. However, they 
are not easily understood at first glance and as such may not be useable beyond quick comparison of 
control systems. 
The testing scenarios developed in this thesis were used to determine the most physiologically suitable 
control system for a single LVAD, which met the criteria for the third objective of this thesis. A review 
of the literature revealed that there has been a significant volume of research into physiological control 
of single rotary LVADs, but not as much in the area of dual LVAD control. Some of the findings from 
single LVAD control could potentially be used in the area of dual LVAD control. However, it was 
found that direct comparisons between controllers was not possible due to the inconsistent evaluation 
frameworks used by authors. Therefore a quantitative experimental comparison of a number of different 
control systems was performed using the testing protocol described in the previous chapter. It was found 
that Frank-Starling like control produced the best all-round performance, and thus was used as the basis 
of a dual LVAD control system in the next chapter. It produced zero suction events (compared to 0.12 
s-1 caused by constant speed control), kept left atrial pressure below 25mmHg for nearly all of the total 
simulation time, and increased pump flow in exercise by 3.1 L.min-1 (compared to 1.62 L.min-1 with 
constant speed control). However, this control system does rely on the implantation of flow and pressure 
sensors, which are not available for long term clinical use. Additionally, some LVAD controllers were 
missing from the comparison stage due to insufficient information from the literature. Despite these 
shortcomings, it was decided that the Frank-Starling control system was suitable for adaptation into a 
dual LVAD physiological control system. 
With respect to the final objective, a novel master/slave control system was developed which utilised 
the Frank-Starling control system as a foundation. A number of different combinations of master and 
slave were assessed using the evaluation protocol developed in this thesis. The most successful 
controller combined a Frank-Starling like control system for the LVAD and a preload-matching 
controller for the RVAD. Under in-vitro evaluation, this MS system produced fewer suction events than 
constant speed control, did not cause pulmonary congestion and increased cardiac output without 
placing extra strain on the ventricle. This controller was more adept at balancing ventricular volumes 
than dual independent control systems. The LVAD was also established to be the preferred master pump 
instead of the RVAD, primarily due to its improved ability to prevent pulmonary congestion. However, 
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this control system relies on pressure and flow sensors to operate. Limitations in this experiment include 
only using linear PI control and only performing each test once. 
6.1 Thesis Contributions 
Each of the four experimental chapters in this thesis contributed to the literature. Firstly, the comparison 
of three different operating modes for dual LVADs provided details as to which circumstances would 
be best suited for each of the three operating modes. Another contribution from this work was that it 
showed, using both in-vitro and in-vivo methods, that changes in pump speed would be required to 
accommodate changes in vascular resistance, something that could be achieved using a physiological 
control system. Secondly, this thesis highlighted the inconsistencies in the literature with respect to the 
evaluation of physiological control systems for rotary blood pumps, and proposed a new thorough and 
quantitative method of evaluating these systems. Thirdly, this quantitative evaluation protocol was used 
to compare nine different physiological control systems and rank their performance with respect to 
suction avoidance, pulmonary congestion avoidance and their ability to increase flow during exercise. 
This work not only validated the work done by other investigators but also provided a new perspective 
on previous work. The experimental evidence produced during this stage was strong enough to support 
the decision to adapt Frank-Starling control from single LVAD to dual LVAD control. All of these 
contributions led to the design and evaluation of a novel master/slave control system, which was shown 
to be able to balance flows in all scenarios evaluated. 
6.2 Thesis Limitations 
There were a number of limitations in this study. In Chapter 2, the MCL did not replicate any 
autoregulatory mechanisms beyond the Frank-Starling response. Additionally these autoregulatory 
mechanisms were potentially compromised in the in-vivo studies due to anaesthesia. This means that 
the behaviour of the control system may be different when used in a recovery animal or in clinic. 
Secondly, VentrAssist rotary LVADs were used both in-vitro and in-vivo. The VentrAssist was too 
large to be used as an RVAD, and had to be positioned outside the chest cavity. Additionally, the long 
VentrAssist inflow cannula was not ideal for RVAD support, as it had to be pushed through the RV 
wall, across the tricuspid valve and into the RA. Smaller pumps should be utilised for future long-term 
studies. The VentrAssist is also no longer used clinically, which puts into question the clinical relevance 
of this study. However, as it is a third generation centrifugal LVAD its behaviour is similar to that of 
other third generation pumps (such as the HeartWare HVAD).Thirdly, the PVR changes induced in-
vivo by tying a band around the PA were not necessarily physiological. Future work should investigate 
whether pharmacological changes in PVR are more physiological and repeatable. Finally, only PVR 
changes were performed in-vitro and in-vivo, which established the need for RVAD speed control. 
Whilst it can be inferred that changes in SVR would require changes in LVAD speed, experimental 
evidence is required to verify this assumption. Finally, only one animal study was performed. More 
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animals are required in order to determine if the discrepancies between MCL and in-vivo results 
observed in this experiment are significant. 
In Chapter 3, whilst the MCL offers numerous advantages over a NM, it is not as customisable and 
therefore limited the detail with which scenarios could be evaluated. Secondly, whilst the pressure and 
flow sensors were correctly offset to zero at the start of each simulation, calibration was not performed 
as frequently. Thirdly, the model of ventricular suction was not validated due to time constraints. Given 
that a previously validated suction model was used (albeit in a numerical model), it was assumed that 
it would give a similar response in the MCL. However, the use of pneumatic regulators and a different 
volume threshold may have modified the suction behaviour. Future work should incorporate validation 
of this suction mechanism. 
In Chapter 4, the biggest limitation was that only a number of control systems were compared. Notable 
omissions included work by Arndt et al. [82], [83], Vollkron and colleagues [84], Choi et al. [80], [95] 
and Gwak et al. [86], [87]. These controllers were omitted because their complexity, in conjunction 
with insufficient detail of controller parameters in their published descriptions, made it difficult to 
implement them in this experimental setup within the time frame. Comparisons with these untested 
systems may require collaboration with the initial investigators in future studies. The second limitation 
of this study was that it was assumed that all feedback variables were measured using accurate and 
reliable sensors. This assumption was necessary in order to assess the efficacy of each control objective 
in isolation. Both pressure and flow sensors were required, and for long term use these sensors need to 
have high accuracy and low drift. Currently there are no commercially available pressure sensors that 
meet this criteria, although there are some in development [159], [160]. Flow sensors are an available 
alternative, as one is incorporated into the HeartAssist 5 LVAD [171]. Therefore, the assumption that 
sensors were available is not reflective of the current situation in clinic. Further investigation is required 
to determine whether the use of flow [172] and/or pressure [110] estimation algorithms instead of 
sensors affects the performance of these control systems. Finally, no repetition was performed of the 
results. The repeatability of the MCL was already established in the previous chapter, so it was assumed 
that repeating experiments in this chapter was redundant. However, given the benefit of hindsight, the 
results presented in this chapter could be held with more confidence had repetition been performed. 
In Chapter 5, one limitation of this study was that the only implementation technique investigated was 
dual PI control systems. PI controllers were used for their simplicity in their implementation and to 
minimise steady state error. Additionally, only a simple implementation was required to assess the 
feasibility of different control strategies. PID controllers may have given a faster response, however 
they would have increased the number of variables for optimisation from 4 to 6, increasing the 
optimisation time. Additionally, PI and PID controllers are linear, while the BiVAD and circulatory 
system is non-linear, which means that they may not be the most optimal control implementation. More 
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complex non-linear multivariable control approaches, such as self-organising multivariable fuzzy logic 
control, previously used for control of anaesthesia [180], may offer some benefit. Another limitation is 
that only one heart condition was evaluated, and the constants in the controller equations were only set 
for that condition. No work was performed to evaluate the system for different heart contractilities. 
6.3 Future Work 
The following areas are ideas as to how this work could be extended in the future by other researchers. 
Firstly, more in-vivo studies into characterisation of the three operating modes of dual LVADs could 
be performed, with the aim of establishing the differences between in-vivo and in-vitro results. 
Secondly, the evaluation framework could be extended by the inclusion of a simulation of the baroreflex 
and other autoregulatory features. This would aid in advanced performance assessment of physiological 
control systems and provide a more realistic picture of what might happen in the clinic. Thirdly, 
comparison of even more controllers could be performed, not only using systems that were omitted 
from this thesis but also incorporating pressure and flow estimation strategies and suction detection and 
avoidance algorithms. Fourthly, control systems could be compared using different models of LVADs, 
particularly those that are currently used in clinic. Fifthly, the only control theory technique used in this 
thesis was proportional integral control. Given the use of fuzzy logic control in the past, future work 
could involve investigating the use of fuzzy logic in both single and dual LVAD Starling-like control. 
Sixth, the ideal time domain characteristics of physiological control systems for rotary VADs are 
unknown. Future work could involve characterising the time domain response of the healthy heart to 
changes in preload in order to set a “gold standard” for future physiological control systems to reach. 
Finally, a hugely novel area of future work will be to migrate physiological control system evaluation 
out of the laboratory and into clinical trials. 
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8 Appendix A 
Constants for MCL settings 
The following tables contain the values used to simulate various degrees of heart failure (as well as 
exercise) in the mock circulation loop used in this thesis. These constants relate to the equations found 
in Chapter 2 (Equations (2.1) and (2.2)) and Chapter 3 (Equation (3.1)). 
8.1 Left Ventricle 
Constant Unit Healthy Mild Heart Failure Severe Heart Failure Healthy Exercise 
Kven - - 2.2 2.2 2.2 2.2 
Ksm1 - - 0.39 0.29 0.29 0.40 
Ksm2 mL-1 1 1 1 1 
CEDV mL 0.00 300.00 200.00 0.00 
Csm1 - - -0.54 -0.54 -0.54 -0.54 
KHR Min 0.023 0.012 0.012 0.023 
 
8.2 Right Ventricle 
Constant Unit Healthy Mild Heart Failure Severe Heart Failure Healthy Exercise 
Kven - - 5 5 5 5 
Ksm1 - - 0.20 0.16 0.13 0.26 
Ksm2 mL-1 1 1 1 1 
CEDV mL 70.00 0.00 100.00 100.00 
Csm1 - - -0.10 -0.10 -0.10 -0.10 
KHR Min 0.043 0.017 0.017 0.043 
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9 Appendix B  
Repeatability Testing Results for Test Bed Simulations. 
As described in section 3.4.5.1, the repeatability of the evaluation protocol was assessed. This was 
achieved by simulating the sequence of patient scenarios (postural change, Valsalva manoeuvre and 
exercise) ten times each for two levels of ventricular contractility. To quantify the repeatability, a 
number of haemodynamic signals were recorded and compared. 
Comparison was performed using Matlab (The Mathworks, Natick, MA). The built-in function corrcoef 
was used to determine repeatability. This function takes a set of signals and determines the correlation 
between each pair of signals. This function produces two outputs. The first is an array of correlation 
coefficients. This coefficient is a number between -1, which implies strong negative linear correlation 
between two signals, and 1, which implies that there is strong positive correlation between two signals. 
Zero implies no correlation between the two signals. The whole matrix then shows the correlation 
coefficient for each pair of signals. The second output is a matrix of p-values, which is the probability 
that there is no correlation between a pair of signals. A p-value less than 0.05 indicates that the two 
signals are statistically correlated. Both of these matrices are mirrored about the major diagonal. 
In the context of this study, strong positive correlation indicates that two signals are tracking each other 
over time, indicating high repeatability. The following tables show the results of performing the 
correlation testing on a number of haemodynamic signals (mean systemic arterial pressure, mean 
pulmonary arterial pressure, mean left atrial pressure, mean right atrial pressure, mean systemic flow 
rate and mean pulmonary flow rate) for all ten tests and for two levels of left ventricular contractility. 
The result is a pair of 10 x 10 matrices for each haemodynamic variable, showing the correlation 
coefficient and p-value between each signal. The major diagonal is left blank, since a signal will always 
be 100% correlated with itself. 
All of the p-values for each pair of signals for every variable are all less than 0.05, indicating that there 
is strong repeatability between each of the ten tests. 
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9.1 Healthy Left Ventricle 
Mean Arterial Pressure 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 0.91 0.92 0.91 0.85 0.92 0.99 1 1 0.99  1 - - 0 0 0 0 0 0 0 0 0 
2 0.91 - - 0.99 0.99 0.98 0.99 0.87 0.89 0.91 0.91  2 0 - - 0 0 0 0 0 0 0 0 
3 0.92 0.99 - - 1 0.98 1 0.87 0.90 0.91 0.89  3 0 0 - - 0 0 0 0 0 0 0 
4 0.91 0.99 1 - - 0.99 1 0.86 0.89 0.90 0.88  4 0 0 0 - - 0 0 0 0 0 0 
5 0.85 0.98 0.98 0.99 - - 0.98 0.80 0.82 0.85 0.84  5 0 0 0 0 - - 0 0 0 0 0 
6 0.92 0.99 1 1 0.98 - - 0.87 0.89 0.91 0.90  6 0 0 0 0 0 - - 0 0 0 0 
7 0.99 0.87 0.87 0.86 0.80 0.87 - - 0.99 0.99 0.99  7 0 0 0 0 0 0 - - 0 0 0 
8 1 0.89 0.90 0.89 0.82 0.89 0.99 - - 0.99 0.99  8 0 0 0 0 0 0 0 - - 0 0 
9 1 0.91 0.91 0.90 0.85 0.91 0.99 0.99 - - 0.99  9 0 0 0 0 0 0 0 0 - - 0 
10 0.99 0.91 0.89 0.88 0.84 0.90 0.99 0.99 0.99 - -  10 0 0 0 0 0 0 0 0 0 - - 
                       
Mean Pulmonary Arterial Pressure 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 0.99 0.99 1 0.99 0.99 1 1 1 1  1 - - 0 0 0 0 0 0 0 0 0 
2 0.99 - - 1 1 1 1 0.98 0.99 0.99 0.99  2 0 - - 0 0 0 0 0 0 0 0 
3 0.99 1 - - 1 1 1 0.99 1 0.99 0.99  3 0 0 - - 0 0 0 0 0 0 0 
4 1 1 1 - - 1 1 0.99 1 0.99 0.99  4 0 0 0 - - 0 0 0 0 0 0 
5 0.99 1 1 1 - - 1 0.98 0.99 0.99 0.99  5 0 0 0 0 - - 0 0 0 0 0 
6 0.99 1 1 1 1 - - 0.99 1 0.99 0.99  6 0 0 0 0 0 - - 0 0 0 0 
7 1 0.98 0.99 0.99 0.98 0.99 - - 1 1 0.99  7 0 0 0 0 0 0 - - 0 0 0 
8 1 0.99 1 1 0.99 1 1 - - 1 1  8 0 0 0 0 0 0 0 - - 0 0 
9 1 0.99 0.99 0.99 0.99 0.99 1 1 - - 1  9 0 0 0 0 0 0 0 0 - - 0 
10 1 0.99 0.99 0.99 0.99 0.99 0.99 1 1 - -  10 0 0 0 0 0 0 0 0 0 - - 
                       
 
  
 151 
 
Mean Left Atrial Pressure 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 0.99 1 1 0.99 1 0.99 1 1 0.99  1 - - 0 0 0 0 0 0 0 0 0 
2 0.99 - - 1 1 1 1 0.98 0.99 0.99 0.99  2 0 - - 0 0 0 0 0 0 0 0 
3 1 1 - - 1 1 1 0.99 1 0.99 0.99  3 0 0 - - 0 0 0 0 0 0 0 
4 1 1 1 - - 1 1 0.99 1 1 0.99  4 0 0 0 - - 0 0 0 0 0 0 
5 0.99 1 1 1 - - 1 0.97 0.99 0.99 0.99  5 0 0 0 0 - - 0 0 0 0 0 
6 1 1 1 1 1 - - 0.98 1 0.99 0.99  6 0 0 0 0 0 - - 0 0 0 0 
7 0.99 0.98 0.99 0.99 0.97 0.98 - - 0.99 0.99 0.99  7 0 0 0 0 0 0 - - 0 0 0 
8 1 0.99 1 1 0.99 1 0.99 - - 1 0.99  8 0 0 0 0 0 0 0 - - 0 0 
9 1 0.99 0.99 1 0.99 0.99 0.99 1 - - 0.99  9 0 0 0 0 0 0 0 0 - - 0 
10 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 - -  10 0 0 0 0 0 0 0 0 0 - - 
                       
Mean Right Atrial Pressure 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 0.98 1 0.99 0.96 0.98 0.98 1 1 0.98  1 - - 0 0 0 0 0 0 0 0 0 
2 0.98 - - 0.98 0.98 0.98 0.98 0.94 0.97 0.98 0.99  2 0 - - 0 0 0 0 0 0 0 0 
3 1 0.98 - - 0.99 0.96 0.99 0.98 1 1 0.98  3 0 0 - - 0 0 0 0 0 0 0 
4 0.99 0.98 0.99 - - 0.98 1 0.96 0.99 0.99 0.98  4 0 0 0 - - 0 0 0 0 0 0 
5 0.96 0.98 0.96 0.98 - - 0.98 0.91 0.95 0.96 0.98  5 0 0 0 0 - - 0 0 0 0 0 
6 0.98 0.98 0.99 1 0.98 - - 0.94 0.97 0.99 0.98  6 0 0 0 0 0 - - 0 0 0 0 
7 0.98 0.94 0.98 0.96 0.91 0.94 - - 0.99 0.98 0.96  7 0 0 0 0 0 0 - - 0 0 0 
8 1 0.97 1 0.99 0.95 0.97 0.99 - - 1 0.98  8 0 0 0 0 0 0 0 - - 0 0 
9 1 0.98 1 0.99 0.96 0.99 0.98 1 - - 0.98  9 0 0 0 0 0 0 0 0 - - 0 
10 0.98 0.99 0.98 0.98 0.98 0.98 0.96 0.98 0.98 - -  10 0 0 0 0 0 0 0 0 0 - - 
                       
Mean Systemic Flow Rate 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 1 1 1 1 1 1 1 1 1  1 - - 0 0 0 0 0 0 0 0 0 
2 1 - - 1 1 1 1 0.99 1 1 1  2 0 - - 0 0 0 0 0 0 0 0 
3 1 1 - - 1 1 1 1 1 1 1  3 0 0 - - 0 0 0 0 0 0 0 
4 1 1 1 - - 1 1 1 1 1 1  4 0 0 0 - - 0 0 0 0 0 0 
5 1 1 1 1 - - 1 0.99 0.99 0.99 1  5 0 0 0 0 - - 0 0 0 0 0 
6 1 1 1 1 1 - - 1 1 1 1  6 0 0 0 0 0 - - 0 0 0 0 
7 1 0.99 1 1 0.99 1 - - 1 1 1  7 0 0 0 0 0 0 - - 0 0 0 
8 1 1 1 1 0.99 1 1 - - 1 1  8 0 0 0 0 0 0 0 - - 0 0 
9 1 1 1 1 0.99 1 1 1 - - 1  9 0 0 0 0 0 0 0 0 - - 0 
10 1 1 1 1 1 1 1 1 1 - -  10 0 0 0 0 0 0 0 0 0 - - 
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Mean Pulmonary Flow Rate 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  
Test 
Numb
er 
1 2 3 4 5 6 7 8 9 10 
1 - - 1 1 1 1 1 1 1 1 1  1 - - 0 0 0 0 0 0 0 0 0 
2 1 - - 1 1 1 1 1 1 1 1  2 0 - - 0 0 0 0 0 0 0 0 
3 1 1 - - 1 1 1 1 1 1 1  3 0 0 - - 0 0 0 0 0 0 0 
4 1 1 1 - - 1 1 1 1 1 1  4 0 0 0 - - 0 0 0 0 0 0 
5 1 1 1 1 - - 1 1 1 1 1  5 0 0 0 0 - - 0 0 0 0 0 
6 1 1 1 1 1 - - 1 1 1 1  6 0 0 0 0 0 - - 0 0 0 0 
7 1 1 1 1 1 1 - - 1 1 1  7 0 0 0 0 0 0 - - 0 0 0 
8 1 1 1 1 1 1 1 - - 1 1  8 0 0 0 0 0 0 0 - - 0 0 
9 1 1 1 1 1 1 1 1 - - 1  9 0 0 0 0 0 0 0 0 - - 0 
10 1 1 1 1 1 1 1 1 1 - -  10 0 0 0 0 0 0 0 0 0 - - 
 
9.2 Mild Left Heart Failure 
Mean Arterial Pressure 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 0.99 0.99 0.99 0.99 0.99 1 1 0.99 0.99  1 - - 0 0 0 0 0 0 0 0 0 
2 0.99 - - 0.99 0.99 0.99 1 0.99 0.99 0.99 0.99  2 0 - - 0 0 0 0 0 0 0 0 
3 0.99 0.99 - - 1 1 0.99 1 1 0.99 1  3 0 0 - - 0 0 0 0 0 0 0 
4 0.99 0.99 1 - - 1 0.99 0.99 1 0.99 1  4 0 0 0 - - 0 0 0 0 0 0 
5 0.99 0.99 1 1 - - 0.99 1 0.99 0.99 1  5 0 0 0 0 - - 0 0 0 0 0 
6 0.99 1 0.99 0.99 0.99 - - 0.99 0.99 0.99 1  6 0 0 0 0 0 - - 0 0 0 0 
7 1 0.99 1 0.99 1 0.99 - - 1 0.99 1  7 0 0 0 0 0 0 - - 0 0 0 
8 1 0.99 1 1 0.99 0.99 1 - - 0.99 0.99  8 0 0 0 0 0 0 0 - - 0 0 
9 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 - - 0.99  9 0 0 0 0 0 0 0 0 - - 0 
10 0.99 0.99 1 1 1 1 1 0.99 0.99 - -  10 0 0 0 0 0 0 0 0 0 - - 
                       
Mean Pulmonary Arterial Pressure 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 1 1 1 1 1 1 1 1 1  1 - - 0 0 0 0 0 0 0 0 0 
2 1 - - 1 1 0.99 1 0.99 0.99 1 1  2 0 - - 0 0 0 0 0 0 0 0 
3 1 1 - - 1 0.99 1 0.99 0.99 1 1  3 0 0 - - 0 0 0 0 0 0 0 
4 1 1 1 - - 1 1 1 1 1 1  4 0 0 0 - - 0 0 0 0 0 0 
5 1 0.99 0.99 1 - - 1 1 1 0.99 1  5 0 0 0 0 - - 0 0 0 0 0 
6 1 1 1 1 1 - - 1 1 1 1  6 0 0 0 0 0 - - 0 0 0 0 
7 1 0.99 0.99 1 1 1 - - 1 0.99 1  7 0 0 0 0 0 0 - - 0 0 0 
8 1 0.99 0.99 1 1 1 1 - - 1 1  8 0 0 0 0 0 0 0 - - 0 0 
9 1 1 1 1 0.99 1 0.99 1 - - 1  9 0 0 0 0 0 0 0 0 - - 0 
10 1 1 1 1 1 1 1 1 1 - -  10 0 0 0 0 0 0 0 0 0 - - 
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Mean Left Atrial Pressure 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 1 1 1 1 1 1 1 1 1  1 - - 0 0 0 0 0 0 0 0 0 
2 1 - - 1 1 1 1 1 1 1 1  2 0 - - 0 0 0 0 0 0 0 0 
3 1 1 - - 1 1 1 1 1 1 0.99  3 0 0 - - 0 0 0 0 0 0 0 
4 1 1 1 - - 1 1 1 1 1 1  4 0 0 0 - - 0 0 0 0 0 0 
5 1 1 1 1 - - 1 1 1 1 1  5 0 0 0 0 - - 0 0 0 0 0 
6 1 1 1 1 1 - - 1 1 1 1  6 0 0 0 0 0 - - 0 0 0 0 
7 1 1 1 1 1 1 - - 1 1 1  7 0 0 0 0 0 0 - - 0 0 0 
8 1 1 1 1 1 1 1 - - 1 1  8 0 0 0 0 0 0 0 - - 0 0 
9 1 1 1 1 1 1 1 1 - - 1  9 0 0 0 0 0 0 0 0 - - 0 
10 1 1 0.99 1 1 1 1 1 1 - -  10 0 0 0 0 0 0 0 0 0 - - 
                       
Mean Right Atrial Pressure 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 0.95 0.99 0.94 0.97 0.93 0.98 0.99 0.93 0.98  1 - - 0 0 0 0 0 0 0 0 0 
2 0.95 - - 0.96 0.94 0.94 0.99 0.96 0.96 0.99 0.96  2 0 - - 0 0 0 0 0 0 0 0 
3 0.99 0.96 - - 0.96 0.98 0.95 0.99 1 0.94 0.99  3 0 0 - - 0 0 0 0 0 0 0 
4 0.94 0.94 0.96 - - 0.96 0.95 0.98 0.96 0.95 0.99  4 0 0 0 - - 0 0 0 0 0 0 
5 0.97 0.94 0.98 0.96 - - 0.94 0.98 0.98 0.94 0.98  5 0 0 0 0 - - 0 0 0 0 0 
6 0.93 0.99 0.95 0.95 0.94 - - 0.96 0.95 1 0.96  6 0 0 0 0 0 - - 0 0 0 0 
7 0.98 0.96 0.99 0.98 0.98 0.96 - - 0.99 0.95 1  7 0 0 0 0 0 0 - - 0 0 0 
8 0.99 0.96 1 0.96 0.98 0.95 0.99 - - 0.95 0.99  8 0 0 0 0 0 0 0 - - 0 0 
9 0.93 0.99 0.94 0.95 0.94 1 0.95 0.95 - - 0.96  9 0 0 0 0 0 0 0 0 - - 0 
10 0.98 0.96 0.99 0.99 0.98 0.96 1 0.99 0.96 - -  10 0 0 0 0 0 0 0 0 0 - - 
                       
Mean Systemic Flow Rate 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 1 1 1 1 1 1 1 1 1  1 - - 0 0 0 0 0 0 0 0 0 
2 1 - - 1 1 1 1 1 1 1 1  2 0 - - 0 0 0 0 0 0 0 0 
3 1 1 - - 1 1 1 1 1 1 1  3 0 0 - - 0 0 0 0 0 0 0 
4 1 1 1 - - 1 1 1 1 1 1  4 0 0 0 - - 0 0 0 0 0 0 
5 1 1 1 1 - - 1 1 1 1 1  5 0 0 0 0 - - 0 0 0 0 0 
6 1 1 1 1 1 - - 1 1 1 1  6 0 0 0 0 0 - - 0 0 0 0 
7 1 1 1 1 1 1 - - 1 1 1  7 0 0 0 0 0 0 - - 0 0 0 
8 1 1 1 1 1 1 1 - - 1 1  8 0 0 0 0 0 0 0 - - 0 0 
9 1 1 1 1 1 1 1 1 - - 1  9 0 0 0 0 0 0 0 0 - - 0 
10 1 1 1 1 1 1 1 1 1 - -  10 0 0 0 0 0 0 0 0 0 - - 
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Mean Pulmonary Flow Rate 
Correlation Coefficient  P-value (< 0.05 indicates correlation is present) 
Test Number 1 2 3 4 5 6 7 8 9 10  Test Number 1 2 3 4 5 6 7 8 9 10 
1 - - 1 1 1 1 1 1 1 1 1  1 - - 0 0 0 0 0 0 0 0 0 
2 1 - - 1 1 1 1 1 1 1 1  2 0 - - 0 0 0 0 0 0 0 0 
3 1 1 - - 1 1 1 1 1 1 1  3 0 0 - - 0 0 0 0 0 0 0 
4 1 1 1 - - 1 1 1 1 1 1  4 0 0 0 - - 0 0 0 0 0 0 
5 1 1 1 1 - - 1 1 1 1 1  5 0 0 0 0 - - 0 0 0 0 0 
6 1 1 1 1 1 - - 1 1 1 1  6 0 0 0 0 0 - - 0 0 0 0 
7 1 1 1 1 1 1 - - 1 1 1  7 0 0 0 0 0 0 - - 0 0 0 
8 1 1 1 1 1 1 1 - - 1 1  8 0 0 0 0 0 0 0 - - 0 0 
9 1 1 1 1 1 1 1 1 - - 1  9 0 0 0 0 0 0 0 0 - - 0 
10 1 1 1 1 1 1 1 1 1 - -  10 0 0 0 0 0 0 0 0 0 - - 
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10 Appendix C  
This appendix describes the Frank-Starling control system used in Chapter 4 and as the master control 
system in Chapter 5. It describes three different methods of calculating a target flow rate for a given 
measured preload/pump inlet pressure. 
10.1 Starling-like Control Descriptions 
A Frank-Starling control approach was used for LVAD control. This approach directly mimics the 
native preload-sensitivity of the ventricle. Direct mimicking of the native ventricular function should 
ensure pump and ventricular output matches cardiac demand. The fundamental principle of Starling 
control involves setting a target pump flow rate based on preload. LVAD inlet pressure was used as a 
direct measure of pump preload, and it was assumed that a sensor was available to do measure this. This 
simplified the development of the control system. 
Guyton defines the relationship between flow and preload as sigmoid [20]. However, for this control 
system a linear relationship between pump flow and preload was used as it was simpler to implement. 
Upper and lower limits on flow were added to prevent excessive flow and back flow respectively. Figure 
10.1 shows the relationship between pump flow and preload that will be maintained by the control 
system. 
 
 
At each time step, the current values of pump inlet pressure (Pin) and VAD flow (Qmeas) were measured, 
which defined the current operating point. The target flow for that operating point was calculated, and 
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Figure 10.1: Target control line for the Starling-like control system for rotary LVAD 
control. 
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the speed of the pump adjusted to minimise the error between target and measured flow. Three different 
methods could be used for calculating the target flow, as described by Salamonsen and colleagues 
(2012) [127]. 
10.1.1 Vertical Flow Target 
The first method, vertical flow target (VFT), is the most straightforward, and is shown in Figure 10.2. 
The target flow rate was located vertically from the operating point towards the target line (Equation 
(10.1)). 
 𝑄𝑉𝐹𝑇 = 𝐾𝑠𝑐(𝑃𝑖𝑛 − a) (10.1) 
Where Ksc (L.min-1.mmHg-1) is the magnitude of the slope and a is the horizontal offset of this slope. 
These constants were set at 2 L.min-1.mmHg-1 and 5.5 mmHg respectively, which resulted in normal 
cardiac output, systemic and pulmonary arterial pressures (5 L.min-1, 90-100mmHg and 18-20mmHg 
respectively) at rest. 
 
 
Vertical flow target is the most logical and straightforward calculation. However, the initial estimate 
for target flow using Equation (10.1) may over- or underestimate the final steady-state value as the 
operating point moves closer to the target control line. This is because as speed changes, both preload 
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Figure 10.2: Calculation of target flow using the vertical target flow calculation 
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and flow change, so the movement of the operating point is never vertical. This overestimation may 
result in overshoot of the control line, and consequently longer settling times. Higher values of Ksc 
accentuate this effect, producing high variation in target flow for small variations in Pin, resulting in the 
operating point continually "hunting" for its steady state. For these reasons, vertical flow error was not 
evaluated in this thesis. Instead, two more complex approaches were investigated – Radial flow about 
the X-Intercept and Radial Flow about the Target Control Line. 
10.1.2 Radial Flow about X-Intercept 
Target flow calculated radially about the x-intercept (RAXI), uses an arc drawn from the operating point 
to the target control line (Figure 10.3). The arc has its centre located at the x-intercept of the control 
line, and the error is calculated using Equation (10.2).  
 
𝑄𝑇𝑅𝐴𝑋𝐼 =  sin (tan
−1 𝐾𝑠𝑐) √(𝑃𝑖𝑛 − 𝑎)
2 +  (𝑄𝑚𝑒𝑎𝑠)
2
 (10.2) 
Where Qmeas represents the measured VAD flow, and all other constants as previously described. This 
method predicts a target value that is closer to the final steady-state value on the target control line. It 
also accommodates for steeper slopes in that small variations in Pin are damped by the Qmeas term. 
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10.1.3 Radial Flow About the Target Control Line 
The final method, target flow radial about the control line (RACL) is similar to RAXI but uses an arc 
with its centre located on the target control line, horizontally from the operating point (Figure 10.4). 
Equation (10.3) is used to determine the target flow rate. Like RAXI, this method sets a target flow rate 
close to the final steady state value on the control line, and accommodates for steep slopes.  
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Figure 10.3: Calculation of target flow using radial about the x-intercept (TRAXI) method. 
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 𝑄𝑇𝑅𝐴𝐶𝐿 = 𝑄𝑚𝑒𝑎𝑠(1 − 𝐾𝑠𝑐1) + Ksc2(PinM − a) (10.3) 
 
Where Ksc1 and Ksc2 (L.min-1.mmHg-1) are related to the slope Ksc by equations 10.4 and 10.5 
 𝐾𝑠𝑐1 = 𝑐𝑜𝑠 (𝑡𝑎𝑛
−1 𝐾𝑠𝑐) (10.4) 
 
 𝐾𝑠𝑐2 = 𝑠𝑖𝑛 (𝑡𝑎𝑛
−1 𝐾𝑠𝑐) (10.5) 
Since Ksc was set at 2 L.min-1.mmHg-1, Ksc1 and Ksc2 were set as 0.447 and 0.894 L.min-1.mmHg-1 
respectively.  
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Figure 10.4: Calculation of target flow using radial about the control line (RACL) method. 
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11 Appendix D 
11.1 Optimisation Loop 
Tuning of the gains (Kp and Ki) of the PI control implementation for each system was performed using 
Quasi-Newtonian optimisation. Optimisation was chosen as the tuning method because the complexity 
and time-varying nature of the cardiovascular system made tuning via traditional control design 
methods, such as pole placement, difficult. 
A numerical model of the cardiovascular system was used to optimise the control gains[181]. A patient 
with severe LHF patient was simulated, and left pump support initiated with speed set at 2100 RPM. 
The Quasi-Newtonian tuning loop was then started. The goal of the optimisation loop was to determine 
the set of gains k that minimised the objective function S(k) (Equation (11.1)) 
 
𝑆(𝒌) =  ∫ (
𝑄𝑚𝑒𝑎𝑠(𝑡) − 𝑄
∗(𝑡)
𝑄𝑡𝑎𝑟𝑔𝑒𝑡(𝑡)
)
2
 𝑑𝑡
𝑡1
𝑡0
 (11.1) 
 
Where Q*(t) is the desired, or ideal, controller response.  
11.2 Ideal System Response 
The ideal system response Q*(t)  was represented as a second-order system, with a rise time of 1 second 
to ensure responsive tracking and a ten percent overshoot as a suitable compromise for the fast response. 
The general form of a second order transfer function is shown in Equation (11.2) 
 
𝐺(𝑠) =  
𝜔2
 𝑠2 + 2𝜁𝜔𝑠 + 𝜔2
 (11.2) 
Where ζ is the damping ratio and ω the natural frequency. The overshoot of a second order transfer 
function can be determined using Equation (11.3). 
 
𝑂𝑆% = 100 e
−𝜁
𝜋
√1−𝜁2 
(11.3) 
Given an overshoot as a design specification, the damping ratio can be calculated by rearranging 
Equation (11.3), producing Equation (11.4). 
 
𝜁 =
ln (
𝑂𝑆%
100 )
√𝜋2 + ln2
𝑂𝑆%
100
 (11.4) 
The rise time of a second order system can be determined using Equation (11.5). 
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𝑡𝑟 =
1
𝜔
(
1
√1 − 𝜁2
) (𝜋 − tan−1 (
√1 − 𝜁2
𝜁
)) (11.5) 
Rearranging, the natural frequency of the system can be determined using Equation (11.6). 
 
𝜔 =
1
𝑡𝑟
(
1
√1 − 𝜁2
) (𝜋 − tan−1 (
√1 − 𝜁2
𝜁
)) (11.6) 
Substituting the design specifications (overshoot 10% and rise time 1 second) into Equations (11.4) and 
(11.6) produced the transfer function of the ideal system response, shown in Equation (11.7).” 
 𝑄∗(𝑠)
𝑄𝑡𝑎𝑟𝑔𝑒𝑡(𝑠)
=  
7.462
𝑠2 + 3.23𝑠 + 7.462
 (11.7) 
 
This was converted to a discrete transfer function in order to make a direct comparison with the discrete 
PI control system. Transformation was performed using Matlab with a sampling period of 1 second. 
The resulting discrete transfer function is given in Equation (11.8) 
 𝑄∗(𝑧)
𝑄𝑡𝑎𝑟𝑔𝑒𝑡(𝑧)
=  
𝑧 + 0.2747
𝑧2 + 0.2352𝑧 + 0.03957
 (11.8) 
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11.3 Optimisation Loop 
S(k) was determined for a step reduction in target output over a time period of 30 seconds. 
The optimisation loop consisted of the following steps. 
1. Initial simulation.  
i. A patient with severe LHF was simulated and supported with an LVAD operating at 
constant speed. 
ii. The FS control system was turned on at t = 30 seconds, using an initial guess for the 
gains (X0 = [Kp0 Ki0]).  
iii. At t =60 seconds, the target flow rate of the FS control system was decreased by 20% 
in a step wise manner. The system was given 30 seconds to settle. S(X0) was determined 
for this step response. 
2. Calculate 𝑆′(𝑿𝟎) =  
i. Vary Kp by 5%. 
ii. Repeat step 1 after substituting in this new gain. 
iii. Calculate S1, and change in S using Equation (11.9). 
 𝜕𝑆
𝜕𝐾𝑝
=  
𝑆1 − 𝑆0
𝐾𝑝1 −  𝐾𝑝0
 (11.9) 
 
iv. Return the varied gain back to its original value, then repeat i - iii with all gains. 
v. Calculate the approximate gradient of the system (𝑆′(𝑿𝟎)) at the original set of gains 
using Equation (11.10). 
 
𝑆′(𝑿𝟎)  ≈
∆𝑆0
∆𝑿
=  
𝜕𝑆
𝜕𝐾𝑝
+
𝜕𝑆
𝜕𝐾𝑖
 (11.10) 
 
3. Calculate second gain set using Equation (11.11) and apply to the controller. 
 𝑿𝟏 = 𝑿𝟎 + −𝑋𝑠𝑡𝑒𝑝𝑯𝟏(𝑆
′(𝑿𝟎)) (11.11) 
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Where Xstep = 0.05 and H1is an n x n identity matrix, where n is the number of gains being optimised 
(in this example, n = 2). 
4. Repeat Step 3 using X1 to calculate 𝑆′(𝑿𝟏) 
5. Determine new set of gains using Equation (11.12). 
 𝑿𝒌+𝟏 = 𝑿𝒌 + −𝑋𝑠𝑡𝑒𝑝𝑯𝒌+𝟏(𝑆
′(𝑿𝒌)) (11.12) 
 
where  
𝑯𝒌+𝟏 =  (𝑰 − (
𝒚∆𝑿𝑻
𝒚𝑻∆𝑿
))
𝑇
𝑯𝒌 (𝑰 − (
𝒚∆𝑿𝑻
𝒚𝑻∆𝑿
)) + (
∆𝑿∆𝑿𝑻
𝒚𝑻∆𝑿
) 
and 
𝒚 = 𝑆′(𝑿𝒌+𝟏) −  𝑆
′(𝑿𝒌) 
6. Repeat steps 5 and 6 until S’(Xk), S(Xk) or |ΔX| falls below a defined threshold, or until 
maximum number of iterations is reached. 
The parameters used for the optimisation process are given in Table 11.1. 
 
Table 11.1: Parameters used for optimisation 
process. 
Parameter 
Value 
S’(Xk) Threshold 0.1 
S(Xk) Threshold 0.01 
|ΔX| Threshold 0.5 
Max iterations 20 
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12 Appendix E 
Morphological Filter Description 
This appendix contains a description of the morphological filter used to condition all signals prior to 
use in the physiological control systems described in this thesis. This description was published in the 
journal Medical and Biological Engineering and Computing in 2013, in Volume 51 Issue 8. 
Briefly, signal conditioning was required for all feedback signals before their use in a physiological 
control system. Ideally, the pulsatile component of the signal caused by residual heart contractility 
should be removed without attenuating other clinically significant components or damping sharp 
changes in signal magnitude. Generally, linear or non-linear filters can be used. Linear filters (such as 
Butterworth filters) require a trade-off between response time and attenuation. Additionally, the have 
higher requirements for bit precision than some non-linear filters. Therefore, it was decided that a non-
linear filtering approach should be utilised. 
There are a number of different non-linear approaches that could be used. Morphological filters were 
chosen because of their previous use in processing other biological signals as well as their relatively 
simple computation requirements. More detail of the structure of a morphological filter and its 
implementation can be found in this appendix, as well as in [182].  
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Abstract 
A morphological filter (MF) is presented for the determination of beat-to-beat mean rotary left ventricular assist 
device (LVAD) flow rate, measured using an implanted flow probe. The performance of this non-linear filter was 
assessed using LVAD flow rate (QLVAD) data sets obtained from in-silico and in-vivo sources. The MF was 
compared with a 3rd order Butterworth filter (BWF) and a 10-second moving average filter (MAF). Performance 
was assessed by calculating the response time and steady state error across a range of heart rates and levels of 
noise. The response time of the MF was 3.5 times faster than the MAF, 0.5 seconds slower than the BWF, and 
had a steady state error of 2.61%. It completely removed pulsatile signal components caused by residual 
ventricular function, and tracked sharp transient changes in QLVAD better than the BWF. The use of a two-stage 
MF improved noise immunity compared to the single-stage MF. This study showed that the good performance 
characteristics of the non-linear MF make it a more suitable candidate for embedded real-time processing of QLVAD 
than linear filters.  
Keywords 
Morphological filter; Ventricle-Assist Device; Cardiac Output; Signal Processing 
Abbreviations 
MF: Morphological Filter; LVAD: Left Ventricular Assist Device; QLVAD: Left Ventricular Assist Device Flow 
Rate; SE: Structuring Element; IIR: Infinite Impulse Response; BWF: Butterworth filter; FIR: Finite Impulse 
Response; Rsa: Systemic Arterial Resistance; t: Time; BPM: Beats Per Minute; fc: Cut-off Frequency; MAF: 
Moving Average Filter; RMSSSD: Root Mean Squared Steady State Difference; 
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Introduction 
Rotary left ventricular assist devices (LVADs) mechanically support patients with left ventricular 
failure whilst they await a heart transplant. Continuous measurement of LVAD flow rate (QLVAD) by an 
implantable sensor may aid with the clinical management of these patients, and may also be required in 
future for feedback control of pump speed [8]. Flow sensors are currently incorporated into one type of 
LVAD [5]. Online filtering of signals obtained from these implantable sensors is necessary to obtain 
beat-to-beat mean QLVAD in real-time. 
A requirement of a signal filter for QLVAD is to attenuate the pulsatile components of the flow 
signal (caused by residual heart contractility) to obtain beat-to-beat mean flow. A suitable filter must 
achieve this without attenuating other clinically significant signal components or damping sharp 
transient changes in signal magnitude. Obtaining a responsive beat-to-beat mean flow will allow 
clinicians to make appropriate decisions quickly regarding pump speed settings, which will obviously 
be beneficial to the patient. Additionally, attenuation of the heartbeat removes undesirable modulation, 
which makes it easier to design feedback control systems. Such control systems may reduce ventricular 
suction events [8] which may improve patient quality of life. An additional challenge is to minimise the 
computational complexity of the filter, enabling the use of low-power consumption embedded 
processors. Possible filters for this application can be broadly classified into two main categories: linear 
or non-linear filters. 
Linear filters have previously been used to remove baseline drift and noise from ECG 
measurements [6]. However, it can be shown that these filters distort the QRS and ST complexes. This 
impedes the detection of QRS complex and consequently reduces the discriminatory power of any 
diagnostic system in which the filter is used [9]. Morphological filters (MFs) were shown to better 
preserve these complexes than linear filters due to their inherent ability to better preserve signal 
morphology [1]. An additional advantage of MFs is that they are computationally simple and have lower 
requirements for bit precision than linear filters. The successful use of MFs in filtering one type of 
biosignal, as described above, in conjunction with their implementation advantages, encourages their 
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use as a filter for QLVAD. To our knowledge, MFs have not yet been applied to biosignal processing 
applications other than ECG. 
The aim of this study was to develop and evaluate a MF for the measurement of mean beat-to-
beat QLVAD. Flow data generated in-silico and obtained from an in-vivo experiment were filtered using 
a MF, and the result compared to two linear filters. 
Methods 
Morphological Filters 
MFs utilise mathematical morphology, of which the fundamental operations are erosion and 
dilation. These operations involve shifting a structuring element (SE) of a specified shape and size along 
the time dimension of a signal and at each time step either subtracting (eroding) or adding (dilating) the 
SE to the signal. Morphological opening (erosion then dilation) of a 1-D signal can be interpreted as 
moving the SE along a 1-D data set from underneath, and the resulting signal is the set of highest points 
reached by the structuring element, producing a set of local minima [9]. In the opposite manner, 
morphological closing (dilation then erosion) of the signal passes the SE through the data set from 
above, resulting in a set of lowest points reached by the element, producing a set of local maxima. For 
a more detailed description of mathematical morphology, see [2]. 
The MF algorithm used in this study estimated the mean y of the signal x in the following 
manner. Firstly, closing and opening operations with a flat structuring element B were performed 
simultaneously. The beat-to-beat mean flow was then determined by the weighted average of the closing 
and opening operations (Equation 1). 
y = w.(x • B ) + (1-w ).(x ∘ B ) (1) 
Where the symbols • and ∘ denote morphological closing and opening respectively, and 0 < w 
< 1, which can be adjusted to accommodate different waveform shapes. Opening and closing operations 
were implemented using the fast implementation of 1-D time-series morphological filtering proposed 
by Wang and He (1994) to reduce computational complexity [12]. 
 169 
 
For implementation in embedded processors, comparisons and addition operations are favoured 
over multiplication due to faster (single clock cycle) instruction times and the universal implementation 
of these operations in processor hardware. An additional consideration when selecting a processor is 
the bit precision required for each operation – the higher the precision, typically the higher the power 
requirements and cost of the microcontroller. Using the aforementioned MF approach, at each time step 
only two comparisons, two multiplications and one addition are performed, independent of structuring 
element length [12]. The few arithmetic operations required and the reliance on comparison operators 
means that the requirement for bit depth is small. Only a small amount of internal memory is required 
to store the result of the comparison from the previous time step, and 8-bit implementation would be 
sufficient. 
In contrast, the implementation of linear filters requires higher bit precision. For infinite 
impulse response (IIR) filters, the resultant pole location after hardware implementation may be 
different to the desired pole location due to quantisation, resulting in alterations in either resonant 
frequency or bandwidth [4]. Additionally, limit cycles (oscillatory behaviour when no input is present) 
may occur because of the rounding operation as a result of a low bit resolution. As an example, Figure 
1 shows a comparison of the frequency and step responses of a third order low-pass Butterworth filter 
(BWF) implemented with different levels of bit precision. Twelve-bit precision resulted in a non-unity 
gain in the pass-band, producing an undesirable step response. Sixteen-bit precision was required to 
obtain desired filter characteristics (to within 0.5 dB). 
Finite impulse response (FIR) filters are inherently stable and their coefficients do not require 
as high precision as IIR filters. However, a higher order FIR filter is required to obtain the same 
characteristics as an equivalent IIR filter. Additionally, the accumulation operation requires a 
reasonable amount of bit resolution to prevent overflow. Specifically, an extra bit of precision is 
required every time the result in the accumulator is doubled.  
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Having established that the requirements for bit precision and computational complexity are 
lower for MFs than for IIR and FIR filters, the next step is to determine if the non-linear behaviour of 
MFs is advantageous when determining beat-to-beat mean QLVAD. 
Filter Evaluation 
 We assessed the suitability of a MF for filtering QLVAD using Simulink (The Mathworks, 
Natick, MA) so that the proposed algorithm could be tested in a simulated environment. The evaluation 
procedure involved subjecting QLVAD data to the MF and two other linear filters (Figure 2) and 
comparing the response time and steady-state error between them. Two different QLVAD data sets were 
used. The first was generated from a numerical model of the cardiovascular system (in-silico) and the 
second obtained from an acute non-recovery animal experiment (in-vivo). Generating data in-silico 
enabled evaluation of the filter across a range of different heart rates and noise levels. The in-vivo data 
were used to evaluate the MF using a true QLVAD signal, obtained from an implantable flow probe, which 
contained realistic pulsatile signal components.  
Source Data: In-Silico 
A lumped parameter model of a rotary LVAD and cardiovascular system [3] was used to 
generate the first set of QLVAD data for filter comparison. A patient with severe left ventricular failure 
was simulated, and left ventricular mechanical support provided by a VentrAssist LVAD (Ventracor, 
Sydney, Australia). Severe left ventricular failure was simulated by reducing the end-systolic left 
ventricular elastance from the normal healthy value of 3.54 mmHg/mL to 1.06 mmHg/mL. All other 
model parameters were kept at the healthy values as specified in [3]. LVAD speed was set at 2600 RPM 
in order to produce normal haemodynamics: mean arterial pressure of 100mmHg and a total cardiac 
output of approximately 5 L/min. Simulations were performed using Simulink (The Mathworks, Natick, 
MA). 
To simulate a change in pump flow, a step change in systemic arterial resistance (Rsa) was 
performed. This simulated the dilation of arterial blood vessels that may occur during exercise. The 
pump speed was unchanged. The simulation protocol was as follows: the simulation commenced at 
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time t = 0, with the pump switched off and cannula occluded. At t = 10 second, the pump was switched 
on at a speed of 2600 RPM. At t = 60 seconds, the Rsa was decreased from 0.74 mmHg.s/mL to 0.56 
mmHg.s/mL. Then at t = 120 seconds the initial value was restored. Total simulation time was 180 
seconds. The protocol was repeated over a range of heart rates from 30 to 120 beats per minute (BPM), 
generating a set of QLVAD data encompassing a typical range of heart rates. For each heart rate, systolic 
fraction was automatically adjusted with heart rate using the relationship described by Vollkron et al. 
(2002) [11].  
To evaluate the robustness of the MF to noise, normally distributed noise was added to the 
signal and the above protocol repeated. The magnitude of this noise was varied from 2.5% to 70% of 
the maximum flow signal, producing a range of signal-to-noise (SNR) ratios encompassing 6.6 to 
35.6dB. 
Source Data: In-Vivo  
Haemodynamic data were acquired as part of an ongoing in-vivo evaluation of blood pumps 
using ovine models at the Medical Engineering and Research Facility located at The Prince Charles 
Hospital (Brisbane, Queensland, Australia). Animals were treated in accordance with the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes (Code of Practice) and the 
Animal Care and Protection Act (Qld). Ethics approval was obtained prior to the experiment from the 
Animal Ethics Committee of the Queensland University of Technology (Ethics Approval Number 
1100001052). 
A single acute non-recovery ovine experiment was performed. After anesthetizing the sheep, a 
VentrAssist LVAD (Ventracor, Chatswood, Australia) was implanted into the left ventricle. The pump 
speed was set initially to maintain normal haemodynamics as described in the aforementioned section. 
After the sheep was stabilised, pump speed was increased to 2800 RPM. Controlled changes in flow 
were then produced by performing step reductions in pump speed: first, from 2800 to 2400 RPM, then 
from 2400 to 2000 RPM. 
 172 
 
In the experiment, QLVAD was measured using an ultrasonic flow-Doppler probe (TS410-
10PXL, Transonic Systems, Ithaca, NY, USA). Data were sampled at 100Hz using dSPACE 1103 data 
acquisition hardware (Ceanet Pty Ltd, Sydney, Australia).  
Filter Implementation 
The MF was implemented with a flat SE with a width of 201 elements. At a sampling frequency 
of 100Hz, this SE covered 2 seconds of input data. This width ensured that for all the evaluated heart 
rates, the window would always encompass at least one heartbeat. As this was an initial investigation 
into using a MF for determination of mean beat-to-beat QLVAD, the weighting constant w was fixed at 
0.33 as per conventional calculations of mean arterial pressure that use the maximum and minimum 
arterial pressures [7]. This weighting factor assumes a triangular waveform shape, which is a reasonable 
approximation for QLVAD.  
In an attempt to improve noise immunity, a two-stage MF was also evaluated using the in-silico 
data set. This filter consisted first of a noise-removing MF section (of the same structure as the proposed 
beat-to-beat MF, but with different parameters) cascaded with the single-stage beat-to-beat MF 
previously described. The noise-removal MF used a flat SE with a width of 21 elements, chosen to 
remove high frequency noise without causing significant signal delays. Weighting factor w was set at 
0.5, since it was assumed that the noise was equally spread around the mean. Note that while a MF was 
used as the noise-removal stage, other non-linear filters, such as a median filter, could be used instead. 
 The performance of the MF was compared to two low-pass linear filters. For linear filters, 
correct selection of filter order and cut-off frequency requires consideration of the trade-off between 
response time and stop-band attenuation. A low cut-off frequency (fc) would ensure attenuation of all 
pulsatile signal components, but would be slow to respond to transient changes. A higher cut-off 
frequency speeds up response time but at the cost of reduced attenuation of pulsatile components. For 
this reason we designed two linear filters that highlighted this trade-off: a low-order BWF and a long 
window MAF. Table 1 shows the order, cut-off frequency and attenuation across a range of frequencies 
for these two filters. Both filters were implemented with a sampling frequency of 100Hz. 
 173 
 
The BWF an example of an IIR filter, whose characteristics include efficient implementation 
and a mildly non-linear phase response. For this study a 3rd-order filter with a cut-off frequency (fc) of 
0.5 Hz was selected. A low order was chosen for simple implementation and fc was chosen to attenuate 
pulsatile components caused by the heartbeat without compromising response time. The MAF is an 
example of a FIR filter, whose characteristics include guaranteed stability and a linear phase response. 
For this study, a long averaging window (10 seconds) was used, in order to completely remove the 
pulsatile components of the signal for all heart rates. This MAF filter has been previously implemented 
during a clinical trial of rotary LVAD feedback control mechanisms [8, 10]. 
Performance Evaluation 
Comparison was performed by calculating the response time of each filter, and the root mean 
squared steady state difference (RMSSSD) between MF, BWF and the MAF. Conventional frequency 
domain analysis techniques were not used in this study to make comparisons because these techniques 
are only suitable for the linear filters (BWF and MAF). 
The response time was defined as the time required for the filtered signal to move from 10 to 
90% of final value after a step change in Rsa (in-silico) or speed (in-vivo)). For the in-silico data, the 
response times across all heart rates were expressed as mean ± standard deviation. Comparisons 
between each filter were made using Student’s t-test, performed using Matlab (The Mathworks, Natick, 
MA). A p-value less than 0.05 was considered significant. 
The RMSSSD between the MF and the MAF was used as a measure of MF accuracy. The MAF 
had zero steady state error due to its high order and low fc, so its use as a benchmark is reasonable. The 
RMSSSD was calculated over a 30 second period, 30 seconds after the change in flow, to ensure that 
the MAF had settled, and was calculated separately for both the increase and decrease in resistance. The 
RMSSSD was determined for all heart rates using the in-silico data, using both the clean signal and all 
noisy signals. The noise immunity of the single-stage MF, two-stage MF and BWF was assessed by 
comparing the RMSSSD (expressed as mean ± standard deviation). 
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Results 
In-Silico 
Figure 3 shows the mean response times of each filter for both the decrease and increase in Rsa 
for all different heart rates using the clean in-silico data. Statistically significant differences between 
two filters are marked with an asterisk. The only difference in response time between the MF and the 
BWF was during the reduction in Rsa, in which the BWF was 0.5 seconds faster. The response time of 
the MAF was nearly 3.5 times slower than the MF and BWF. Interestingly the response time of the 
BWF depended on the change in resistance, whilst the response times of the MF and MAF did not.  
Figure 4 shows that the MF and BWF both exhibited very low RMSSSD for heart rates less 
than 40 BPM. For heart rates between 40 and 115 BPM, the BWF was more accurate than the MF. The 
maximum RMSSSD was 2.6% at 70 BPM. The heart rate at which maximum RMSSSD occurred for 
the MF increased as Rsa decreased.  
 A section of the QLVAD waveform at a heart rate of 70 BPM is shown in Figure 5. The MF over-
estimated the beat-to-beat mean QLVAD, which was the reason its RMSSSD was higher than the BWF. 
All pulsatile signal components were removed by the MF. In contrast, the BWF did not completely 
attenuate the pulsatile component, which was the main contributor to its RMSSSD value. 
Figure 6 shows the RMSSSD for the singe stage MF, the two stage MF and the BWF, for each 
level of SNR during the decreased Rsa. As the SNR decreased, the RMSSSD of all filters increased. The 
RMSSSD of the single stage MF increased exponentially as SNR decreased, reaching a maximum of 
14.6±5.7% at an SNR of 6.6 dB. The two-stage MF exhibited noise immunity similar to that of the 
BWF, and improved upon the single stage MF by reducing the RMSSSD to 4.22± 0.6 % at the lowest 
SNR. 
In-Vivo 
 Figure 7 shows the pump flow rate obtained in-vivo, processed using the three different filtering 
techniques. The initial flow rate was 6.5 L/min when the pump was operated at 2800 RPM. 
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Approximately 38 seconds later, QLVAD reduced, coinciding with the first reduction in speed. At 
approximately 110 seconds after the commencement of the experiment, QLVAD reduced again, 
coinciding with final speed reduction.  
 Table 2 shows the response time and RMSSSD for each filter, evaluated using the data set 
obtained in-vivo, for the two changes in speed. It is difficult to compare the in-vivo and in-silico results 
directly due to the differing nature of these two experiments, however some general observations can 
be made. Like the in-silico results, both MF and BWF produced faster response times than the MAF. 
Unlike the in-silico results however, the MF had a faster rise time than the BWF. The RMSSSD differed 
depending on the LVAD speed, however more data sets are required to determine if this was significant. 
The RMSSSD obtained in-vivo was higher than the RMSSSD obtained from the clean in-silico data at 
the same heart rate (120 BPM) however this may just be due to the presence of noise in the acquired 
signal. The MF tracked the flow signal better than the BWF during the sharp transient drops in flow 
that occurred when the speed changed (at 38 and 110 seconds). Both the MF and the BWF exhibited 
oscillations at a frequency of 0.2Hz, the same frequency as the mechanical ventilator used to support 
the animal.  
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Discussion 
 MFs are attractive as implantable biosignal processors due to their low requirements for bit 
precision and low computational complexity, provided they are responsive and accurate. The purpose 
of this study was to establish that using a MF to filter QLVAD can remove pulsatile signal components 
without attenuating transient changes or compromising accuracy. These results showed that the MF 
produced similar response times to a low-pass 3rd-order BWF using in-silico and in-vivo data, was flat 
during steady state and maintained a RMSSSD lower than 2.7% with a clean signal. To our knowledge 
this is the first report of the use of a non-linear filter for the filtering of QLVAD. 
 Evaluation using the clean in-silico data highlighted the advantages of using a non-linear filter 
to obtain beat-to-beat mean QLVAD. The non-linear MF removed pulsatile components of the signal, 
whilst having a fast response time and low steady state error. In contrast, linear filter design requires a 
compromise between response time and stop-band attenuation. The low-order BWF used in this study 
was responsive to changes in flow, but could not completely attenuate pulsatile components of the 
signal. Additional filtering would be required to remove the pulsatile component before this signal could 
be used in a feedback control system, otherwise the controller output may also oscillate. Complete 
attenuation of the pulsatile signal was achieved with the MAF, but at the cost of a slower response time 
due to a lower fc. The non-linear MF exhibited the advantages of both types of linear filters evaluated 
and thus may be used to obtain a responsive, accurate and pulsatile-free QLVAD signal suitable for 
monitoring or feedback control. 
 The MF exhibited the same response time as the BWF for a decrease in Rsa when assessed with 
the in-silico data, but was 0.5 seconds slower in response to an increased Rsa. This indicates that the 
change in QLVAD with a change in Rsa may exhibit hysteresis. However, because the difference in rise 
times is so small this phenomenon is not likely to be noticed in the clinical environment. 
 The MF was compared with a MAF that was previously utilised in the only feedback control 
system for a rotary LVAD to have undergone clinical evaluation [8, 10]. Whilst those authors did not 
report any difficulties with the slow response time of this filter, the results from our study suggest that 
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the substitution of the MAF with a MF would result in a more responsive flow signal being fed to any 
feedback control system. This would improve control performance without any increase in bit precision. 
 It was observed that the RMSSSD of the MF varied with heart rate. The variation with heart 
rate may be explained by the fact that the systolic fraction (relative time spent in systole each cardiac 
cycle) increases with heart rate [11]. This will have an impact on the shape of the QLVAD waveform. The 
MF algorithm assumes that the waveform shape is fixed, and so as heart rate (and therefore systolic 
period) changed, the accuracy of the estimated mean also changed. However, the maximum RMSSSD 
was only 2.6%, which was acceptable. If further improvement in RMSSSD is required then a method 
of adapting w in Equation 1 with changes in beat-to-beat interval would have to be investigated. 
 The beat-to-beat mean QLVAD signal must be immune to noise, so that clinicians can accurately 
monitor end-organ perfusion, and so the performance of any feedback control system is not 
compromised. Our results showed that the RMSSSD of the single-stage beat-to-beat MF was vulnerable 
to noise with a SNR of less than 25dB. However, the accuracy of the two-stage MF, which consisted of 
a noise-removal component in addition to the beat-to-beat MF, was immune to high levels of noise. The 
addition of the second stage comes at the cost of increased computational complexity: at each time step 
the two-stage MF performed four comparisons, two additions and three multiplications (since the 
weighting factor in the noise-removal stage is 0.5). However, the two-stage MF still required fewer total 
multiplication operations than the 3rd order BWF used in this study, which required seven multiplication 
operations each time step. Note that while a MF was used as the noise-removal stage, other types of 
non-linear filters could also be used. 
Evaluation using the data obtained in-vivo again confirmed the benefits of using the non-linear 
MF to obtain beat-to-beat mean QLVAD. The MF was just as responsive as the BWF, was able to remove 
the pulsatile signal components, did not attenuate the low-frequency pulse due to the mechanical 
ventilation and had low steady state error. An additional advantage of the MF was its ability to track 
sharp transient changes in flow better than either of the linear filters. This was because the low-pass 
linear filters attenuated high-frequency signal components, which included the transient changes in flow 
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observed in the in-vivo data. The MF filter however responded very quickly to the sharp drop in 
minimum flow and therefore produced a more realistic beat-to-beat mean QLVAD. Whilst this may not 
provide immediate advantages to a clinician monitoring LVAD flow, it may be beneficial for feedback 
control of QLVAD. Another advantage of the MF over conventional linear filters is that removal of the 
periodic noise caused by the heartbeat from the feedback signal simplifies controller design 
significantly and also reduces unnecessary oscillations in the pump control signal that would be present 
if pulsatility remained.  
Only the single-stage MF was used to process the in-vivo data. While there was some noise 
present in the signal, it was not of a high enough magnitude to reduce accuracy. Despite the good noise 
immunity of the single-stage MF, we suggest that a two-stage filter be used for processing QLVAD in real 
time due to the unknown nature of noise. 
The MF presented here can remove pulsatility from the QLVAD signal, which may simplify the 
feedback signal when used to directly control QLVAD. This simplifies controller design while also 
eliminating unnecessary oscillations in the pump control signal that would otherwise be present if 
pulsatility remained in the feedback signal. However, some proposed control algorithms, such as that 
presented by Schima et al. (2004) [8], utilize the pulsatility as a measure of preload. If pulsatility needs 
to be isolated, the MF algorithm proposed in this study could be modified to obtain a responsive measure 
of the pulsatility in the following manner. The MF calculates local minima and maxima (by performing 
simultaneous opening and closing operations) of the pulsatile waveform each time step. The pulsatility 
can then be calculated by subtracting the minimum from the maximum each cardiac cycle. This 
calculation could be performed in conjunction with Equation 1 each cardiac cycle without dramatically 
increasing computational complexity, since it is only a single addition operation.  
In this study, we have evaluated the performance of the MF using data generated in-silico and 
in-vivo. Both data sources offer distinct advantages. The in-silico environment contained a large 
number of easily modifiable parameters and can create reproducible results. This enabled us to assess 
the MF thoroughly. However, these signals are only simulated approximations of the true QLVAD 
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waveform. The in-vivo data set was an example of a true QLVAD signal, and its inclusion in this paper 
shows the advantages of the MF are applicable outside of the in-silico environment. We acknowledge 
that the experimental conditions were different between the in-silico and in-vivo data and as such direct 
comparisons cannot be made between them. To accommodate for this, the MF was always compared 
to the same two linear filters for each data set. 
Stability of any filter is an important characteristic, and should be ensured before 
implementation. The non-linear nature of the MF meant that traditional pole-zero analysis could not be 
performed to determine stability. However, like an FIR filter, the MF does not utilize any feedback. 
Therefore, it is inherently stable. Also, there was no instability observed in these experiments, which 
indicates that this filter is stable. Furthermore, unlike an IIR filter, the stability of the MF is not affected 
by reducing the bit precision. Reductions in bit precision would only result in a more quantized output; 
however this is not an issue as we do not foresee any reason to reduce the bit precision of the MF below 
that of the input signal. 
 There are some limitations associated with using a non-linear filter. Firstly, there is a lack of 
theoretical tools that can predict the performance of non-linear filters, and therefore their characteristics 
must largely be determined empirically. Secondly, the MF algorithm in this study effectively relied on 
determining the maximum and minimum flow each heartbeat. Therefore, this filter can only update at 
most once per heartbeat. If the filtered signal is utilised for a feedback control mechanism then this 
places some limitation on the sampling frequency of the controller.  
This was an initial investigation of the benefits of MF to obtain mean beat-to-beat QLVAD. Future 
work will involve investigating how to adapt the weighting factor w in Equation 1 to ensure maximum 
accuracy, perhaps by responding to changes in the beat-to-beat interval. Additionally, future studies 
will investigate how the effects of the non-linearities of the MF would affect the complexity of a 
physiological control system. However, since the MF simplifies the feedback signal by removing the 
pulsatile component, we do not anticipate that it will increase the system complexity. 
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MFs have previously been established as a suitable means for removing noise and baseline drift 
from ECG signals. They are also advantageous in that their low computational complexity and low 
requirements for bit precision make them simple to implement on implantable embedded processors, 
which encourages their use in other biosignal applications. In this paper we evaluated the suitability of 
MFs to filter QLVAD signals obtained from an implantable flow probe. The MF completely attenuated 
pulsatile signal components and was able to track sharp transient changes in flow. This combination of 
characteristics cannot be achieved with a linear filter, whose design requires compromise between 
response time and attenuation. Due to the advantages of simpler implementation, low minimum bit 
precision, fast response time, noise immunity and low steady-state error, the MF proposed in this study 
can be used in place of a low pass linear filter to process the signal from an implantable LVAD flow 
sensor. This will result in a responsive, stable and accurate signal that can be used for monitoring by 
clinicians or utilised in a feedback control system. Whilst this study focused on obtaining a beat-to-beat 
mean QLVAD, these results indicate that a MF could also be applied to finding the mean, maxima or 
minima of other biosignals, such as arterial pressure.  
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Figures 
 
 
Fig 1 Comparison of the Bode magnitude plot (left) and step response (right) for 12 and 16 bit precision 
implementations of a 3rd order low-pass Butterworth filter. 
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Fig 2 Schematic of the filter evaluation framework. Source data was generated in-silico and obtained from in-
vivo studies. 
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Fig 3 Mean ± SD response time of the clean LVAD flow signal after a step decrease (a) and a step increase (b) 
in systemic arterial resistance using three different filters for fixed heart rates between 30 and 120 BPM.  
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Fig 4 RMSSSD between the MF and the MAF, and between BWF and MAF for normal and low systemic 
arterial resistance (Rsa) over a range of heart rates. 
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Fig 5 Segment of QLVAD waveform, filtered using the three different filtering techniques under evaluation. 
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Fig 6 Root mean squared steady state difference for one and two stage MFs and the BWF across a range of 
signal-to-noise ratios. 
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Fig 7 Rotary LVAD flow data obtained in-vivo, and filtered using three different filtering techniques.  
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Tables 
Table 1 Attenuation across the range of heart beat frequencies for the two linear filters used for comparison. 
Filter Order 
Cut-off 
Frequency (Hz) 
Attenuation (dB) 
0.1 Hz 0.5 Hz 1 Hz 2 Hz 
BWF 3 0.5 0.0 -3.0 -18.3 -36.1 
MAF 1000 0.04 -13.3 -24.0 -29.9 -36.0 
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Table 2 Response times for all filters and RMSSSD between MF and MAF, and BWF and MAF, using in-vivo 
source data 
Speed 
Change 
Response Time (sec) RMSSSD (%) 
MF BWF MAF MF BWF 
1 0.04 0.23 9.14 1.24 1.33 
2 0.11 0.43 7.09 2.08 1.77 
 
 
 
 
